var title_f8_43_8880="Bivalving of torsed ovary 2";
var content_f8_43_8880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    A second bivalve of this ovary leads to further release of capsular pressure allowing increased arterial perfusion and thus a less dusky appearance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This ovarian bivalve procedure demonstrates that the ovarian tissue, despite an initially non-viable appearance, can retain perfused and viable tissues. Bivalving may serve as a valuable intra-operative triage tool to assess viability and avoid unnecessary extirpation of viable ovaries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8880=[""].join("\n");
var outline_f8_43_8880=null;
var title_f8_43_8881="Results after incision and drainage of breast abscess";
var content_f8_43_8881=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Results after incision and drainage of breast abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results one week post incision and drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8881=[""].join("\n");
var outline_f8_43_8881=null;
var title_f8_43_8882="Thoracic spine meningioma MRI";
var content_f8_43_8882=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Thoracic spine meningioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced thoracic MRI scans in a 75-year-old woman with progressive paraparesis due to a mid-thoracic spinal meningioma. Left panel: The sagittal study reveals a dural-based lesion at T7-8. Right panel: The axial image shows the ventrally-located lesion (arrow) causing spinal cord compression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Welch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8882=[""].join("\n");
var outline_f8_43_8882=null;
var title_f8_43_8883="Glucarpidase: Patient drug information";
var content_f8_43_8883=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Glucarpidase: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/27/7605?source=see_link\">",
"     see \"Glucarpidase: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/35/35380?source=see_link\">",
"     see \"Glucarpidase: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14266243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Voraxaze&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13753300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3634417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high methotrexate levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13753293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3634421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to glucarpidase or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13753295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13753359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13753296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13753358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13753297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17135 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-29CCF0041E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8883=[""].join("\n");
var outline_f8_43_8883=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14266243\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13753300\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13753293\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13753295\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13753359\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13753296\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13753358\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13753297\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/27/7605?source=related_link\">",
"      Glucarpidase: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/35/35380?source=related_link\">",
"      Glucarpidase: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_43_8884="Endoscopic ultrasound: Normal pancreaticobiliary anatomy";
var content_f8_43_8884=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic ultrasound: Normal pancreaticobiliary anatomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/43/8884/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/43/8884/contributors\">",
"     Lyndon V Hernandez, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/43/8884/contributors\">",
"     Manoop S Bhutani, MD, FASGE, FACG, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/43/8884/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/43/8884/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/43/8884/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/43/8884/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/43/8884/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major area of endosonographic diagnosis and intervention involves diseases of the pancreaticobiliary tract. A high degree of understanding of cross-sectional anatomy of the pancreaticobiliary tract is required to attain competence in this area [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8884/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Endoscopic ultrasound (EUS) provides high resolution images of the pancreatic duct as well as the parenchyma, and complements the ductal images seen in endoscopic retrograde cholangiopancreatography (ERCP).",
"   </p>",
"   <p>",
"    This topic review will discuss normal pancreaticobiliary anatomy using radial scanning endoscopic ultrasound (EUS). The role of EUS in the evaluation of choledocholithiasis, pancreatic cancer, and chronic pancreatitis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=see_link\">",
"     \"Endoscopic ultrasound in patients with suspected choledocholithiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1929?source=see_link\">",
"     \"Endoscopic ultrasound in the staging of exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29591?source=see_link\">",
"     \"Endoscopic ultrasound in chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS examination resembles standard endoscopy of the upper gastrointestinal tract. The operator performs the procedure while the patient is in left lateral decubitus position. Echoendoscopes are usually side-viewing and have an ultrasound transducer located at its tip that emits high frequency acoustic waves to the surrounding tissues. The latter permits the acquisition of unique \"real-time\" views of the gut wall and the surrounding organs and blood vessels.",
"   </p>",
"   <p>",
"    Radial scanning EUS uses a scanning plane perpendicular to the axis of the echoendoscope (",
"    <a class=\"graphic graphic_figure graphicRef62721 \" href=\"UTD.htm?10/40/10885\">",
"     figure 1",
"    </a>",
"    ). The image is similar to that of CT scan; if the patient is supine, the view is up from the feet. As a general rule, the upper part of the screen is anterior, and the right part of the screen is to the patient's left side. EUS depends upon a thorough knowledge of structures visualized in relation to the various transducer positions in the gastrointestinal tract (",
"    <a class=\"graphic graphic_table graphicRef69569 \" href=\"UTD.htm?25/10/25771\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    EUS examination of the pancreaticobiliary tract can be performed by using one of two approaches: starting with transgastric sonographic views and then proceeding transduodenally, or vice versa. The transgastric approach provides images of the pancreatic body and tail, whereas the transduodenal approach allows imaging of the pancreatic head. It is important to understand that normal pancreaticobiliary anatomy with either of these approaches can be variable and is by no means exactly reproducible in every patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRANSGASTRIC IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transgastric approach involves wedging the tip of the echoendoscope in the antrum and gradually pulling it back toward the body of the stomach using subtle movements. From the antrum, the gallbladder may come into view as an anechoic structure with a three-layered wall (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51586 \" href=\"UTD.htm?25/50/26401\">",
"     image 1",
"    </a>",
"    ). The gallbladder may also be viewed from the first and second portions of the duodenum. Gallbladder stones appear as round hyperechoic structures that cause posterior shadowing.",
"   </p>",
"   <p>",
"    The confluence of the splenic vein and the portal vein is seen as the transducer is pulled back from the antrum; it is also referred to as the \"club head\" because of its resemblance to a golf club (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69269 \" href=\"UTD.htm?35/30/36327\">",
"     image 2",
"    </a>",
"    ). Posterior to the confluence is the cross section of the superior mesenteric artery, with hyperechoic walls.",
"   </p>",
"   <p>",
"    The splenic vein is an important landmark to identify the body of the pancreas. The pancreas is located between the splenic vein and the transducer. The neck and body of the pancreas and glimpses of the pancreatic duct can be seen anterior to the splenic vein. The pancreas has a grainy \"salt and pepper\" pattern that appears more hyperechoic than the liver (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80886 \" href=\"UTD.htm?15/56/16265\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Further visualization of the body of the pancreas can be achieved by slowly pulling the transducer into the gastric body. The pancreatic duct appears anechoic and in cross-section measures approximately 2 mm in the pancreatic body. Based upon our experience and the experience of other endosonographers, the diameter of the pancreatic duct approximately follows the 3-2-1 rule (ie, 3 mm in the head, 2 mm in the body, and 1 mm in the tail of the pancreas).",
"   </p>",
"   <p>",
"    Another vascular structure that may be examined is the splenic artery. The splenic artery can be distinguished from the splenic vein because it is tortuous and may not be seen in a single plane; by contrast, the splenic vein appears as a long continuous structure. Following these vessels to the patient's left side leads to the hilum of the spleen, which marks the leftward limit of the tail of the pancreas. Further withdrawal of the scope toward the fundus will show the celiac trunk (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55352 \" href=\"UTD.htm?22/25/22935\">",
"     image 4",
"    </a>",
"    ) bifurcating into the hepatic artery and the splenic artery (the whale's tail sign).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TRANSDUODENAL IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transduodenal sonographic imaging is performed by wedging the tip of the echoendoscope into the apex of the duodenal bulb. The balloon of the echoendoscope is inflated and the shaft of the echoendoscope is placed along the greater curvature of the stomach (the long position). This obtains a longitudinal view of the common bile duct and pancreatic duct converging into the ampulla (surrounded by the pancreatic head) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62822 \" href=\"UTD.htm?29/41/30360\">",
"     image 5",
"    </a>",
"    ). This view can also be achieved from the duodenal bulb or by slowly advancing the tip of the echoendoscope beyond the duodenal bulb into the second portion of the duodenum. Obtaining this view is important for excluding an obstructive process (eg, tumor) in the",
"    <span class=\"nowrap\">",
"     periampullary/pancreatic",
"    </span>",
"    head area. Another landmark in this area is the \"stack sign,\" an image configuration that shows the common bile duct, pancreatic duct, and the portal vein almost parallel to each other.",
"   </p>",
"   <p>",
"    The tip of the echoendoscope is deflected upward as it passes beyond the major ampulla, much like the technique in ERCP. The echoendoscope is then gradually withdrawn with subtle left and right tip deflection. Reference points in the third part of the duodenum are the inferior vena cava and aorta, which may be seen in cross-sectional and longitudinal views, depending upon the orientation of the tip of the echoendoscope. The uncinate process of the pancreas may be seen between the transducer and the aorta. At the level of the uncinate process, the ventral anlage of the pancreas comes into view in up to 75 percent of normal subjects. This triangular area represents the embryologic ventral bud of the pancreas that later forms the posterior and inferior aspect of the head of the pancreas. Because it appears hypoechoic (due to reduced fat content compared with the dorsal pancreas), it may be mistaken for a malignant tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     AGE-RELATED CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal aging can be associated with endosonographic changes in the pancreas. An illustrative study included 120 patients without known pancreatic disease who agreed to undergo EUS during endoscopic evaluation for non hepatobiliary indications [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8884/abstract/3\">",
"     3",
"    </a>",
"    ]. At least one parenchymal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ductular abnormality was identified in 28 percent of patients, with a trend of increasing abnormality with age. The most common finding was hyperechoic stranding. Abnormalities were more common in men. Other studies have also shown a strong trend toward increasing duct diameter with age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8884/abstract/4\">",
"     4",
"    </a>",
"    ]. These considerations are particularly important when using EUS in the diagnosis of chronic pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29591?source=see_link\">",
"     \"Endoscopic ultrasound in chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148591716\">",
"    <span class=\"h1\">",
"     POST-SURGICAL IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radial EUS imaging of the entire pancreas can be challenging in patients who have undergone upper gastrointestinal (GI) surgery, as normal landmarks have been lost or post-surgical inflammation and staples may cause artifacts. Data on the safety and feasibility of EUS imaging in patients with surgically altered anatomy are limited. In a retrospective study of 188 patients who had upper GI surgery, EUS examination was generally successful, except in patients who had undergone Roux-en-Y surgery where the inability to reach the proximal duodenum precluded imaging of the head of the pancreas and common bile duct [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8884/abstract/5\">",
"     5",
"    </a>",
"    ]. EUS examination was successful in patients who had undergone Billroth II surgery as long as the afferent limb was intubated. The authors recommended performing an EGD prior to EUS to better define the anatomy and rule out strictures or a long Roux limb. Although EUS with altered anatomy may be generally successful, if a suspected lesion is not found on EUS, the possibility that the lesion is present but not being seen (false negative result) due to anatomic issues should be kept in mind.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H145486538\">",
"    <span class=\"h1\">",
"     TRAINING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal models have been proposed to demonstrate pancreaticobiliary anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8884/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. One found that a live swine model improved the ability to identify the mesenteric vein, vena cava, splenic mesenteric artery, celiac tree, pancreatic gland, and bile duct [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8884/abstract/8\">",
"     8",
"    </a>",
"    ]. This may potentially benefit those who are unable to undergo traditional methods of clinical training.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H145486587\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic ultrasound (EUS) provides high resolution images of the pancreatic duct as well as the parenchyma and complements the ductal images seen with endoscopic retrograde cholangiopancreatography (ERCP). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EUS examination of the pancreaticobiliary tract can be performed by using one of two approaches: starting with transgastric sonographic views and then proceeding transduodenally, or vice versa. The transgastric approach provides images of the pancreatic body and tail, whereas the transduodenal approach allows imaging of the pancreatic head (",
"      <a class=\"graphic graphic_table graphicRef69569 \" href=\"UTD.htm?25/10/25771\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The transgastric approach involves wedging the tip of the echoendoscope in the antrum and gradually pulling it back toward the body of the stomach using subtle movements. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transgastric imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transduodenal sonographic imaging is performed by wedging the tip of the echoendoscope into the apex of the duodenal bulb. The balloon of the echoendoscope is inflated, and the shaft of the echoendoscope is placed along the greater curvature of the stomach (the long position). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Transduodenal imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radial EUS imaging of the entire pancreas can be challenging in patients who have undergone upper gastrointestinal (GI) surgery, as normal landmarks have been lost and post-surgical inflammation or staples may cause artifacts. (See",
"      <a class=\"local\" href=\"#H148591716\">",
"       'Post-surgical imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Savides TJ. Normal radial anatomy by endoscopic ultrasound. In: Techniques in Gastrointestinal Endoscopy, Bhutani MS (Ed), WB Saunders, Philadelphia 2000. p.56.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8884/abstract/2\">",
"      Hawes RH, Zaidi S. Endoscopic ultrasonography of the pancreas. Gastrointest Endosc Clin N Am 1995; 5:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8884/abstract/3\">",
"      Rajan E, Clain JE, Levy MJ, et al. Age-related changes in the pancreas identified by EUS: a prospective evaluation. Gastrointest Endosc 2005; 61:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8884/abstract/4\">",
"      Ikeda M, Sato T, Morozumi A, et al. Morphologic changes in the pancreas detected by screening ultrasonography in a mass survey, with special reference to main duct dilatation, cyst formation, and calcification. Pancreas 1994; 9:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8884/abstract/5\">",
"      Wilson JA, Hoffman B, Hawes RH, Romagnuolo J. EUS in patients with surgically altered upper GI anatomy. Gastrointest Endosc 2010; 72:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8884/abstract/6\">",
"      Bhutani MS, Aveyard M, Stills HF Jr. Improved model for teaching interventional EUS. Gastrointest Endosc 2000; 52:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8884/abstract/7\">",
"      Bhutani MS, Wong RF, Hoffman BJ. Training facilities in gastrointestinal endoscopy: an animal model as an aid to learning endoscopic ultrasound. Endoscopy 2006; 38:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8884/abstract/8\">",
"      Barthet M, Gasmi M, Boustiere C, et al. EUS training in a live pig model: does it improve echo endoscope hands-on and trainee competence? Endoscopy 2007; 39:535.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2659 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8884=[""].join("\n");
var outline_f8_43_8884=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H145486587\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRANSGASTRIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TRANSDUODENAL IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AGE-RELATED CHANGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148591716\">",
"      POST-SURGICAL IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H145486538\">",
"      TRAINING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H145486587\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2659\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2659|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/50/26401\" title=\"diagnostic image 1\">",
"      Normal gallbladder EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/30/36327\" title=\"diagnostic image 2\">",
"      Splenic vein EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/56/16265\" title=\"diagnostic image 3\">",
"      Pancreatic parenchyma EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/25/22935\" title=\"diagnostic image 4\">",
"      Whales tail EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/41/30360\" title=\"diagnostic image 5\">",
"      Pancreatic duct EUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2659|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/40/10885\" title=\"figure 1\">",
"      Radial echoendoscope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2659|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/10/25771\" title=\"table 1\">",
"      Identified structures EUS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29591?source=related_link\">",
"      Endoscopic ultrasound in chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=related_link\">",
"      Endoscopic ultrasound in patients with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1929?source=related_link\">",
"      Endoscopic ultrasound in the staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_43_8885="Ivacaftor: Pediatric drug information";
var content_f8_43_8885=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ivacaftor: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?21/58/22437?source=see_link\">",
"    see \"Ivacaftor: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/1/30740?source=see_link\">",
"    see \"Ivacaftor: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13764717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kalydeco&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15801070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kalydeco&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F13821748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cystic Fibrosis Transmembrane Conductance Regulator Potentiator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F13821757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/58/22437?source=see_link\">",
"      see \"Ivacaftor: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cystic Fibrosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;6 years and Adolescents: Oral: 150 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Coadministration with CYP3A4 strong inhibitors (eg, ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, telithromycin): Oral: 150 mg twice",
"     <b>",
"      weekly",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Coadministration with CYP3A4 moderate inhibitors (eg, erythromycin, fluconazole): Oral: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Oral: 150 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Coadministration with CYP3A4 strong inhibitors (eg, ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, telithromycin): Oral: 150 mg twice",
"     <b>",
"      weekly",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Coadministration with CYP3A4 moderate inhibitors (eg, erythromycin, fluconazole): Oral: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Children &ge;6 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: No dosage adjustment provided in manufacturer's labeling (not studied); use with caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Children &ge;6 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate impairment (Child-Pugh class B): Oral: 150 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe impairment (Child-Pugh class C): Oral: Manufacturer recommends 150 mg once daily or less frequently; has not been studied, use with caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in patients who develop elevations of aminotransferases:",
"     </b>",
"     Children &ge;6 years, Adolescents, and Adults: ALT or AST &gt;5 times ULN: Oral: Hold ivacaftor; may resume if elevated transaminases resolved and after assessing benefits vs risks of continued treatment",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13764950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kalydeco&trade;: 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13821758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with high-fat-containing foods (eg, butter, cheese pizza, eggs, peanut butter).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13821754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13821749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cystic fibrosis (CF) in patients who have a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (FDA approved in ages &ge;6 years and adults);",
"     <b>",
"      Note:",
"     </b>",
"     Has not been shown effective in CF patients who are homozygous for the F508del mutation in the CFTR gene",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F13765399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Acne, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, musculoskeletal chest pain, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Nasal congestion, nasopharyngitis, oropharyngeal pain, pharyngeal erythema, pleuritic chest pain, rhinitis, sinus congestion, upper respiratory tract infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Bacteria in sputum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13821750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ivacaftor or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13821769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ivacaftor is a CYP3A substrate; strong CYP3A4 inducers (eg, rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, St John&rsquo;s wort) may reduce efficacy; concurrent use should be avoided. Consider dose reduction with concurrent moderate or strong CYP3A4 inhibitors (eg, erythromycin, ketoconazole, voriconazole) use; ivacaftor may inhibit CYP3A and P-gp substrates (eg, midazolam, diazepam, digoxin, cyclosporine, tacrolimus); monitor and use with caution. Not effective in CF patients who are homozygous for the CFTR gene F508del mutation; avoid use in these patients. Use with caution in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) or end-stage renal disease; ivacaftor use has not been studied. Cataracts  have been observed in animal studies using juvenile rats exposed to ivacaftor (at doses approximately one-tenth the maximum recommended human dose); cataracts have not been observed in studies involving older animals. It is unknown if this potential concern seen in animals studies is relevant to humans.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13821751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May increase hepatic transaminases; monitor liver function at baseline, every 3 months during first year of therapy and then periodically thereafter; temporarily discontinue treatment if ALT or AST &gt;5 times ULN; use with caution in hepatic impairment; dosage adjustment recommended in patients with moderate to severe (Child-Pugh class B or C) impairment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13769023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2C9 (weak), CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13769021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Ivacaftor. Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ivacaftor. Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: Ivacaftor may increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13821753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A high-fat meal increases the  exposure (ie, AUC) by two- to fourfold. Serum concentrations may be increased when taken with grapefruit or Seville oranges; avoid concurrent use.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13764718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13764719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13821759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CF mutation test (prior to therapy initiation if G551D mutation status unknown); ALT/AST at baseline, every 3 months for 1 year, then annually thereafter or as clinically indicated; FEV",
"     <sub>",
"      1",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13821755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potentiates epithelial cell chloride ion transport of defective (G551D mutant) cell-surface CFTR protein thereby improving the regulation of salt and water absorption and secretion in various tissues (eg, lung, gastrointestinal tract).",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13821779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: FEV",
"     <sub>",
"      1",
"     </sub>",
"     increased, sweat chloride decreased within ~2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13821756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Variable; increased (by two- to fourfold) with fatty foods",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 353 L &plusmn; 122 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~99%; primarily to alpha",
"     <sub>",
"      1",
"     </sub>",
"     acid glycoprotein, albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; extensive via CYP3A4; forms 2 major metabolites [M1 (active;",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      6",
"     </sub>",
"     potency) and M6 (inactive)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: ~12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Feces (88%, 65% of administered dose as metabolites); urine (minimal, as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13821799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/1/30740?source=see_link\">",
"      see \"Ivacaftor: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with a high-fat meal (eg, eggs, butter, peanut butter, cheese pizza); may take a couple of weeks to see effect, and a few months for full effect. Avoid grapefruit juice, Seville oranges; avoid herbal product St John&rsquo;s wort. Therapy may require periodic testing to check liver enzymes; may cause dizziness, headache, or nausea; notify the prescriber for worsening of any symptoms or development of any unanticipated effects.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Accurso FJ, Rowe SM, Clancy JP, et al, &ldquo;Effect of VX-770 in Persons With Cystic Fibrosis and the G551D-CFTR Mutation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(21):1991-2003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8885/abstract-text/21083385/pubmed\" id=\"21083385\" target=\"_blank\">",
"        21083385",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramsey BW, Davies J, McElvaney NG, et al, &ldquo;A CFTR Potentiator in Patients With Cystic Fibrosis and the G551D Mutation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(18):1663-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8885/abstract-text/22047557/pubmed\" id=\"22047557\" target=\"_blank\">",
"        22047557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83327 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8885=[""].join("\n");
var outline_f8_43_8885=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13764717\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15801070\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821748\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821757\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13764950\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821758\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821754\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821749\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13765399\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821750\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821769\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821751\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13769023\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13769021\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821753\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13764718\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13764719\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821759\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821755\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821779\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821756\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13821799\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83327\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83327|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/58/22437?source=related_link\">",
"      Ivacaftor: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/1/30740?source=related_link\">",
"      Ivacaftor: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_43_8886="Boari flap";
var content_f8_43_8886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Boari flap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 648px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These figures represent the Boari flap technique used to repair extensively damaged middle third ureters.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8886=[""].join("\n");
var outline_f8_43_8886=null;
var title_f8_43_8887="PCP x-ray and BAL";
var content_f8_43_8887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F88410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F88410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Radiographic and bronchoalveolar lavage features of PCP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 575px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with AIDS who develop PCP typically present with a cough, fever, and exertional dyspnea. A chest x-ray (Panel A) characteristically has interstitial and alveolar infiltrates in a perihilar distribution. In AIDS patients, BAL demonstrates the associated inflammatory cell burden, rich in lymphocytes (CD8",
"    <sup>",
"     +",
"    </sup>",
"    T cells) and macrophages, with a relative paucity of neutrophils (see the Wright-Giemsa stained smear in Panel B). A methenamine silver stained smear of BAL fluid from patients with AIDS (Panel C) reveals abundant numbers of Pneumocystis cyst forms. In immunocompromised patients without AIDS, PCP has a more fulminant onset and can rapidly progress to respiratory failure. The chest x-ray from such patients (Panel D) usually has diffuse lung infiltrates in a pattern that is consistent with severe lung injury, whereas the BAL fluid (see the Wright-Giemsa stained smear in Panel E) has an abundance of inflammatory cells, particularly neutrophils. A methenamine silver stain of the BAL fluid (Panel F) again demonstrates cyst forms, although usually significantly fewer than in patients with AIDS (compare with Panel C).",
"    <div class=\"footnotes\">",
"     PCP:",
"     <em>",
"      Pneumocystis",
"     </em>",
"     pneumonia; BAL: bronchoalveolar lavage.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with&nbsp;permission from Macmillan Publishers Ltd: Nature Reviews Microbiology. Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 2007; 5:298. Copyright &copy; 2007.",
"     <a href=\"file://www.nature.com/nrmicro\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      www.nature.com/nrmicro",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8887=[""].join("\n");
var outline_f8_43_8887=null;
var title_f8_43_8888="Cheyne-Stokes breathing and obstructive sleep apnea in heart failure";
var content_f8_43_8888=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/43/8888/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/43/8888/contributors\">",
"     Atul Malhotra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/43/8888/contributors\">",
"     James C Fang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/43/8888/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/43/8888/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/43/8888/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/43/8888/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/43/8888/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of sleep disordered breathing are common among patients with heart failure: obstructive sleep apnea (OSA) and Cheyne-Stokes breathing (CSB):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      OSA is characterized by reductions or cessations of airflow during sleep, despite ongoing respiratory effort. It is due to upper airway obstruction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H18#H18\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Obstructive sleep apnea syndromes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CSB is characterized by cyclic crescendo-decrescendo respiratory effort and airflow during wakefulness or sleep, without upper airway obstruction. When the decrescendo effort is accompanied by apnea during sleep, it is considered a type of central sleep apnea syndrome (CSAS). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H20#H20\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Central sleep apnea syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H22#H22\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Cheyne-Stokes breathing pattern'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We refer to OSA and CSB collectively as sleep disordered breathing (SDB) in this review. They frequently coexist and can be clinically difficult to distinguish from one another because there is overlap in pathophysiology and clinical manifestations. SDB in patients with heart failure is under-recognized but important because it may independently predict mortality due to heart failure and may contribute to disease progression.",
"   </p>",
"   <p>",
"    In this review, the prevalence, risk factors, pathogenesis, clinical manifestations, diagnosis, and treatment of SDB in patients with heart failure are discussed. In addition, the impact of treatment on heart failure-related outcomes is reviewed. The impact of treatment on SDB-related outcomes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=see_link\">",
"     \"Central sleep apnea: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;While obstructive sleep apnea (OSA) is more common than Cheynes-Stokes breathing (CSB) in the general population, CSB may be more common than OSA in patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Single-center observational studies estimate that the prevalence of SDB may be as high as 50 percent among all patients with heart failure and as high as 70 percent among patients with heart failure who are referred to a sleep laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The prevalence may be even higher among patients with acute decompensated heart failure, as suggested by a study that detected an apnea hypopnea index &ge;10 events per hour of sleep in 22 out of 29 such patients (76 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such prevalence estimates are limited by referral bias, variable definitions of SDB, variable severities of heart failure, and variable optimization of the medical management of the heart failure.",
"   </p>",
"   <p>",
"    SDB appears to be common even among patients whose heart failure is optimally managed. A prospective cohort study followed 108 patients who visited a heart failure clinic with stable heart failure, which was defined as clinical stability without hospitalizations or medication changes within the past 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/6\">",
"     6",
"    </a>",
"    ]. SDB was detected in 61 percent of patients and was independently associated with the presence of atrial fibrillation and a worse New York Heart Association (NYHA) functional class.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for sleep disordered breathing (SDB) in patients with heart failure vary according to the type of SDB. With respect to Cheynes-Stokes breathing (CSB), risk factors include male gender, advanced age, atrial fibrillation, and hypocapnia (ie, transcutaneous carbon dioxide &le;38 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/4\">",
"     4",
"    </a>",
"    ]. With respect to OSA, risk factors include advanced age and an increasing body mass index (BMI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of OSA and Cheynes-Stokes breathing (CSB) are best conceptualized as distinct processes, although they share common pathophysiologic principles:",
"   </p>",
"   <p>",
"    The pathogenesis of obstructive sleep apnea (OSA) involves abnormalities in pharyngeal anatomy, pharyngeal function, and ventilatory control. In patients with heart failure, edema of the upper airway is an additional factor that may contribute to pharyngeal airway narrowing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/7\">",
"     7",
"    </a>",
"    ]. The pathogenesis of OSA is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24454?source=see_link\">",
"     \"Mechanisms and anatomic sites of upper airway obstruction in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of CSB is uncertain, but the favored hypothesis is based on the observation that patients who have heart failure and CSB tend to have lower arterial carbon dioxide tensions (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) than patients who have heart failure without CSB [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. It is best conceptualized as a sequence of events:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an effort to correct the hypocapnia, a hypersensitive respiratory control center initiates an apnea. This occurs when the PaCO",
"      <sub>",
"       2",
"      </sub>",
"      is below the \"apneic threshold\". The PaCO",
"      <sub>",
"       2",
"      </sub>",
"      then begins to rise.",
"     </li>",
"     <li>",
"      The duration from the beginning of the apnea until the respiratory control center detects the increasing PaCO",
"      <sub>",
"       2",
"      </sub>",
"      is prolonged due to the increased circulatory time caused by the heart failure. Although some circulatory delay is required for CSB to occur, its importance as a contributor to CSB is debated [",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypercapnia exists by the time the respiratory control center terminates the apnea.",
"     </li>",
"     <li>",
"      The hypercapnia then stimulates robust hyperpnea, which yields marked hypocapnia and allows the cycle of events to repeat.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The net effect is oscillation of ventilation between apnea and hyperpnea. Elimination of the hypocapnia with inhaled CO",
"    <sub>",
"     2",
"    </sub>",
"    , continuous positive airway pressure (CPAP), or oxygen can markedly attenuate CSB [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both OSA and CSB can impair systolic and diastolic cardiac function by a variety of mechanisms. First, intermittent hypoxemia and arousals induce adrenergic surges that may lead to heart disease progression. Second, the extremely negative intrapleural pressures increase ventricular transmural wall stress and afterload [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The second mechanism can be described in detail as follows. Transmural pressure of the left ventricle is the pressure inside the left ventricle minus the pressure outside the left ventricle (ie, approximately the intrathoracic or pleural pressure). During spontaneous inspiration, the intrathoracic pressure becomes more negative, which increases the transmural pressure. The increase in transmural pressure contributes to left ventricular wall stress during left ventricular ejection (ie, afterload). This effect is greater in patients with heart failure who must generate more negative intrathoracic pressures to overcome low lung compliance caused by pulmonary congestion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sleep history should be sought from both the patient and the spouse because, in many cases, it is only the spouse who is aware of the abnormal ventilatory pattern. Sleep disordered breathing (SDB) can be asymptomatic or symptomatic in patients who have heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When obstructive sleep apnea (OSA) is the predominant type of SDB, poor sleep quality and snoring are common. As a result, sleep disruption and easy fatigability often exist and may be out of proportion to the severity of the heart failure. However, sleepiness is relatively uncommon in patients with heart failure for reasons that remain unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When Cheynes-Stokes breathing (CSB) is the predominant type of SDB, symptoms due to CSB may be indistinguishable from those due to the heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/1\">",
"       1",
"      </a>",
"      ]. Symptoms of poor sleep quality (eg, excessive daytime sleepiness) are subtle and generally unreliable. Occasionally, patients with CSB report paroxysmal nocturnal dyspnea (due to the hyperpnea that follows an apnea) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SDB may contribute to nocturnal angina in patients with heart failure, presumably due to hypoxemia and catecholamine surges [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, recurrent arrhythmias may occur, such as atrial fibrillation or ventricular tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/4,20\">",
"     4,20",
"    </a>",
"    ]. These arrhythmias often occur in the absence of any symptoms or signs of SDB. Thus, a high index of suspicion should be maintained and evaluation for SDB should be considered in heart failure patients with recurrent arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of suspected sleep disordered breathing (SDB) is the same for patients with or without heart failure. An in-laboratory overnight polysomnogram is the gold standard diagnostic test. In-home portable monitoring is also available. These tests are described separately, as are the diagnostic criteria for obstructive sleep apena (OSA) and central sleep apnea syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=see_link\">",
"     \"Portable monitoring in obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=see_link\">",
"     \"Central sleep apnea: Risk factors, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with heart failure who report snoring, excessive daytime somnolence or fatigue, and poor sleep quality should have their sleep patterns assessed via polysomnography in a sleep laboratory. Polysomnography should also be considered in patients with heart failure who have nocturnal angina, recurrent arrhythmias, refractory heart failure symptoms, or in whom an abnormal respiratory pattern has been witnessed.",
"   </p>",
"   <p>",
"    The 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on the diagnosis and treatment of chronic heart failure indicate that screening for SDB is reasonable in selected patients (eg, those with risk factors) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link&amp;anchor=H27159755#H27159755\">",
"     \"Cardiovascular effects of obstructive sleep apnea\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure accompanied by sleep disordered breathing (SDB) is associated with a worse prognosis than heart failure in the absence of SDB [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/22\">",
"     22",
"    </a>",
"    ]. This is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With respect to obstructive sleep apnea (OSA), a prospective cohort study followed 164 patients who had heart failure and a left ventricular ejection fraction of 45 percent or less [",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/23\">",
"       23",
"      </a>",
"      ]. At a mean of three years, patients who had OSA (defined as an apnea hypopnea index (AHI) of at least 15 events per hour) had a higher cardiac mortality than patients who did not have OSA (8.7 versus 4.2 deaths per 100 patient-years).",
"     </li>",
"     <li>",
"      With respect to Cheynes-Stokes breathing (CSB), a prospective cohort study followed 62 patients with NYHA class II to III heart failure&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/24\">",
"       24",
"      </a>",
"      ]. At a mean of 28 months, cardiac mortality was associated with an AHI greater than 30 events per hour. The AHI was a better predictor of cardiac mortality than demographic variables, Holter monitoring, exercise studies, echocardiography, or autonomic testing. CSB was found to predict mortality in numerous other studies of patients with heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/2,25-28\">",
"       2,25-28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies do not definitively indicate whether SDB is associated with increased cardiac mortality because it is a marker of more severe heart failure, a precipitant of worsening heart failure, or both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two aspects of therapy to consider in patients with heart failure complicated by sleep disordered breathing (SDB): the impact of heart failure therapy on SDB and the impact of SDB therapy on heart failure.",
"   </p>",
"   <p>",
"    With respect to the impact of heart failure therapy on SDB, case series and observational studies suggest that the following interventions are associated with improved SDB: medical management (eg, ACE inhibitors, beta blockers, and diuretics) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/7,23,29,30\">",
"     7,23,29,30",
"    </a>",
"    ], cardiac transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/31-33\">",
"     31-33",
"    </a>",
"    ], cardiac resynchronization (ie, biventricular pacing) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], and left ventricular assist device (LVAD) implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/37\">",
"     37",
"    </a>",
"    ]. These interventions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=see_link\">",
"     \"Management of refractory heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The impact of SDB therapy on heart failure-related outcomes is the focus of this section. A major limitation with this body of evidence is that most studies evaluated the impact of SDB therapy on surrogate outcomes (eg, blood pressure, catecholamine levels, cardiac function) and did not measure clinically important outcomes (eg, quality of life, hospitalizations, mortality, functional class).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Positive airway pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have heart failure complicated by obstructive sleep apnea (OSA) or Cheynes-Stokes breathing (CSB), positive airway pressure may improve cardiac function, blood pressure, exercise capacity, and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/13,26,38-44\">",
"     13,26,38-44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      OSA &ndash; With respect to patients whose heart failure is complicated by OSA, two small randomized trials (n = 55, n = 24) found that CPAP improved left ventricular ejection fraction compared to untreated controls [",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/39,40\">",
"       39,40",
"      </a>",
"      ], although this finding has not been universal [",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/41\">",
"       41",
"      </a>",
"      ]. A randomized trial that directly compared CPAP to bilevel positive airway pressure (BPAP) found greater improvement in cardiac function among patients receiving BPAP [",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CSB &ndash; With respect to patients whose heart failure is complicated by CSB, positive airway pressure appears to improve exercise capacity, cardiac function, and nocturnal oxygenation, while decreasing catecholamine levels [",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/13,26,38,44\">",
"       13,26,38,44",
"      </a>",
"      ]. The best data come from the Canadian Positive Airway Pressure (CANPAP) trial in which 258 patients who had heart failure and CSAS were randomly assigned to receive CPAP or no CPAP for two years [",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/38\">",
"       38",
"      </a>",
"      ]. The CPAP group had a greater reduction in the apnea hypopnea index (AHI), as well as greater improvements in mean nocturnal arterial oxyhemoglobin saturation, left ventricular ejection fraction, and the six-minute walk distance than the control group. However, there were no differences in the number of hospitalizations, quality of life, or transplant-free survival. There was an early mortality hazard associated with CPAP use, which may have been related to decreases in cardiac output among patients who were particularly preload dependent (eg, hypovolemic patients, patients with atrial fibrillation).",
"      <br/>",
"      <br/>",
"      In a post hoc subgroup analysis from the CANPAP trial, patients whose AHI was reduced to less than 15 events per hour by CPAP therapy had significant improvement in ejection fraction and transplant-free survival compared to controls, although the latter barely reached statistical significance (",
"      <a class=\"graphic graphic_figure graphicRef83625 \" href=\"UTD.htm?40/34/41518\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/44\">",
"       44",
"      </a>",
"      ]. There are two potential interpretations of this result. First, therapies that effectively and consistently lower the AHI may improve outcomes. Alternatively, improvement of AHI may not be a result of the CPAP per se, but simply a marker of a good prognosis that is unrelated to CPAP therapy.",
"      <br/>",
"      <br/>",
"      Adaptive servoventilation (ASV), a modified method of delivering positive airway pressure, may also be effective in heart failure patients with SDB. This was illustrated in a meta-analysis of 14 randomized studies comparing ASV to a control condition (subtherapeutic ASV, CPAP, supplemental oxygen or no treatment) in adult patients with stable heart failure, which found that ASV significantly improved AHI, left ventricular ejection fraction, and exercise capacity [",
"      <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/45\">",
"       45",
"      </a>",
"      ]. There are ongoing large randomized trials that will further clarify the role of ASV in this patient population. Until results are available, the role of ASV is primarily in symptomatic patients who fail or do not tolerate CPAP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=see_link&amp;anchor=H902709#H902709\">",
"       \"Central sleep apnea: Treatment\", section on 'Adaptive servo-ventilation (ASV)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unknown whether positive airway pressure therapy improves heart failure-related mortality in patients with sleep apnea. A retrospective cohort study of 30,719 patients with newly diagnosed heart failure found that patients who were tested, diagnosed, and treated for sleep apnea with positive airway pressure therapy, supplemental oxygen, or both, had a better two-year overall survival than patients who were tested and diagnosed with sleep apnea but not treated (hazard ratio 0.49, 95% CI 0.29-0.84) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/46\">",
"     46",
"    </a>",
"    ]. However, the study did not distinguish heart failure-related mortality from mortality due to other causes, distinguish patients with OSA from patients with CSB, or define the severity of the sleep apnea. It is difficult to draw conclusions about treatments effects from such observational studies, since therapy may be a marker of a good prognosis rather than the cause of an improved cardiac outcome.",
"   </p>",
"   <p>",
"    Taken together, the evidence suggests that positive airway pressure may improve heart failure-related outcomes in patients who have persistent SDB despite optimization of their heart failure. The treatment of SDB, including indications and the choice of therapy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=see_link\">",
"     \"Central sleep apnea: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nocturnal oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of supplemental oxygen to treat CSB is controversial. Some clinical trials have demonstrated that low flow nocturnal oxygen (2 to 3",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    reduces CSB and improves left ventricular function, heart failure functional class, sleep quality, and cognitive function [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/14,30,47-49\">",
"     14,30,47-49",
"    </a>",
"    ]. However, oxygen may also increase oxidant injury and reduce cardiac function, especially in high concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Long-term outcome data are required before routine use of nocturnal supplemental oxygen can be recommended in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    in patients with heart failure complicated by SDB was evaluated in a double-blind cross-over trial of 15 such patients who received either theophylline or placebo twice daily for five days [",
"    <a class=\"abstract\" href=\"UTD.htm?8/43/8888/abstract/53\">",
"     53",
"    </a>",
"    ]. Theophylline reduced the number of apneas plus hypopneas, as well as the percentage of sleep time during which the arterial oxyhemoglobin saturation was less than 90 percent. Clinical outcome data are required before routine use of theophylline can be recommended in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two types of sleep disordered breathing are common among patients with heart failure: obstructive sleep apnea (OSA) and Cheyne-Stokes breathing (CSB). They are referred to collectively as sleep-disordered breathing (SDB). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have heart failure and SDB can be asymptomatic or symptomatic. Symptoms typically include snoring",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      consequences of disrupted sleep (eg, excessive daytime sleepiness, fatigue). Nocturnal angina, paroxysmal nocturnal dyspnea, and recurrent refractory arrhythmias may occur with either type of SDB. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The routine evaluation of patients with heart failure should include questions about potential SDB symptoms. Patients who report snoring, excessive daytime fatigue, or poor sleep quality may benefit from assessment via polysomnography in a sleep laboratory. Polysomnography should also be considered in patients with heart failure who have nocturnal angina, recurrent arrhythmias, or refractory heart failure symptoms. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heart failure accompanied by SDB is associated with a worse prognosis than heart failure in the absence of SDB. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary therapy for patients whose heart failure is complicated by SDB is optimization of the medical management of heart failure because it improves both heart failure-related and SDB-related outcomes. For patients who have persistent SDB despite the optimization of heart failure therapy, positive airway pressure may also improve both heart failure-related and SDB-related outcomes. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of SDB, including indications and the choice of therapy, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"       \"Management of obstructive sleep apnea in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=see_link\">",
"       \"Central sleep apnea: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/1\">",
"      Javaheri S, Parker TJ, Liming JD, et al. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. Circulation 1998; 97:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/2\">",
"      Corr&agrave; U, Pistono M, Mezzani A, et al. Sleep and exertional periodic breathing in chronic heart failure: prognostic importance and interdependence. Circulation 2006; 113:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/3\">",
"      Javaheri S, Parker TJ, Wexler L, et al. Occult sleep-disordered breathing in stable congestive heart failure. Ann Intern Med 1995; 122:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/4\">",
"      Sin DD, Fitzgerald F, Parker JD, et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 1999; 160:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/5\">",
"      Padeletti M, Green P, Mooney AM, et al. Sleep disordered breathing in patients with acutely decompensated heart failure. Sleep Med 2009; 10:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/6\">",
"      MacDonald M, Fang J, Pittman SD, et al. The current prevalence of sleep disordered breathing in congestive heart failure patients treated with beta-blockers. J Clin Sleep Med 2008; 4:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/7\">",
"      Bucca CB, Brussino L, Battisti A, et al. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest 2007; 132:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/8\">",
"      Naughton M, Benard D, Tam A, et al. Role of hyperventilation in the pathogenesis of central sleep apneas in patients with congestive heart failure. Am Rev Respir Dis 1993; 148:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/9\">",
"      Hanly P, Zuberi N, Gray R. Pathogenesis of Cheyne-Stokes respiration in patients with congestive heart failure. Relationship to arterial PCO2. Chest 1993; 104:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/10\">",
"      Leung RS, Bradley TD. Sleep apnea and cardiovascular disease. Am J Respir Crit Care Med 2001; 164:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/11\">",
"      Steens RD, Millar TW, Su X, et al. Effect of inhaled 3% CO2 on Cheyne-Stokes respiration in congestive heart failure. Sleep 1994; 17:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/12\">",
"      Naughton MT, Benard DC, Rutherford R, Bradley TD. Effect of continuous positive airway pressure on central sleep apnea and nocturnal PCO2 in heart failure. Am J Respir Crit Care Med 1994; 150:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/13\">",
"      Naughton MT, Benard DC, Liu PP, et al. Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea. Am J Respir Crit Care Med 1995; 152:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/14\">",
"      Hanly PJ, Millar TW, Steljes DG, et al. The effect of oxygen on respiration and sleep in patients with congestive heart failure. Ann Intern Med 1989; 111:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/15\">",
"      Malhotra A, Muse VV, Mark EJ. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 12-2003. An 82-year-old man with dyspnea and pulmonary abnormalities. N Engl J Med 2003; 348:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/16\">",
"      Naughton MT, Rahman MA, Hara K, et al. Effect of continuous positive airway pressure on intrathoracic and left ventricular transmural pressures in patients with congestive heart failure. Circulation 1995; 91:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/17\">",
"      Lanfranchi PA, Somers VK, Braghiroli A, et al. Central sleep apnea in left ventricular dysfunction: prevalence and implications for arrhythmic risk. Circulation 2003; 107:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/18\">",
"      Arzt M, Young T, Finn L, et al. Sleepiness and sleep in patients with both systolic heart failure and obstructive sleep apnea. Arch Intern Med 2006; 166:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/19\">",
"      Franklin KA, Nilsson JB, Sahlin C, N&auml;slund U. Sleep apnoea and nocturnal angina. Lancet 1995; 345:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/20\">",
"      Javaheri S. Effects of continuous positive airway pressure on sleep apnea and ventricular irritability in patients with heart failure. Circulation 2000; 101:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/21\">",
"      Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/22\">",
"      Wang H, Parker JD, Newton GE, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol 2007; 49:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/23\">",
"      Dark DS, Pingleton SK, Kerby GR, et al. Breathing pattern abnormalities and arterial oxygen desaturation during sleep in the congestive heart failure syndrome. Improvement following medical therapy. Chest 1987; 91:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/24\">",
"      Lanfranchi PA, Braghiroli A, Bosimini E, et al. Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation 1999; 99:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/25\">",
"      Findley LJ, Zwillich CW, Ancoli-Israel S, et al. Cheyne-Stokes breathing during sleep in patients with left ventricular heart failure. South Med J 1985; 78:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/26\">",
"      Sin DD, Logan AG, Fitzgerald FS, et al. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 2000; 102:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/27\">",
"      Hanly PJ, Zuberi-Khokhar NS. Increased mortality associated with Cheyne-Stokes respiration in patients with congestive heart failure. Am J Respir Crit Care Med 1996; 153:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/28\">",
"      Brack T, Th&uuml;er I, Clarenbach CF, et al. Daytime Cheyne-Stokes respiration in ambulatory patients with severe congestive heart failure is associated with increased mortality. Chest 2007; 132:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/29\">",
"      Solin P, Bergin P, Richardson M, et al. Influence of pulmonary capillary wedge pressure on central apnea in heart failure. Circulation 1999; 99:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/30\">",
"      Walsh JT, Andrews R, Starling R, et al. Effects of captopril and oxygen on sleep apnoea in patients with mild to moderate congestive cardiac failure. Br Heart J 1995; 73:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/31\">",
"      Murdock DK, Lawless CE, Loeb HS, et al. The effect of heart transplantation on Cheyne-Stokes respiration associated with congestive heart failure. J Heart Transplant 1986; 5:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/32\">",
"      Braver HM, Brandes WC, Kubiet MA, et al. Effect of cardiac transplantation on Cheyne-Stokes respiration occurring during sleep. Am J Cardiol 1995; 76:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/33\">",
"      Mansfield DR, Solin P, Roebuck T, et al. The effect of successful heart transplant treatment of heart failure on central sleep apnea. Chest 2003; 124:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/34\">",
"      Stanchina ML, Ellison K, Malhotra A, et al. The impact of cardiac resynchronization therapy on obstructive sleep apnea in heart failure patients: a pilot study. Chest 2007; 132:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/35\">",
"      Sinha AM, Skobel EC, Breithardt OA, et al. Cardiac resynchronization therapy improves central sleep apnea and Cheyne-Stokes respiration in patients with chronic heart failure. J Am Coll Cardiol 2004; 44:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/36\">",
"      Sharafkhaneh A, Sharafkhaneh H, Bredikus A, et al. Effect of atrial overdrive pacing on obstructive sleep apnea in patients with systolic heart failure. Sleep Med 2007; 8:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/37\">",
"      Padeletti M, Henriquez A, Mancini DM, Basner RC. Persistence of Cheyne-Stokes breathing after left ventricular assist device implantation in patients with acutely decompensated end-stage heart failure. J Heart Lung Transplant 2007; 26:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/38\">",
"      Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005; 353:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/39\">",
"      Mansfield DR, Gollogly NC, Kaye DM, et al. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med 2004; 169:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/40\">",
"      Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 2003; 348:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/41\">",
"      Smith LA, Vennelle M, Gardner RS, et al. Auto-titrating continuous positive airway pressure therapy in patients with chronic heart failure and obstructive sleep apnoea: a randomized placebo-controlled trial. Eur Heart J 2007; 28:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/42\">",
"      Khayat RN, Abraham WT, Patt B, et al. Cardiac effects of continuous and bilevel positive airway pressure for patients with heart failure and obstructive sleep apnea: a pilot study. Chest 2008; 134:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/43\">",
"      K&ouml;hnlein T, Welte T, Tan LB, Elliott MW. Assisted ventilation for heart failure patients with Cheyne-Stokes respiration. Eur Respir J 2002; 20:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/44\">",
"      Arzt M, Floras JS, Logan AG, et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 2007; 115:3173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/45\">",
"      Sharma BK, Bakker JP, McSharry DG, et al. Adaptive servoventilation for treatment of sleep-disordered breathing in heart failure: a systematic review and meta-analysis. Chest 2012; 142:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/46\">",
"      Javaheri S, Caref EB, Chen E, et al. Sleep apnea testing and outcomes in a large cohort of Medicare beneficiaries with newly diagnosed heart failure. Am J Respir Crit Care Med 2011; 183:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/47\">",
"      Andreas S, Clemens C, Sandholzer H, et al. Improvement of exercise capacity with treatment of Cheyne-Stokes respiration in patients with congestive heart failure. J Am Coll Cardiol 1996; 27:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/48\">",
"      Sasayama S, Izumi T, Seino Y, et al. Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-stokes respiration. Circ J 2006; 70:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/49\">",
"      Krachman SL, Nugent T, Crocetti J, et al. Effects of oxygen therapy on left ventricular function in patients with Cheyne-Stokes respiration and congestive heart failure. J Clin Sleep Med 2005; 1:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/50\">",
"      Mak S, Azevedo ER, Liu PP, Newton GE. Effect of hyperoxia on left ventricular function and filling pressures in patients with and without congestive heart failure. Chest 2001; 120:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/51\">",
"      Mak S, Egri Z, Tanna G, et al. Vitamin C prevents hyperoxia-mediated vasoconstriction and impairment of endothelium-dependent vasodilation. Am J Physiol Heart Circ Physiol 2002; 282:H2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/52\">",
"      Haque WA, Boehmer J, Clemson BS, et al. Hemodynamic effects of supplemental oxygen administration in congestive heart failure. J Am Coll Cardiol 1996; 27:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/43/8888/abstract/53\">",
"      Javaheri S, Parker TJ, Wexler L, et al. Effect of theophylline on sleep-disordered breathing in heart failure. N Engl J Med 1996; 335:562.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7682 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8888=[""].join("\n");
var outline_f8_43_8888=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Positive airway pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nocturnal oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7682\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7682|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/34/41518\" title=\"figure 1\">",
"      Effect of CPAP on CSA associated with HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=related_link\">",
"      Central sleep apnea: Risk factors, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=related_link\">",
"      Central sleep apnea: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=related_link\">",
"      Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=related_link\">",
"      Management of refractory heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24454?source=related_link\">",
"      Mechanisms and anatomic sites of upper airway obstruction in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=related_link\">",
"      Portable monitoring in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_43_8889="Loiasis prevalence map";
var content_f8_43_8889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Map of the estimated prevalence of eye worm history in Africa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 409px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGZAkADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1n4ZeAfB158NvCd1eeE/D9xczaTaSSzS6bCzyOYUJZiVySSSSTXTf8K48D/8AQm+G/wDwVwf/ABNHwn/5JZ4N/wCwLZf+iErqqAOV/wCFceB/+hN8N/8Agrg/+Jo/4Vx4H/6E3w3/AOCuD/4muqooA5X/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/ia6qigDlf8AhXHgf/oTfDf/AIK4P/iaP+FceB/+hN8N/wDgrg/+JrqqKAOV/wCFceB/+hN8N/8Agrg/+Jo/4Vx4H/6E3w3/AOCuD/4muqooA5X/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/ia6qigDx34y+C/Bul+ArmSz8MeH7W9mubWCAw6fCksjNPGCiYXJJXdwOcZruP8AhXHgf/oTfDf/AIK4P/iaxLS7tPFnxciuLG4gvtM8NWDjzYZN6JfTuUZcjgukUbAjqvm9s16LQByv/CuPA/8A0Jvhv/wVwf8AxNH/AArjwP8A9Cb4b/8ABXB/8TXVUUAcr/wrjwP/ANCb4b/8FcH/AMTR/wAK48D/APQm+G//AAVwf/E11VFAHK/8K48D/wDQm+G//BXB/wDE0f8ACuPA/wD0Jvhv/wAFcH/xNdVRQByv/CuPA/8A0Jvhv/wVwf8AxNH/AArjwP8A9Cb4b/8ABXB/8TXVUUAcr/wrjwP/ANCb4b/8FcH/AMTR/wAK48D/APQm+G//AAVwf/E11VFAHK/8K48D/wDQm+G//BXB/wDE0f8ACuPA/wD0Jvhv/wAFcH/xNdVRQByv/CuPA/8A0Jvhv/wVwf8AxNH/AArjwR/0Jvhr/wAFcH/xNdVXA+I9S1HxVrNz4W8L3Mtla25CazrMJw1sCM/Zrc952BGW6RKc/eKgAHJ6n4P8J+MNdn0Dw34Y8P2mlWcnl6rqsGmwhmYfetbdgvD/AN+QH5Og+Y/L3Mvw08GERiHwn4cj2dQdKgbcMdCSmfxrodH0mx0TSLbStHt0srK2j8uGKJeEA/me5J5JJJ5NXQyliu4FlxkelNaaoW+jPONR+H2kxyL9m8C+EJI0O75NOh/eD+6QU+X6gn6VDbfDTwxeGG4svCnh+zYMyXENxp0UyjuGQ7cMOnfGD6ivTXUsOGKn1FVx5cDKxXG1djPtxx+HvXRGv7tlFX/rfoYSo3d23Y861H4aeDoraOzvNE8P28zFpIrtdKhQEjJZX4x0PA4HHHStqw+GngS1skH/AAi3h+4Xr50unQOWz3zt/lxXWXyW88DR3USzR9ShGc/hVPS7ezt2lk0xUERO14on+UEd9vQHjHaiU+enZ/krf8AFDkndf8ExG+G/g14pPL8I+G43b7pbSIDs/DbzVM+AfB5iEdz4J8PwzA/NJDpELoR6j5M9Py966EXSLcC4ikdV/wCWlrNJ5RjY98H+XTuKu/2nHtGI5N5ztU4wcd85xilyOPS5XMn1OUtvBHw+mle3h8LeG5J1PzK2lwqwB742VTHgDwl581ufDHhmQohIeLSbbdkeq7DluR0wMV3EMMFzBG67FdcjdC/3TnJGfrVTyEjcz2l3BJ+8yfOYEITwcEYPPoc048l3p9/cl81l+hgWfgHwdPM4bwR4bRFOG3abbkg4HTCkY69TmrR+HHglSSfCHhvHYf2VB/8AE1uW1jKkibmjhiB3skOQXf8A2mPUY7VT8U69Y+HrOS8127t7LTztSKd8lhKTwoTq7HqAoJ4NZyUW/dNIt21Oeuvh/wCF3kiS18C+Ho9zAmVtOtioUdQRtODz2B5rn/gz4F8Jaj8MdButR8LaDdXckTeZNNp0Lu5EjDJJXJ6V0UPxU8KPEGtby9v4UGJbmx0y5mhjOAfmZEIB56Z471mfCKG8ufhf4esIjcW0Ulu7zTFSjoplcgKTzuYEduB74oVptLRJdRP3Nd7mlqPgnwdbXKRReBvDMjP8saf2bBvkPcgbOFHGWP8Ahm5afDTwZHABceEvDcsx5dhpcAGfYbeBXRWWm2ljMrR72nK7A8srO5UdgSenfH41fY4BJzgUTlGyjBDjF3vI4yDwF4Jed4ZPA+gROpO0tpUBVx6ghf0PNWR8OfA56eDfDX/grg/+JrommSceVDNskYZB2847kZqaKNYo1RBhRUSXyKizkbb4d+DXEnn+CPDURDlVxp0Dbl7N9zjPpU//AArjwP8A9Cb4b/8ABXB/8TXVVHOjPEyo5QkY3DqKW7HsjjpfA3gRJmgXwX4eeYYwi6TDzkZ67eB7mkj+GvhBpW8/wh4b8t1wFTS4BsP125P1rsIbeKHHlIFwMcVDLJOLlzARIFABhbC9f4g307Vas9I/j/WhDv8AaOXsPhr4Qjg23fhLwxLIGOGXSoB8ueM/L1xVg/DjwRkf8Ud4bx3H9lwf/E100c6uyLtZXYFtrDkD39KFuYGkKCRd+cYPGT7etS7tt2KVkrHN/wDCuPA//Qm+G/8AwVwf/E1DN4A8CxOif8IZ4caR/uoulwZPv93gV2FV7cKbi4ccncFznpgDj8yaSS3Y35HGxfD/AMGXN1PH/wAIh4aiSPapUaXblskZ/u8cfWpLT4b+Chujk8J+HWeP5cHTbc8ZOGPydcfyrrbW0W3klk3u7ytuZmP5D8OlOig2XE0xd2aTAwcYUDsPzJrSUo6pEKL3Zy9v8N/BiwoJvB/hp5AMMw0qAZPr92pP+FceCP8AoTfDf/grg/8Aia6dXzKyEEYAIJI5qSs3uWjzPUfAvhO11R7NfBvh5kni327JptupBHDglkPPzAjA7dKydc8FeFR8R/B+i/8ACL+H7OzaC5vnc6ZBm9kjj8sW/CgcCUynIOfLXHTI9U1O0iujbeaOY5dynJBBwehHSuM8ORjxP8SdV1+RGk03REOkaY79DPk/a5VBHXISLcOvluBx11qTjKMbLXqZwi4yd3oa/wDwrjwP/wBCb4b/APBXB/8AE0f8K48D/wDQm+G//BXB/wDE11VFYmp4x8WPA/hPSYvDGpWPhbQ4BHrVvbXATT4RG8M2YmDrtwQCykEjggYqQ+DfCwJB8LeHsj/qFwf/ABFd38S9CuvEngjU9N02RI9QYJPas/3fOidZIwfQFkAJ7A15v4g8WIvw11LxTaLcWp+yyPGph8x7ecOYypXodkmQT04z0rrwzjZ8x5mPjLmi49dC5/wh3hb/AKFbw9/4K4P/AIij/hDvC3/QreHv/BXB/wDEVQ+Gvi2x8U+GrF01a2vtXjt1N8iKI5FfOCSg6D3HB68ZxXV11xUJK6R5s3OD5WzD/wCEO8Lf9Ct4e/8ABXB/8RR/wh3hb/oVvD3/AIK4P/iK3KKrkj2J55dzD/4Q7wt/0K3h7/wVwf8AxFc1pjeA9Q8X6h4bTwno8V/ZjJaXSbYRzYClghwSSA65BA616DXld54f1KW98V6rYWsserWGrLf6czxlRcAW8avGD3VxuTjvj0qJxStZGtJ81+ZnTeHNH8HeINFt9Ts/CeiJbz7tqy6VbhhtYqcgKR1B71X8ceE/DUHgfxJNB4b0KKaLS7uSOSPToUZGWFyGUhcgggEEVZ+E0FzbfD7SIr62ntLgLIXhnQo6Zlc4IPI4IrR8ff8AIg+Kf+wRef8Aoh6TinC9ugczVSyfU7r4T/8AJLPBv/YFsv8A0QldVXK/Cf8A5JZ4N/7Atl/6ISuqryz6IKKK5uXxx4aW41O2i1qwnvtOjkkuLWK4VpVCKWYbc8kAHPp3xQB0lYPivxXpnhiO2F+bia7u2KWtjZwtPc3BAy2yNeSFHJPQDqeRXJ6ZqvjXxzplpLa2UPhLSLuJJzfG5S7u5YnAYCJANkZIPLPuxnhT1rpvC/g3TPD13cXsL3l7qlwgil1DULhri4aMHIQM33VzztXAzzigDGj+K3htP+QkusaUFYRytqGlXECQOcbVkcpsUkEMMnGD1qyPip4E8/yf+Es0ffuZSTcrtBXrlun0557ZrtCMjBrzn4NLDb+Gbjw9qFolprFhczS3tg0YCRedPJKhj7NFydjc/dOcEEAAmbxnqPii8a2+G8dheW0H/H1rF8H+xq2OIoguGlfnJIIVR1JJwJv7N+I0/wDrPEvhq1/64aNLJj/vq4rugMDjpRQBwh8PeOycnx5aKR2XQkx+spP61VuvAGv3elz2tz8QtcZ7sMl2Vt7dUZGPzLEuzdFwcAhjjrXotFAFXS9Ps9KsILHTbWG1s4VCRwwoFVAOwAq1RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRQelAHKePfEF3pkNnpOgxrN4k1dmhsUf7kIAHmXEn+xGCCR1YlVHLVo+E/D9t4Z0O10yyaSRYwWmnmYtJcSsdzyue7sxLE+/HFee/D3xBD4n8UP401SSCwSew+wabZrJvZIfMLSNM2APMLoo2jhQp5Oc16yjBwGUgqRwRzVyhKFnJWuTGcZfCxjHcDwwB464NEc8byPGjAsn3vaoru7jtwFlyHc4CpycevtXOP4rtI4mwHXEm0yGMlSM/Mfc9ela06E6q91Gc60Kb1Z0j3Si7jgUrls5JPoM4H4VX1G+S0i/fMEkZysSA7mc9sD/ADisBtf0q1SXUrK3uLiaVhEm/K7z/dTd6Y5xxyKl0r7fLfNczSRNgA3E5IXZ1/cICOADyxOCc1t9VcVzSVku+l2Ze35vdi7vy7GutrfAM81zEZCpA/d/KvfHqfrxwOnNV49Oki8lLe4hSF1Yy25jAExJznPUdT65FWZ7qGeSKCMNIhk2EqcAEevt0Pv2qzeWpuLXyEllhXGN8TYcY9Dg4+tZc8o2vpfyNOVPbW3mU5tMklXYu2FcgjbI5I/z6dKq6tplwtosenwwvIzszTSSMrRnHDBsk5/StOwtbiKOMXd008keVDgbd47bh0J96ZPc20l40SySyTxjDRRE/Lnuacas1LR3S9RShFx10uY2hQm3jW2vZoJzM5y6SuDKTzkg8E/zrftvs1ykvlwptB8pgUAzjt9KrRR3gkWNZLlYwCN0gjf6cjk1ft4hDHt+XcTliqhdx9cClXqcz5r6jpQ5VaxKAABivO9bkj1z4s+G49Jhknm0BrhtSucAw26TQYWLJ6ys3lN8vKqDnhsHb+KGtal4d8B6vq+ixRS3dpEJf3iFwkYYb32gjcVXcwGQOOTTvh74ei8O6FKkWpHVJL+6l1Ka82oqzSTHezKF4CknIGTx3rmNzp6iuI/OhePcyFhjcpwRUgBA65qIQlgfMkZicjj5cA/T+dNdxMgVDe2sfnHZKjgkxNnDKecH0/xxV2obaBbeMIhYqAANxz0FPjjSIMEULuYscdyeppyae2woq242OCONtyglsY3MSTjOcZNLFKkhcIclG2sO4NRxXKysdqvtwCGK9c1MqKrMwUBm6kDrQ7/a3BeQj7eN5xyMc45pHjV5Edh8yZ2nPTNRXjECFRCJQ0qgjIG3vu98YFWCcDJ4FLZXHuxEJKjcMHuKzZo4Lq5eVZVlaLgxo3II6d8bs9z61ZYfacFXZMHPyOPnAPT6f41SktvLa1NvbP5TT73i4AjPOW6evvWtNWb1szObv00L0MMcc7O0jtMwydz9unTpSyXEAdwzIWhIL7jjYD0PNLcW63B2yqrR8eobIPrWf/Zc/nqDPE0AJDbo8ySKc5Vmz2J44pR5ZayYPmWkUagkG/b37e9Z2mhprc3dqVXzXdgCOHXJwT7+/pxSXlmkEQKNMWmaOF2Lk/KWGfp35681qIqoqqgCqBgADAAobUY+71Grylr0GQS+amSpVgdrKexp7uqLl2CjpknFVpj9muBLz5UpCvzwp7N/Q/hVplDDDAEehFQ0t+hSfQieANOJQzq23aQp4Iznn/Pc1KDnPBGPWlopXHY5rx1rv/CN+EdW1wRm8FnGZI4VIGXBwAT2G4jJ7DNS+AdAbwv4O0vSJZRPc28WbiUHIkncl5XHHQuzH8az/iRpz3Xwq8S2UaFpm0u48tMjlxGxUfmBWHZfGPwzd6ZY/YZrq/1a7WJbewitpInuZX2jbG0gVCAWyW3YABJolvYI7HphOOT0orynxR4ni8a6Tp/haxjubPUNYv307U7SU7ZrS3hAe7BK5X5kKorA4InUg81oQWXiLwHd2sWnHU/E3hYwmBLFVh+1WDAjy9rsU8yPGVO4lhhTk80hno1eA/EHwDqUPjyx03wjbana6DrSTz332eQm1hvFDskrg5AUlhujICPgcEiu6utU+Id1N/aVh4ftLGytSB/ZN1cxvc6gGIyfMU7ISo5Ay245BxxUqeJPHdsRLqHgWCa2c7tthq8bzRqeApV1VWbPJIYAA8ZIwWm1sJpPc878I634Nh/s5xFoGieJrmL7LdWsUSQSxTK22WFsfdHmKdoYjcAMZrvSCCQQQRwQaS28QeH9duNU8OeL9DXQdV1KLbcWl8Y8XybcAxzIdshUEcA7l9BjNZOueG9b8EaYmo6fq974g0OyUC60+9ija6S3AwZIZlVSzIAG2ODuAIznGeynibaSR5VbAN+9TdzVopsE0Vxbw3FtKk9vMiyxSxnKyIwyrA9wRTq7TzArkPG3iKTR/Enhe0hcrBI815qG08/ZkAj/AC3yZ/4BXYe1eJJfJ4r/AGktU0rzAbS30m40oHOVH7ohz/32zflWVWXKlY3oQUm29kme3OpR2VvvKcGsHx9/yIPin/sEXn/oh6seFb+TUvDWm3VwCLkxeXOD1EsZMb5/4EhP41X8ff8AIg+Kf+wRef8Aoh6qTvBvyM4q00n3O6+E3/JLPBv/AGBrP/0QldRG6SAmN1YAlSVOeQcEfga8jXVtR0j4GeBJbC5On2s1jp1vfakkYleyheFF8xUPBO4ouTnaGLYOMVryfD/UPDkEknw31cabczJtuYNS33MFzIRg3DDOVn6EuOGx8wPUeQfTGf4r8XnxVdWXhrQ7fXbeK71f7FeXyWkqRyW0TOLjyp14HzxiMtkEBiR612t34H8L3eh2mjXWgaZNpdoMW9u9upWLnOVyOCe5785zml8D+Gz4X0eW0k1C41G4uLmW8nuJlVN0srbnKooAVdxJ2j1NdDQA2NEijWONFSNQFVVGAAOgAp1FFABXn2vxXnhLxxL4msdOvNT0vVoI7XU4LOJpriCSLd5MyIMlkIZkZR0O1hn5q9BooAyvDfiDS/Eumi/0W7W5tw5if5SrxuPvI6MAyMOMqwB5FateNaBp0Gk/GfWL/wARX2uabqOpXzf2ev2jbp2oxeSiIhA4aVQD8rYPAIzjj2WgAooooAjuJoraCSa4kSKGNSzu7BVUDqST0FcMvxCuNSVpvC/hPXNasFOReqYbeGZM8tCZXVpO+MAA9jg5qL4uwwatL4S8PyxR3T3+swzSWjqGWS3gzJMXU8FANoOeMso713+zbHsi2oAMKAOB+FAHCya1481WUNonhqx0i2iAZ/7duQZLgn+BFgZwnA5ZieSMKcGj/hYNxp4aPxJ4R8RafcRjdI9ram+twvdxLFngDnBVW9q7kuNgZTkdsd6VW3xhgCAR3GD+VOwrkGlajZ6tp1vf6ZcxXVlcIJIpomDK6nuDVqvObiG+8D+ILrU9G0i81Dw3qg8y50+wjDS2t3k5mjjLAbJAQHA5DKG/iapg3jzxOiQTQW3hCwcbpZorhby9dT/Ag2iOJgOCx34P3emaQz0CiuAbQfFfhcR3HhzWrvxHbrxNpmtTJ5jj+9DcKoKsPRwwI7qeasaX8TfDkztaa5exeHtYiyLjT9WkW3eNgcHazHZIpxkMhIIINAHb0VyGufEDQ7LThJpV7a63qEziGzsLC5SSW5lPRRgnaOCSx4UAk9KyrXQvEXiFJTrvjaa0d8b7Hw+scUcAPRRM6tIx4+98uewFNJvVCbS0PRKK4KT4aWhkXy/EvjCGMcsqa5P857kkkn8iKQ+C9X0wyT+FfGWrLMDn7Lq8n9oWzEfwndiRQe5VwR+lFgud9XM+KfG+h+G90N3dpcaoSixaXausl5OznCqkWQTn1OBjJJAGa5+7u/iLqTRaO2kWGkGV1FxrlpfLOkcWfm8qJ0DCQjgblKjOSeMV0fhvwXoHh63jXT9OgNyNzSXsyiS5mdvvvJKfmZmyckn26cUhnhnhO+jluNdshaXVgYtQmu4LO7jEcq207+YjYBII3tIuQT0Gete56BOtpoFl/pUDyeWHl82YDGRn8Oa8v+K3hx/DkI1zTLlftenpLPbw4OZrcDdNbv8A7BUZB7MFPrWBouszalqNra3WiSWTX1s15ZOtxHciaNQpYHYPlIV1bnqDXv8ALTr0o0nLRbO26217djxFOdGpKfLq99fn/wAE+hHt4LlXklDLkYYhsA8evcVy3izSLHS9BXyVkVRMiuwOXKMeQCf5fSsbwYt5HqsEsj3EVkiknexCtkYGAetdteXqTSxxxyAIvzecV3ANg4+XuB/PFcEpLCVlFVLpavX/AIc6PbU69NuVk9jz60h1C6v47m3tJ4gFCQOsZ/cr0XH94/zOa9G0yxR7eOS4hdWIUmGQghGAxnA4z69ax7i+m+ZL/W4YCo3j7LCckZ5znP0rZj1G0t0tQZnKXJRISV4yRwOnGcHrV4qvKslyL7r/AJlYWEItu9/uL7NDEQGaNDwACQPpTpcCMkkDHOScAY9apTLatJI97bxDa4KtJtbdjoQO2Mmo0k01GDRuFI7AsB+XSvNcoR3ep1yqxi7NpfMUxagtys1vcRTwsBmOQ4wP9kgfzq35DvGVlmcksDlPlx7cUwahaAf65fyNSQXUM7FYZAxAyRQ6yltYUZ027KV7+ZPRRTZJEijeSV1SNAWZmOAoHUk+lI3PPfERvvE/j648KXGpXmj6VBp6XpWzYJNqQZyjgSYJSNMKrBcMTIOQMZ7vTLC20vTrWw0+FYLO1iWGGJeiIoAUD6ACuC8NR33jnX9H8ZXUcdhodnHM+jwKp+03KyjZ5sxI+VGUBljGc5VmOVAr0agAooo70AVb6+isgpnEm1sksqEhAOrMewHrVhHWRFdGDIwyrKcgj1FKwDAggEHgg1DaWsNnbpBaxrFCn3UXov09BVe7y+ZPvX8ieiiipKGsoYqWAJByMjpTZ1donWJgjkYDEZx71JRRcLFcQRxzGdj82wR5OBgZ/qTUsUYiiSNc7VGBk5NPIyOaYqBSxGfmOTz3ptt7itYfRRRSGRXEQmhaM9GGKjspTJEUk4lj+V89/f6HrSajatd2kkKTyQMw4kj+8KrQQpp97EisWSeNYlDHLAoD+Yx+v1rSKTi1fUzbal5E2ruyWLbVzuZVPI4BYAnmrtRXMSzwSRN0cEcHFV9OlkYSwzs7SxNjLgAlex44Pfn2pbw9B7S9S7RTElR3ZVYFlxuHcZ6UrMEGW6DnPpUbFX6nE/GuWQfDLWrW3Yi51BE06BFIzLJPIsQTnsd+CeoGT2rtIIY4IIoYY1SKJQqIowFAGAB+Fefalcwaz8YNLs7ohrHRdMOpRo27a11NIYo3x0JRElAPYyV6LSTT2FGcZfC7mTB4d0i38SXXiCGwhTWbmBbaa6UHe8anIU9uw568AdhjWooplBRRRQBzmteGrTxGtzBr1laz2jOAIZEWVJAvKOQw4YEt+HHNchod3/wr3xJDoV5Oy+FL9mSwmuCVWwuByLfe3HlODmPJ4ZSgzlceoBlLlQw3DBI9M1nXulW+oW09rqoivLa4Y74Jo1aN0I+4VOQQOv15rVz5laRmo8rvE821zwxrXgtb+98MW9rqXhkTNeSaOiOt1bK2DKLUg7WGd0gjIHJKr1FT6Jq1hrulW+p6PcrdWFwCY5VBGcHBBB5BB6g1atpk+HWuabaNfu3gnU90Nu93KGXTLgDKRiVjnypFDBQ2drKADhgBl+LNMv8AwNfa74igS0uvCl3dLfXsEUbLdWbMiRySpglXT5A7DAPLHPHOtCu4PllsceLwimuemtfzL+qajDo2lX2qXRxBYwPcv7hFLY/EgD8a8k+FPwvlhsJ/EviKee08U6mTdW8sfD6fuO4OVPBds/Mp/hJU9TXq1vdaVrtrOtpdWWqWkc3ky+U4ljEiENtPbg7T+VXiSxJJySckmuxwU2m9jy41JU4uK0bOR8DXlz/bPifStTtxbX8NzHftGpJjfzkw8kRPWIuhI7jcQeRWj4+/5EHxT/2CLz/0Q9bJhiNytwY089UMSy4+YISCVz6ZAOPWsbx9/wAiD4p/7BF5/wCiHoceWDQKXNNP0MXwJo2neMdS8BRzRT3lhovhe0+3o7yG1FzsgkgjKghfMALOeG+XaCB8te/VxXwX0+z074U+E0sLaG3WbTLa4lEahd8jxKzufUknJNdrXkn0gUUUUAFFFFABRRRQBn69o2neINKuNN1m0ivLGddskUg49iD1BB5DDBBAIINeYfEHwZb6J4QvtWvtU8X+IE02EyW9vJqhjNscgG4DooYtGuWy2/ADcEmvVtSv7TS7Ga91K6gtLOFd0k87hEQepY8Cud1L4h+ErGxa4bX9NuSYlljt7W4SaacMcII41JZyxIAwOSaAOe0bx7qLaPZ6bp2lXnirxDawxw311ZgQ2JnEamQ/aHAQ5yCAoOdw4HbsPDPiax8R6TLe2RkhkgZorm2uh5ctrKo+aOVf4SPyIwQSCDWB8HfDMnhnwzeLJZ/2d/aOoT6gmn5BFlG5ASHIOOEVSQOASQOAKzvi3pkmi2mo+M/D+pSaZrcdp9leJbcTxakSwEMUkZ6tvYKrjBG85yvFAFn4Q2I1DQbPxpq0k154i1qzSSW4lGBDEfmWCFOiRA88cscMxJxjvI5wVYyYQrywznA9a5z4caZLoXgnQNF1FIo7+xs44XRHZl3KuDtZuv8AL04xXVdadrbi32ILcrzsmMg9CQSO9PWJVlZ1LAt1GePrj1pyjvgAnrTqGwSCiiikMKrX9nbXsPl3kMU0YOdsqBh+oNMvnnRSUlihj4BkbqvPXnikS3lkn8y8aKRV4RVXj/eOe9Woq12yHLWyRnWvhbw5Z3DXdhoWlQXTIUM8FoiOVPUblGcH0zWpBEY3CpDFFGOgVf8AD2qSZX3I0ZwBkNk4AHr7morITPFHLLKSWG4rgYxjind8u4WV9i0SQOBk0uAO1MAYfxZ5zj+lOB6A8HGcVmULQenTNFIfagZgeKfDcOvLGzSmOVAY+eVZG+8CPcd68Y0nQYLTSfDXhf4gaBd6XqEYNnp2tRXS7GnXITypY33RuUAwHADFCMEjFfQ9eb/Fy6t5NW8D6d5iSXba5FcC2iYNOUSOX94E67Fbbubooz3xVzqzlTVNvRHNVoQalJLX/Io/DTWJ9e8D6NqV5Is148JiuJVIIleNmQvx0LFd2MD71dSSO9cP4TiisviF44tbWOOCN5rG68uMAKTJAwZsDgFmTnuTyetdjM/kkyOMrgd849cCvPnDmkrdTwqySm7dSC/tVnikZVWRwm3a4+Vu+D6ivMNKvdJuNXvv+El128sNfGpbILGG9kiBhD/uAluDtlRkwSxVvvNyMcerWl1HdIXiztBxk1I0aFslATjFaOtOC9lO6sTCfKeLeGPFmp+GPCemJey2JsJdKuLu3dLR3eAxzxoPMzKokB87JOYwuOTgZqzo3xQ1PULaNbm50TTlOoTWrapcRh7YKkMciDbHcMu9y5AxMR8p6nivZKKw512NHWi7txOR+EP/ACS7wt/2D4f/AEEV3OknGoR+4I/SqlJHKVdXjJDA5Bx0IpJ+9zExqWqKp53Otpk0Uc0LxTIskUilXRxkMDwQR3FQWN2t1FnG11+8vpVqvQTUldH0kJxnFSjszxrx54Dh8J+Cr/WfD+q+IVvNGiWSxzqDuthaq6mZIoz8rL5QIw4bhFGeK9ht5o7iCOe3kSWGRQ6SIcqykZBBHUEUXIJt5QsaykocRt0bjofrXA/BDUdNPgDRtGt79ZNV061WG9spW23FrKDh43jb5lCtlRxjAGOMUyj0KiiigAooooAZEzsgMibG7rnOKfRRQAyWRYo2eRtqDqafVTVE8yzdMsAzKG2nnG4Zx+FRPNJOhisY/kyYzMxwq44OO5I5H1q1C6uQ5Wdiae4fLpaRrNKoyQWwB7E+vtVO5vryQiK0tnR8HfI4yFwASAMjd6A5AzWlDEkMYjiUKg6AVJTUox6XBxk+pzqwXUl/FFqV5uPlBxGh8pWJbBUkHLYAH4/WuhRVRFRAFVRgAdhUMtuslzDM33ot2OPXH+FT06lTnsKEOW4VTuQhv7POPMG8jntjB/mKuVgahqu3VoI4EV2jD7ix7cDP58fnWakou77P8ia9WFKN5G/VW73RvHOmCEyGXuQcdDSWF4t2hwNrr95c0mrvJFplzJBA9xMiFkiU4LsOQPzopNSat1KU4zhzxegt/GNnnqWWWMZDL6d8juK4PxleXPiLxA3hfSL25tbGzRbvWru1l2SAN/qbVHHKtJ99iMEIB/fFa/jrxPNo/wANNY1/TXtTd2tm0ieaSEWUDoQcHOTwpwScDjNUPDmlpo2lSW8c89zNdTve3dzcALLczvgs7AABcAKoUDChQO1RXm6a5Xuc+JrxpQbW72K/hjwno3h2/nudJtZI7i7MazyzXMs7uFJwMyMxHLE8etegXl1BZQGa6lSKIEAuxwMk4Fc5F/ro/wDfH861/EOkrrWnG0eZoRvV9ygHofQ1ng+WU/3j00ucuBnNxnJasl07VbLUnmWxuEmMJ2vtzx/iPcVerm/B2gto8Vy9wB9olkKg5BxGpO38+v4+1dJXZXjTjUcabuj0aMpygnNWYU1QRnc27Jz06e1OpDnPXisTUAo3EgDJ6n1qOVvldkj3yRglQRjJx0B/SpajVArSEA5c5Jz7Y/pTQmZ2pWdtdWEseoWUM0dygS4jmVZIgo5IcNwV/CvJ/CcnjKDw1fjwLb2WpeFvPmtdFh1MlJhAR8s4kLEPbq5YKhAZolUg9Aej8XfaPE/idPAsNw8Vg1h9q1iVs+a1u0m0QIwI5lwwZuyqcctV74keO7PwBp1lZ2mmXF5ql4vk6XYW0D7JWBVdmVUhQAwOOuBwKqb6Ex7nHaj4R/4VsdN1i1u5bq1v5oLDXd8aqm5jtiuY1QBYgjsE2KNu1x3XJ6dgVYhhhgcEVxVrqVz4s1y3h8b3V/bXvyzWWiS2kun2sxjIYuFkJNy6ttbBOFwDt612pJJJJyTyTXdhU1HU8bHyjKpotRKwvH3/ACIPin/sEXn/AKIetysPx9/yIPin/sEXn/oh63n8LOSHxI7r4T/8ks8G/wDYFsv/AEQldVXK/Cf/AJJZ4N/7Atl/6ISuqrxz6c57xx4kPhnSYJ4LT7df3d1DZWdn5vl+fNIwAG7BwAu5iccBTWI/iLx6rEDwFZOP7y68mP1iFHxkdtO8Oaf4hhLGfQtSt71Y1AzMrN5MkYz0LRzOB74rvKAOCXX/AIgSE48DadEFBY+brwO/H8K7YTyfU4FJJ4l8dQ25nm8A27opy0UGto820dSqmIKT6DcM+1d9RQB5H4s1z4g6bpZ8QxzaTp7zzxWlj4cuLczvK0jhV3zK64lJOSq5RVB5bBNbkut/EHSlVL7wvo+rblZjdafqn2eKPGP9Ysy5UEZ+6X6c4611Hinw7p3ifS/sOqxyMiyLNDLDI0csEq/dkjdSCrrngj+VcZpM+ra9p3jnwNqd/Bc6pp9sLSLUvK2+bHcW58t5YwfvA7txGFbHAHIABW8G2Vz8TbbTPF3ihpYNMEguNM0KGQiFCjnbNO3HnOSAy9EAAwDkmu8sfC+gWE6z2OiaXbTLIZVkhtI0YOc5YEDOTk8+9c54G8S29lHp3hLXbVtE121t1ghtpn3RXaRqF328vSQYwccOOcqMZru6ACs/xBo9j4g0a70rVYRNZ3SFJF6EejA9mBwQRyCARWhVXVZbqDTLyXT7dbq9jhdoIGcIJZApKqWPTJwM9qAOL+H2vSX/AIcubLWbiS71DSdQuNMlugm1pTDIVSUjsxTaT6nOOCK6qy1AvdrbsTIGQsJNoUgjHBH48EV5n8Lo5r7R5/FF9fpfX/iLybyZ47Y26IFiWNUCEn7u0jdn5uD6VvaM0qa5fTOwdYZAEyT8ueSAPfippzvztvSK/VLT7zyKmOlGs/5T0KigHIBHQ0VR64UVFNIUQ+WpkfsoOPz9BUH2V5lJupWLHkCMlQh9u5PuapLqyW+iJrq2gu4xHdRJLHkHa4yM/Sks7ZLS3SCIuY0ztDHO0Z4A9h0HsKmAwACSfc0tLmduW+g+VXv1K1yGlljhBIRgS5BwcDt+OafIFih4IREXp0AGKmqmxN1IFUAQo+SxP3yD2HpnvVLX0QnoPjeeRSQiRjHy7uTn3Hb6Zp9vIz71k2iRDhgp9sipQAOgxmqqyeRNIJVIV23eZgBfYE0fFcNi3RVQNPOMx7Y4W6MSd2PUCoPEGuaZ4c0uTUdbvI7OyjIUySZ5JOAAByST0Ayalqw07nJeIp7vxb4vPhjS9QvbDS9OiFxq95YSeXKZWx5NqsgOUJGZHI5wEGQHOd3wt4Q0jw358tpHJcajc/8AHzqN4/m3Vx0+/IeSOBhRhR2ArL+ENpPYfD6xutViFvqOoNLqd6Hj8tvNnkaQ7wecgMq8/wB0DtWvqGqwXRltLK4/0juY5QGXB9OtS5Rj8RlVrQpK8jz/AMKoI/F/xCssiS5TU4J/MPHyPbR+Wh7jaEI/GuqadXVkZ/Kkx0bgiuU8UC40bXrXxXbxmVhb/ZNWso/nkktQxYTxqOWeJiSRg5RmHBArrLG9tNSsorqwuYLu0lXdHNC4dHHsRXJPTW2h4NZXtNbDbG2+zK4+X5zuJXgE+uKtCoRBj7jui5+6MY/D0q9YQIsDvMPNiVsMSxDxr6+4pcrrz3u2RTpurLliV6VEeQkRozEckAZq9eWlrb5/0h939wYJp9rqMMCBFt2Ve5BBJ9zU+zs7TdjVYdRny1ZW/H+vmZlLWrdRWd+8YSUJNKrEDH3guM5HtkUxdIlz88qAeoHNN0ZLbUcsHUv7mq7oTQlJuZGH3QmD9c1t1DbQR20YjjHHUk9SfWvO/jBevrWnzeCdEt7i812/SGdggxBbQCdctcPkYjYI42jLMAwA5zXVThyRsz2cLRdGmovc1NR+IEEt9Np3hDTbnxPqUJ2zfYnRLa3b+7LcMdgP+yu5uOlcyl1car8YfCkut6E3hvUIbS9kVpJYpTqJ2oohWRCdwVS0hVsH5VIGASPT9LtLKw0+K10m1t7WziyscMEYijQZ5AUDA79Kq+KPD2n+JtKNhqkblFdZoZonMctvKv3ZYnHKOOxHuOQSDodBr0VxvgTWtQNzqPhvxFKJtd0plP2jbs+22rk+VcAYAycFHC8B0boCK7KgBsi70K5ZcjGVOCKEXYgUEnA6k5NQXts1x5ZjmaJkYN0yDg5wRVmm9txdQooopDMjxaCfC+r4u3siLSVhdIhcwkKTvCjlsdcDk4rxXQvGTaBY3Fxpd7Fqotbe0N1dxa5Pqlksb3McckkiyYNvLsZnCAlVUEnOK+gaRs8Yx707u1hW6nkEvxSuLu4cWOpaBZaW+rXNjFrN0jS2wjigidBxKgZ3aRgpDAELwCcZ47w58Trvwv4T8D6XYNZyqNP05bi2uIFWRlmcIWjkNwrNgH+CGQAj5iAePpGs+fVIYptgDPg4Zl6D/GplJR3IqVYU1ebscF4R8ZeINS1vSF1IaUdO1S51K2ijt7eRJYfssrorM5kYNuCHICjHXPavSkdHLBGDbTtbB6H0plvcRXC7onDeo7j8KpxTTJcKolWUM53oY9rquSAePfue1XBc6uh86dmtUaEhxGx6YBri7ZvOnadAPLKBQx6tyTn6c102tqTYF9+1YmEjKejgdVPsapataeTJ5qf6tzyPQ1hXjaHMv62/r+tPOzGEpJSXT9SvYT/Z7pHJ+U/K30roLieG2tpbi4ljigiQyPI7BVRQMkkngADnNczXOfFW6Q/DW6gmLSs15ZwrahiDeBriPNvgctvXcpA6jPbNY4ednymeXVrP2T67HN/EDxXoPi6LQLHQZpzeXeu2MjwNA8bz26sZBcCJgPNhwn38bQOSflAr0RH8xQ5xzz1rp2tbdp0naCIzohjWTYNyqcZUHqAcDj2FVIIbbc8U0cYaM8FhglexrerSdVXXQ6MXhHVacXYybWNpriNYxkhgT7DPeuoPAqiJYypisdoc8bgnyr7+9WYfO584R+xUnmnToumtTTCUFQTV73JR0pB34paKs7AqNowZlkyQygjg8EVJQKACqhlmjuI0eJn8xmAMYyqKOhYnofpTL/UoLG4soZ9++7k8qPaMjOM81ajZmL702YYgc5yPWr5XFXa0ZF03ZPY848S2+v6R8TYvEOk6G+s2kmlvpwht5o4XSUyrJucuQChxjcM49KZ4i8T+OtL0S71y707wtpOnWMRmnt7u+lnlkxj5BIiKiMc4Xh8kgYr0N7bfOsq5VjndljnpgY5wK5r4heGW1bwZc22kqyapZsuoaeysObyI74t275WBYAHdxgnocEErPXqEU1p0MCz8Dt400XV9T8aWxt9X1mMLaxYzJo8K5MKxt1EoJ8xiMZY46KKoaFqd3PcXWka9Gtv4l08D7XCv3LhOi3UPrE/5o2VOMc+h+DvEVp4o0KHUbIsrZMVxbyKUktp14eKRTyrqeCD9eQQah8X+EtN8UQwG7823v7Ul7PULZtlxasRyUf0PdTlW7g1VKq6buZYnDqvG3VHM1g/EJli+HvimSRlSP+yrtNzHA3GFwBz3JIAHqRWx/wAIT4zbaG8YaWgjxhk0MEzf9dAZcD/gG38KyfHPw5061+HnizVvEMzeINei0i7eK7u41VLYiF8CCEfLGAec8tnksTjHTPFRaskefSy+pzJydkN8A2XxAu/hz4Rs7TU9Ft9JudOs83lvC6XlpB5SnaqvvR3KgLvOMEk7TXTP8JvDF5+915NQ12+PW81G9kaX6LsKqgH+wq1q/Cf/AJJZ4N/7Atl/6ISuqrhPYPDPjH4evfCPgPVh4dOo3vh67t2gu9Omle6No2AUniLkuFyoVlyQNwYAbTn2bRdSt9Z0ew1OyLG1vYI7mEsu0lHUMuR2OCOKh8T6ZLrXh3UtMgvZrCW8t3gW6hGXi3DG4e/Pt9RWJ8KNSbU/AOlNJZQ2E1or2EtpCCEhe3doSqgkkD93wCSQCOT1oA66iiigAryn4deJLNvHfiSHUra9s9Y1nUphD5tk8UTJbIIliWRh87+XH5pxx+8OOhr1avPdRk+3fHLRrdQ1yum6RcTvGV2C0eV1VJtx/wBYXVJEwPu4J/ioAl+NDRQ+FtNu50ylpremzmUgEQAXUeXOecYJHHPPpmu9qrqdhaapp1zYajBHcWdzGYpYZBlXUjBBrl/hFNPL4FtY7q5muZLW5u7RZZm3O0cVzLGm49yEVRk8nGTzQB2Vea+KVvfHHjSTwxZX15Y6DpUedcaB/KkumljBigRh8wXGWcjAIIGc5xv/ABK1e+0rQbVNJuBa3+oahaadDcNEJRD5syqz7TwcKWxnjOKseDvDLeH/AO0bm91GbVdW1KZZru9miSIvtRURQqABVVVGB6knvQBHNpkOkxQW1lCsNjFGsUEaDCxqoACD0AAGKqpGhuZPLX99IFB/2uuP6110iLIhWRQynqDVAadYtIDGxEgyMpIc4PUfSud0fe3smeTWy9yqXi9GaEa7Y1X0AFQAtPLIMlYVynHBY9zntimhbmDhSJ4h2Y4fH16H8cVBbX6Rpi4SaMlixZ4mA5Pc4wK7Iwdrx1PS5krJ6GJ8RNUufCngjUtU0WK2fUIfLWP7UrMjM8qrl8EMfvE9a4vRPizdajrMljc28FnJbNp1peQCBpZIbya7eCWM5kUbflUq3JAYNhvu16nrek2WuaZLp+qQ+fZylS8e9lyVYMOVIPUA9aybjwP4dn1q71eTTV/tG7mtp55lldfMkt2DQsQGxlSB25xg5FQ23qy0rbHPP8W9Fhg+13en6tbaZJa3F5bX0qReVdRwuiMUAkLjJkTG9VznPTmmaT8XtD1doYdNstQu72W6NmlrbPbTkyeQ0w/eRzNHgqjDO/gj5toBIh034W2Nt4inutUuLe6sJre5tINNiSdIo45nV34knkAI2D/ViMZJOM4x1dj4V0ayvLJ1F/PcWcrXNs95qNzcmN2jaIlTLI3GxmGOnOcZ5osFzk9V+LGmaLok19rcE7wi8vbVgj2tu6CCVkK7JLndKeDzHuLYztXIWvSbSSKa0hlt8GF0VkIGPlIyP0rldR+G3hbUPP8AtGnzr9o+0CbyL64h81bhzJMr7HG5WYk7TkDPAFdOn2awtoYAyxRRqI41ZugAwBz1oV3ogdlqWao3d3E4eFI5Z8gqxjTcF+v+FKf9NkwGcW6jkrld59M+g/rVqONYowkahUXgADAFVpHfcnWWxWs7tXQJKrxSqm5hIu3gdT9K888b6qniTxDpGkaHaXV2+i6za3l9fqoFpbbMs8Zcn5pNjD5FBwXXOK7jxDrGkaNatP4gvrGzteqtcyqgbHX7x5rzr4bQtceHJ7+5t3hOp6leakiSKUdklmYozj1KBCAegxUVJxiuY58RiPYR7s2fiBe67eeHLs+GihviAY0BBYID85jz8plxnbu+XdjNcv4e8GeBNb8L2UllodjPaugAnePbdbl4bzJBhxKGB3c53ZrtiDbyMyr+5YjIH8J9celczqekaloms3WueFo1ukvGEmpaQ7hFuXAA8+Bjwk2AAQflcAZwRmuRybVr/M8iNWU7pvXv/X4DV+GXgtYWiTw5YqGKneoYSAjph87h74PPeug0fSrPRrRLXSLSGyslB220MYRAc8kAdz39azbDxXZ6np8k9l5sM8LmO5truPy5rRgMlZE7HHI7HjBIrzfUPi/Ztqq20ME82MhiZNpx7Af1rysTmbpVHRjFzkt0unq2ejl+TZjmvMsPG6i7NtpK/bXd+h7SrqwBVgcjIx6VXneMMBvfcvOE7fWud0jUpLmx+0WAkkicbnifh0+nqKrXV/LOylSY1HICnv6k15WI4jpUl+7TUuz3X9f8NdO54uPhVwFR0q0bSX9aPY6e3mRJCGfIbCozDkegP+NWiBtAJ288c/pXN2Vw16pilUfKPmP96pvEOq32l+HLq703Tzqd/AAIrdScnJwWIAJYKOSFyxAwOa9jB46OKjGUtG/+G+/uvmiKU/a2t1O10FzvmXnbgNWsHDorJh0buDkYryrwgfFviHShf6L4u8NtY3QDJPb6RLIMcg4DzjkHI5HUciprrwxqgZl1Hx/rf2tPlRdMigs4Y1PJzHsfLe5PHbFevGcKUFzM+goTVCgud9/zNXxl4na+uz4X8G3cc3iaYiOaeECVdKiJG+WXsrBc7UPJbbxjNb/hbwrpPhSzeDRLNImlO+4mY7prl8fflc8uxJJyT1Jqr4Og0bQNLttH0m3jtLePhAG3GRj1Zm6s5PJJ5JrqKuFSNRXi7nTSqwqq8Hcao74wx606iirNTgfF2xPix4BMP7q6kS/WSXdtEsAhUmE4+8d5jcA8Dy2Nd9Xjmo69ZeG/jhq154rui1p/Z0J0t3gnd7cv8skUCKrKwbyyzuOeVXoDXo3hjxdoPikTf2BqlvetDgyohIePOcblOCOh6jsfSgDdooooAZLIsUbSOcKoyTWb/bCZ4hfH1FXb6Ez2skanDEcZ9a5sgqxDAhgcEHsa561SUXoebjsRVoyShojaXVbdiN/mIfpkfpUp1K1AJ83P0BrnznHFNYkMoAJB6n0rNV5nKsxqrsat3qhkQpbgqCOXbg/gKy2C4AYDB4xS5C4BOM8Co3AijldBl8FuSeuKzcnN3Zy1a060rzZAmoRvJIIY55PLcxlkTjI64NPGpQxl388xyfxbiVY47c9ajshEkQlWVmE/zAFsjPUhR271bKKQAyggc8itZ+zhKyTt6/8AAM722LWmXL3U0f8AaUoKggxoDwrDn5j3PStTWZUW0KEje5GB+PWuddY8CMEIx+YbcA/XFJFKwfy5xiTsc8OPUf4U3VlKDX9WOtYySpOm1e/Unrmn26h8W/DthcsVttPsLjVY042yTllgXP8AupJIR7uPSulrktSynxW0BlXPm6RfI59Astuw/U1jSdpXMsNP2dTmtserkcg5PHamyxRzKBKiuAc4YZ5rnILmWCQOjE4GMNyCPSuit5VnhSRejDNdlOqp7bns4fFQxF1azJAABgcYqvqF3HYWM91MHMcKF2CDLHHYDuas0VqrX1Op3toR28jSQRu8ZjZlBKMclfbipKK8b+KOli8+IlldXml211ZDSjGJL3wxca1EsnnZ2hYSNjY5yT0pMaPXrq7t7QRG6uIoBLIsUZkcLvdjhVGepJ6DqamrwCLQ9Za6v7KG41+KSTxNbXkSjSQkEMJMZ8+NjDt+UZXazMFC/Muck6U9746gu7uSO0u7u8s7TUraG/k0yPznRb23EbghACxh8x1RcLIUB2nAoA9lMEctyk8kSmSLIjduSM9SPSpwPU5PrXiN74n8R2s+mW82reI4dJutYktor5tEX+0J4BZvIQLfyCeJVwG8oHAJIwMlp1fxrBayX97pmqjUJtJsozc2mnxrOrm7uclz9nlPEfls8axvs3kqoJzTbbElY9ueRUwGOM8Cn1xvwm1HXtT8I+b4qjuE1FLu4iDXEBheSJZCI2KmOPquOfLTPXaOldlSGec+MYP+EL8SxeM7JJF0mbMOvwxu5BVjGsd15f3cx7cMQM7CTztrvdNv7PVLKK90y7t7yzlGY57eQSRuM4yGBIPIP5VZIyMGuEvvCWpaFqlxqnw9lsLM3Z3Xmk3astnO/H75NnMMuBglQQ3G5SQDQB3dcr8WP+SWeMv+wLe/+iHrObx/c6Tx4x8Mato6AEteW6/b7RQO5kiG5R/votM8da/pHiH4ReMrnQtTstQgGjXm57aZZNp8h+Dg8H2NAGp8J/8Aklng3/sC2X/ohK6quV+E/wDySzwb/wBgWy/9EJXVUAV7+8ttOsp7y/nit7SBDJLNKwVUUDJJJ6CuN+EUM39k61qDWs1rY6rq9xqNjHPxIYJQrb2X+Hc29gp5AYZ5qP4nomsap4U8Kz5+x6tfNPeLgESwWyGUxnPZpBED7ZHeu+oAKKKKACvOfjHab18NTaYkdt4jl1WG0sNTJK/ZN2533Y5eNljZDGeGLDoQCPRq89+Jsxi8T+AxfRTf2KNV3STQx7yt2V8u2RucqhaRyWweUUHGaAPQq4n4QZHhK4TqE1bUlB9R9smrtq4X4Pk/2HrY/hHiDVAv0+1yflQBH8XGfb4OiUsUk8SWW+MHG9U3ycnsFKB/fZjvXUXviDS7SNme8icj+CJt7H8BXG/HW2E3hvRJiyottrtjIzn+BWk8sn/yJg+xI71zzoFlZIzvAbClR976V81n2d1ctnGnSim5K9362PHzTMKuDsqaTv3/AMjoNS8Uz3uR5ZjjzxGH4x7nuf0rKXUp2bMSJ/wBCcVFLZXMa7mibA645IrX0a8+0RtHJt81OcgY3D1r4THZjjl+8rN3+48bA0p5jiFTr1XGT2038t1YvaF4luFPlufMx/A5zx7Hr+BrpI9aSaHLW7gNkY3DkVxGsRC3kivIVIkD/OQOD9a29PmWSABT2yPcGvqOHM5q4mPJOWqO+U8TgassLOd7beaexqf22tknltFJIgHyMSBhfQn196oT+MT9pjiht4ufvFnPA/LrVa9SN3cycsigKD6k/wD1q57VIvIukmjLBnO7Po3tXo5zmdbC2lFu2jdrK34PcwxGY4iC92X5f5HRzazdXnIuAqekXGPx61n3WsXWnyIYZZDIQT8zEgfgahsJEvUDSYWVThyvBA9ai12GKKEkOXO75CT19a86riHWovEQqtdn1/P5X6M5amInOPtFN3Ov8PeIpdXgMaQRreR/6zLYTH94Dqfp+taMFlv3zyMTfAkCQ5AXB4AHYf41w9heR6FBBchFNwVJcnjjvuJ6Ct/T/GlpdECSIpngMrh1J9M16GV8VUJ0nHFPklF216/cvvWh9phMuxcsPCrVV21/Xz7nRWly08sqOnllDjaev1+hp95cLbQmRuewHqaw18S2T3rxvbTrcRjAJUcqfQ56Vz/j/wATyWFlGltHJNq98WtdLs4SN8s5U/Nk8BVHzMx4AHfofdp4+hio82GkmvI4KmLik4Qd5benr6HN6ZaQ+LvHviLWdaH26PRrw6bpsMyq0VsRFE0zKhH3y5++STgY4xXdAYrH8HaN/wAI94X0zS2ZHmt4FFxKhJE0x5kkyeSWcs2TzzWzWVSbk7X0PHr1HOd73CiiiszI4H4jWo0vVNJ8UwKgRJU03U1JCia2mYIjMf8ApnIy4PZXauZsvhXYw6vPd2M7hXch0bAeP1U/413nxF1PSrLw1dWer239oNqMT20GmIT5l65X7i45UdCX/h65HFcf4PPjyPTra1uLCy+1iNY5NXvbsTxOq/xeWu2R3PTnA75NfNcROdBLEUKihN6PVK6XXvdeWp9NkOaYvCTVOjrGW606LSS/J+TO20jSDpgQRyDyQpXaMknPfJ96o+IYI7GOW/llihsx80ryuEVD65JAxWDc+EtZ0qefxDpevR3PieQMl1JfQkWk8JwFiESkmMRkBlIOSdwYndkYV01ha6qLrxXe/wDCRarF8kcl1BHHBb98Rw/cDerct05FfF0aHtZ+0jU5u9k7t9d9Lebd/K90vaxeVTzyLpyi2+/b+uv/AAxbt/iF4dt5Q9rq0VyzDlbaKScgf7QRSR+OKL/xRc+LhJpWiJc2Gmsq/btUaKSGQISd0UCuoJcgYL9FDZGTitqDxunLoHUN1ZIVOfqQeauQ+LrO7YJdNG4PGJUKH8M8V6cMfXw2tOm/m00vlyr8zzZcD4ihBulJ83mrr7v+Cd/pqWPhbwtbRQLDbJ5arBCvCr8vyqPYDFYYO8b92/dyWznJ9axtW/s+LTJtR+1Lb29sm6QzPhVX8entjrXMWvi7TUt7y4S5ubZLSPzpxPaywsqc8hXUFuhHAOTxXoPPZ4u3LSfLHTu7+em7Pls1p4rDVFSq09FtbX9Fr62O/YkAkdRyPrXoURJiQt94gZrwqLxxpcE+jS3l/cNaX4+0RG3tJZmeJdpY7Y0JAAZeo717fp17balYW19YzJPaXMazQyocq6MMhh7EEV9Rw/UdWM52aWi18r/8MdWTXanJprb9SxRRRX0R7gVwN7ofifSvGura9oMei6nHqKRI0d/LLBPAkagCKORVddm7c+No+Z2yTxXfUUAch4e8YS3Gty6H4m05ND1oIJ4ITdrPFdxE7d0TgKSQwwylQRlTyCDXX1xPxh8PzeIfA2oW+n6XZahqipm289AZISeGeFjjbKFyVOQNwGTitbwV4l0rxHpEMmlX/wBplhRUuIpSFuIXAwVmj6o+Qcgjr04oA6CsnXIlCxzAYfO0n1Fa1UNbTNiz9BGQx+nes6y9x3ObFx5qMjCpCwUgEgZ4GT1oUhhlSD9DSHbkFtuR0J7V56a3PnB1IQCwJHI6Uisr/dYN9DTqE76oZn2GRGECuDFKysg6DJ4PPUYINP1J5I0jdJAi7tjA9Du4H64oKiPVd7lh5sYReAASMnH171bZVcAOoYA55Gea65zSqKo1dPX79/xuMp6dEyNO07h7ndh2HTH8OB24qa9mtra1mub54oraBGllklICxoBksSegAqWKFEkcxJ88jZbHVj0rVOg2t3YXFtqkMdzDcxtFLC/KFGGCp9eDUNutU5l/X9dPI2oUJVpWjseUeGPDWp+KtNuNWudZ8VWEl3czyWUcVyYIo4N5+zv5OOBs2nax57jmum0jwjPod9JqV/Pfaxq0sXkm+u5FOxM7ikaKAsalucAHoOTgVePw8ls1DaB4v8T6fNGu2JZbz7ZCvGADHMGyB6ZB960PB3iC/vNR1DQfEMVvDrumrHJI1uf3V3BJuCTRgnK5KMCpztI6kEE9Dhe92etLBXTXMIDwOmfQV01hE0NpEj/eA5/nUjLGmXKqMc5x0qnDqsEkm07kBOAzDg/4VnCCpPVmdCjDCSvOWr2NCiiiug9IKaXUEAsAT0GetOrP1iW7hsWksLT7RddFXKjbn+LkjP0qox5mkTKXKrkcF0moai/2O9by7N2inhVOGfHQsR29BWoKp6XDcQ2pF59n+0M7O5gTapyePxxjmrlOo1e0dkKF7Xe5BPaW1xPbTT28Ms1sxeCR0DNExUqSpP3SVZhkdiR3qeiioLCiiigAooooAK8z+M/gzw7e+BvFOrTaRbLqsGl3cyXkK+VLuELH5nQgsOOVbIPcV6ZXK/Fj/klnjL/sC3v/AKIegA+E/wDySzwb/wBgWy/9EJXVVyvwn/5JZ4N/7Atl/wCiErqqAPPvBS/8JH428R+JL13c6ZdzaJp0Wf3cMSeWZnA7u8gwT2EYA45PoNcH4dJ0T4peJNHJAtdYhj1u1GzaBIAILhc9/uQP/wBtDXeUAFFFFABXnXxel+xXPhDVNSlCeHLDV45dQIwpjYgrBKzHgRpIwLexB7YPoteeat4nkmvn0Hxt4RubTQ9TuDpkV61xHcQXDSEiNWVDvQOMAEjhiBnvQB6GenpXnXwEcyfDxJLi6NzqT3969+zqEcXBuJC4eMf6tuQSnbPpXO2GseKdG1/W9A8L3dtrekWDxxi/1ydy9pMUBa33IC04UFGycEb8FjioLHRPEsOr6rqcnjFrS51R0e7i0zTYkjyi7V2GUuQduAWIyQB6CtIUZz1SOepiqVN2k9TqPjujv4OsNspVBrFh5kQHE6+eo2H8SG/4DWO1xpukWcOoateQWiO4jWS4kCJvJwACe9Z2peDIdYEK674h8UanHDKJo45b9Y1SQdHHlouCMnHPFVrj4beGbxFj1KPVdSt0bclvfanPLFGemVUtwevPvXm47h+WNrwqzatFW/G9zxsa6WKqxm27JdjotC17S9ehnm0W+ivYYJfJklhyVD+gbofqM0uowm3kS8t8Kyt8w7f5PesCP4c+FII0Sz02ez8vPlta39xEUPquHwD74qe3ln8DMbu9kute8KDm7F6xuLvTl7zK2MzRDqykb1AyMgEVwZhws6tJxjL7zmeGjUklTlZ9G+j+Rstqr3ULRW9s7yuCp2/MB+VW9ItdQhgKvZ3MYj5VzGRx6V3dldWTqi2BjeFgrBoFymGAIORxyCDV0EEZByK87AcJRwUuf2jv5L/gnqVcDWxUlUxFbma00SR5xLcr50jXEqqVwvPBH4fnWRqF79oGxFxEpzk9SfX2r0u6s7e8vLiOa3hmTyl3BlGd2Tjntx/SuCl0jytZniQg28EuMOckjAbHv1xXn8T4evg6aqSknCVl53t+tjy8VlmIc406evM7f8P5DLLSi0KyvM8cjDK7O1TwwWgvtkssk1yvH73kZ68dq0SxyRGu5u/OAPqawfE2uW2hvF5Nm1/rl0pFpYxMA8uOrM3RI1/ic8D3OBXwi+sVPc197ZXX3vsrdX01PsMNlGX4dXcLuK3euvfXQw/ipcnTtLh8hPtFze3EVra2YkCtNIW+6M9F53E9BiuU0Pwd42s7e4jn1/RrV9RjCsHDmSzyeTFjgnHQt35rqfAvhxotUn1jWZE1LW5lzLcyJlIc9I4AfuIOenJ6n20r/wAxbqU3RUyE5Yg5HtXrU8TOD+q0bTk921dt9Ek/+HfXsYYnimvSwMHRh7spNeWnmt79PRsyLO71fw9r9lpWstdajYzyGPTtRmKGddsRaSKbABfhSyyY56Hmr9nI3jvxfeeZcE+G9Aubd7YW4G27vFBZmeQjOImwNq4BJ5J5FVfH0unQeC4W8Q2kd/CsnnxRSMwKnBCkMCCDgkcHoSK53wF8SNCMcdjbQR6NFENsKQA+WB7qfzzXuZJmFTDUpVPZNq9nZK111SvvtdJd31NZZDjMfS/tHCU/jS9265vO3d2se2k45J4ozxnt61zkWs/bY9sFzY3CMMH5yM/hioo1e2iZWuIoIc52q5kYewzwBXqz4lwMYN3fN0Vt/wCvQ+ceW43n9n7GV/S347HUA5GRyPas/U7iZZ4re3A8yTPLHAHfJrH0zVBOZDp12tyEO1kYhWz7Hoa434jeIpotRh0Se7XQ4bu1kY30qmWSbcCrRQbflVwBksx43DANc1XOo42hKlh241PPdfLd/IuOU4x4iOGqUpJtq/pfo9vQraXrunav4pu/EV5O0lgtv/Z+mLux56CQmaYqM4VmVAueSqZ6EV6Jo+qRaiv7oR7MZQxnIIHUexFfKOpavatex29sGS0gUQQ85EaKMKM9zxyfWvZvhBqpeMJcSbmB5JPpxn8iPyrxc7yyXsvrEm2+ifRf59/M/VnwzhcDg3PDu81bm/y/rz63PUdSBNjJjsQT9M18xfEa6kt9XkcrvIO3DHgZJ5r6YlgeC3vzJKXSQ7lB/h6cV8sfE+8WfXpo06b8n8P/ANdY8Kw5q8lui+HK840atRrla9H1svv39ChY6spx5U7wSf3dxXn2NTS+JZ7aTat3cSMOu18gfn1rlSR3o4xxX3TwlNu7R7ss2qyjZpX72/Q9/wDCMkninwVNapfRR3JljkiLrlVaORZE3L/dLIoP1NdD4m8MeKPEoji1A6Xp1r50cs6WM7TyP5eWBUyRBeXEfylSMA8nOK8u+GclzasrWYZgFTaP7zk/dx7gmvonRJZZIGEmSiEbSeceq574r4LNpTwNdypWtdtXW17f5Lc+W4nyinWmp1Otnp0dunpc8ZPgG8lntba41GT+z7QXiQzRzNHcBZvLIyEVVOGEmV+7jbx2Ho/hFNah0a1sTcrA1rGsRW2ldYgFGF2jtwB8vbpk1fjs/tt7cSBiITIQCoyWPtUrxPpcgnhLNFkLKjDkCqq1MdVw/tVol8u7f5n41TnesliG/Zpu7Wjtd6+l9X5bGpotxqtpO73F1K6gYVHfere/NdjpupR3nykbJh1XPB+lcNqt00VrGYT/AK3jeOwx2rEikkhkV4ZGR1O5WBPBqcoz7GYSopSlzQ6xev3dn/TP0nB5NTjQUKbfk3qz2SiqGiX41LTILkYDMuHA7MOCPzq/X61SqxrQVSD0aujzJxcJOL3QVzHinwTpPiCcXzRvY63EuINWsj5V1Ee3zj7y/wCw2VPcV0xIAyTgVRu9XsLTAuLuFCecbsn8hSqV6dL+JJL1dgjGUnaKuc34L8UXlxqJ8MeKLVrbxRaWonleNd1vdxBtnnxOOgY/wMAwJIwQM11d3c29uhFzIihgflY8t+HevD/iP4zh8M+MY9f8IRz3k06CDWgpBheNFbysK2CZAznBUgAZBBzx5je/Fq4vrl7kXTOSfnEp2Op9CuDtry8bmU1G2DipvvfRetvy0Pby/Ia2Lf7x8i89L+lz3h3vomfFkGj3Hbhudvb9KrPqbo+2S22t6EkGvLfDvxQFxKscj98ZDbcfj0/MYr1bSdRt9btQsgDkg4OMHI6g+jCvzjFYjMMG/wB9t6Hi5nwNWwsOelUflezX3pf5l/TrtH/eR5IIwydxWitzG3HKn/aHFcpNp80F5HFG2fMzscnH1z/nmp5o7exlWNvPklK5aRZCCPoK9HDcTSoxjHlufMYLLMfiZypRhZx3u7a+W/8AkdNNGJ4jGxw3Byp5U9iKhhllilWG7aNmYfu5B8u/1GPXvWdbX72u03J8yAj5J1+6R7/3TWlMFuokkhKs8bB0z6//AKs19nl2Z4fHQtB79Oqf9bmMlKEnTqK0lunuaemkC/h3dMkD64ro65GGYMqTRNleGBFdarBlBHQjIr1MPpeLPXyyXuyiLXMeMPCg1y4sdS02+bSdfsGJttQjhWUhGBDxOjcPGwP3cjBAIIIrp6K6D0ziPCfii71q2udE8QWT6Z4stLZZLq1I/dzKSV86BgTujLKR1yp4PYm0TkeorO+IRfR/Fng/xLFgql3/AGNdRjgvFdsiq2f9iVIzg9icc4z2/wBlg87zREm/Oc4rCrS52mjhxeEdeSknYdahltohJ98KAfrUmOSeeaWit1odsVZJDJHWNGd2CooyWY4AHqahaOO6jiZJn2BhIDG/De2R1FZXiUHUQNEhCl7ld8zb8GGIH74HckjAH51sWtvFaW0VvbxrHDGoVEXoAK1cVCClfV/l3IUuaTVtF+ZNRRRWRoFFFFABRRRQAUUUUAFcr8WP+SWeMv8AsC3v/oh66quV+LH/ACSzxl/2Bb3/ANEPQB5h4D+OPgrSPAvhfS3ub+6vLTS7W3uFtbGVxFIsSqyk4AOCD0yK6jw38bvC2s+IbjSrj7ZowSISRXOrotrHMc42qWPXkEA9Rn0rP+H0jx+APCwjYoP7Isz8vH/LBK2bpUvIjFeJHcxHqk6CRT+DZFdiwl1e55csxalbl/E4jx38RfDmq2eu+INJ1i50fXPDUs2m2FwtxDt1GQlSY/LJbfCXSMk4HAyD1Fe+xEtGhYqWIBO3p+FeM6v4I8K6wEGpeHdMlMaCNGSHymVR0UFMcCpbez8QaA63HhjX7682kBtN1y58+3kToQsu3zI2HUHLDjBHeolhZrbU1p5hTlpLQ9iZlRSzkKoGSScACuI1j4o+FbC6lsbbUBquqo/lLYaaPPmkk/uDHyg+uSAOckVx914dbxDOL3x3NFrd3/yztFDpY2o/uxxZ+ck9XkyTgYAHFbtlDDYWcdnYQxWtpGNqQQII41HoFHFOGEk9ZOxNTMYp2grlC+1Dxh4kEn2q9TwvpsjMotLJVmvmj6fPPkpGx5PyKSuR82eayz8PvCDriTw9Zyt1MkrSPI5/vM5bcze5Oa6aiuuNCEVojzqmJq1HdsraZp1lpVklnpdnBZ2iElYoV2rk9T7k+p5qzRRWqVtjBu+rCiiigApykqwIwcdjyD7Gm0UAeY2Ft4s8P/EHQfC3hnxEbbTyWuLC3vJU+zrZFm8yEoQHmmQ5KgMflAORg19Bx30FvHNJLtjAb7oA3Z9wM15X4njmsNU0PxTZ2hvLjRJZPPhRA0j2cq7ZjGO7phXAGCQGHfB9CGv6NfwafqK6pZrpk8aSx3XnKscxLYVNx9+3XPGK8+dNRm09j3MPW9pTTvrsbdijhHllUrLKxcqcZA6AfkBXHyMGv7/+8Ll9358fpiuP+K3xt/4Qjxg2h2OmQanItokkm6fyPIleQBQ7MMbdpB46d8Dkcmvxq0C/8TRyWYlRblC98rKzLauqqNpZQQ+WyAynHT1FfGcYYGvjcLFUYttO9l6M39t9XqQqcvMtU7bq63/D8e56zGRulUdn/UjmvO9auUuvitttCALbRAlzInPmh5yUQ+m3Yx45O49hTPFPj2aYWb+Cbe71G7SQ+dbXGmzxRXEARizLKyAKVxkHvnGD0rkPhX4htLyWa1uYbsa9el7u6uXgKxTFSF2ox52opVQOMY9Tz8hTyPFUqEsdODV42s0009m2nbS2vzXZ2yzzGTWHlSpap3u12/y3TOi1jUraHxC9p4g1efS9KFmJrQrevZJPPvYSBpUZSSqhMKTj5icHFZF346Gn+IbHSbK4TULC4ltoJGvoQt1iVRh9xlVmxuU7hDt7E5r0WGK3FnNdXpJhjOAoOO2SSewrmNd+JVtZXSQxBlBXCo2cEfT6etZ4HETjVXsabk0rb2SfdaXv89+vQ6cjyXFZzgIU/ZpKPwyve+61XTy1uedfEDxFr2p+EdKW/k0sQ3VhNeosVtIroI5AmwkyENncDnAxzwetePJeyG6RQFXkDqAcEdQc5/SvYPihruoavJai5dpLKQKVWHqynj5f5VyOneG3utUlsVDvOjldudoUep/X8RX2eUr2WE55RSu3oul36Lpp8j9Bw+V1MPClhPaWcVfysv8ALr/wDC0fxJqljLbSx3scIkUndJkquB06jOf85r0KHxjql3JaQzyxRiVrZfsMm8yyiRVLOpz91dx6g/dOSKqPoun6Ky+bPDLdEMGSLL+X6ZbPf0rSl8WRzaZttUT7SV2NIMAJxglcf5FTiVQrTjL2d/6/rz9D1Vl+KlCPLV5n3d+3S7u1fXa3qrFHwt471QahB58UQWeF3UWiMGG0jghmIYYPoMVkfEDxFeatJZSTF1QXG4HOQuAQM+5zgV0fhCS1gkmmmuI0nPypvOPl6kg9K5DxjGZbS8Fn86JL5gAH3lDZ/wDr1jh6dF4u8YWt19TtrYP2NCra8pRV07a6JNr52+V9NkYSRtIwjjUsx4Ar1HwBdSaaHc3ES+XtwZHA3NggjHoRXE6W0KWCSCWIrISxcMPy+vtUs99bwpkyB27KhyT/AIV0YyDxMXStoa4XCUadByqTXvJfdv8AP+rHtOv/ABIjg0eWFWXftxjeH2/iO31r591K7e+vJbiTOXPHsKLu8lujh8LGOQi9P/r1WpZdllLAp8i1Z49T2NNOnhlaO782MwaUdD9KljKh1MilkB5AOCR9a1vDmm3F7f23kWrXEs0ohtYTwsspBIyeygAsT6A16FSoqcXKRzKKV23ZLd/1/T2PcPhxZ6Z4b8M2eo+IryzshcRl4VuJ1iMnThdxGe3SvRElvL+BGgeCO0kUFTEwYFfYjr+FZWk+B7PTNIIuVTVtbeJFnvrxBIzlcfIgIxHGDnCAAeuTzWLcaRfeHoG1Dwp5to25pJNLmJNjPnJIROsDk5wUwM9VIr89oywONrznXm730v8AD/n8/m7H5vxTmOJxWIs5ShFq+m29rNr5eWp6bp1ukFugjXAxgewp1/AksLFhnjB9xXNeHPHvhzVNNsJRrFhby3UasltPcxrKpP8AyzZc53A8Eeord1W8WC3cjoo6+p7CvuKjo0sJaWiS2Pk5pU4WkrJGPFltGuYn58h8KT7Hj+dYOtXb2OnSTRLmTIVTjIXPc/Sunjs5f7I8mL5ppCHbJxknkivO01vWdVvLu48MW2n32k2c32VklkKPfOFzIYpPuqqEqvIIYhuRX5phYKrOUo25U76uy8lfz/4OybP0vIpPDYOlGtq1bTy/4C0L3hrxtqWj5RpWlibkkgMc+46H69a7C38e3V6gEF5ao5O0KyBXyewDHk/TNeJa5qd/NfXcllYJotnGwWRtSXMgfHzKkSHBAPQ7sHtxXOj+x7t/M1ua/wBTmUEJ54ComRgmNEICn35I9a+qoxxCp2p1ZQXaLvv87fij6qpltPHr2tCjq+rVl/n9ysfQt7rV7HFcXV5ezeVDG0kjNkhUUFmO0egB6CvO9S+IUX2NZr20vtMS9RJba9udro8TjIZihPlsR0VvUfSuM+12M8Jivtd8Q3cTLsaO4u5NrpjG1gpGR9eT3Jqtq+sJLAtlpqeTZqoXAG3IHRQOyjjisKOWc1TmrXlLu7r8Xv8ANGmEyLEOonJKCXlf79vuTMzVfE9tqUjywTk20BykXKsfRiD6+tcXrl9DNewytJEkysikp2U9frVnVpY9QnUyRq8ceQm4c+5/+tVVIokjMaxoIzyVxwa+ww1KnRikl/X9eReYVq1b9zGS5V1s9Wutt/8AyZ9+ul7SkkfUIRECTnnHORX0H8O7fUrOOF5t20IMk9GYH5QPUgcE14r8OWstK8Q2c2sMV0wrkTSKWWIhsBWIHC98np619GeIPF3h7RrOCSS7jhEZU7lQuzN2VQuSxPoO1fL8RVqkpxw9ODlfrYxr4p08N7Dl1esr7RXT5Na3/U2tekL3sUanBRc4zjax96aiyX9vIXYNc25xx/Gvp9evNc3rPjHRJtN1XWNMvbfU4bby0C20oLvI2Asar1JYkAfjV3wJ4gh1C/1C2urafT9QtBGJ7a428bslSrqSrA4PIP4CvlZ4OtSw6qODVv6em/X8V1PyDB4qvSziVW9ouTT10stF+lvXzLCahLa3kdvGsv71WYnbmMY6hs962YJvst7CIvkjuEDqo6I3f8DUBWKS4kkkke8YtnbEuFP1PSkcXL6kktxFt2r8oXkKOw/OujL4VvrFOdKLWqTevU9LifMsFiKcKdBqVRNarW3fX8LfM2rG5RISrKwG9iMdOSa29M1dUAifLRjpx8yj+ornEUIgUdBVuxTdKX7KP1NfoNHH1p1tNbs+Zo15053gztopo5VDRurA+hollSGJ5HJ2oMtgEkD6DmuPvEDRbh1U5rjtQ1628MWCahc+a1xcvsjWNS0krk4WKJRyzHHTt1PFVmOfPAzhD2XO5dnb9Ge9gcTUxlZUYxS0bbvsl5er7nqHiPSbDxH4dvtL1IB7C9gaOQjGQCOGUnow4IPYgHtXmVp4+8T+HbK+j13SrbV7PSjIX1CG+SK4u7ZMt5ywlQpYIPmXcpLZ2jFZ0/xI1KViJvDfihlxjYbJdv1/1nWsvxJ4huPFXhvVNEj8J+JFu7y2eKFzYoVViOCf3nTOM+1cNTiWvOvCFCj7javdq+vZJ9Px7Hr1cFVjHmjJaeT29dLfcz32xvYb62t7i3JaGeJZo3xwVYZHP0NWCW3LgfL3OelcF4Y+KXhjUbBE1LULLQtThXy7rTr+5jhe2lUlWj+YjOCODjkEHvVzQvFdjrXjC6tdF1ew1C1WJWfyLyOUKcfwqpz16npxX2sablfpZXOKVRK3m7HWrbwpcyXCxIJ5AFZ8ckDoM/jU1FFQ23uWlbYKKKKQwooooAKKKKACmsCVIU4PY+lcNceJte8RX1zaeBrK0Sxt5mt5tb1LcYd6ttdYIlw0xU5BYsqZUjLYNIfAepXu2TWvHPia4nAx/oUkVjGD6hY0BP8AwJmoA7yvKPjb4kubnwx4q8O+HEjnuoNJuJ9VuWGY7KAwswQ+ssgGFXsDvPGA21H8Pr2H/j28feMUPYSXFvKP/H4TUXi7w7YeGPgr4w0/TVkKnSb+aaeZ981zM0Ll5ZX6s7Hkn8BgAAAHO+Av+RC8Lf8AYIsv/RCVZ0XQbPxJ461q31WbUjBaabYvDHbalcWqq0kt2HJETqCSI0GTn7oqt4C/5ELwt/2CLL/0Qlb/AIA/5KF4m/7Bem/+jb2vQrO1FW8jxMIk67T8zS/4Vp4c9dd/8H9//wDHqP8AhWnhz113/wAH9/8A/Hq871TQfFT6Rrqwov8AZ0ni+O5Fl/ZkrXMkf2yFvNWXzMbMDdnyyMKee4sw6j4u09NHjhj1WCF7y886w0/SvJZgb+UJIXNpJEAY9rEFoiQS5Yls1w80u57Hs49ju/8AhWnhz113/wAH9/8A/HqP+FaeHPXXf/B/f/8Ax6vO/Dh8R6Bo0OnG+8V29uur3v8AaEsOirPJbo0tw8TQAW5EiykqzsBIFJAGwGui8NSePdcF8l/qF5pEsekW0lszWESq904uFJfcjDjELPGDwdoyBkMc0u4ezj2Oi/4Vp4c9dd/8H9//APHqjuPh34XtreWe4m1mKCJS8kkniG/VUUDJJJnwAB3p/wALtb1bxPpNxruqKba1umRLSzKr+7CKFkfcOW3Sb8ckbVUjqc+ZeI5vG3iDw1qmm3P9vSzXFlOdQtTpSxxW0onQRx20nlfvlZd4PMnyjOVPFHNLuHs49j0XTfAnhDVLKK90y81W8s5RmOe38R30kbjOMhlnIPINWf8AhWnhz113/wAH9/8A/Hqh+Is3iTRfBtovhuW7vr1biKO5ujErTiHndIFjgcbs7R8sLYBJ28Vx/wDwkHjq20rQkkuxNe64ZtMgLWhje2n8wsly6SwRMdsIlLfuwpMaELhuTml3D2cex23/AArTw5667/4P7/8A+PVyv9lQaF4+1bTbCW+ayGmWVwI7q+mutsjS3asQZXYjIjQYBx8op/hrVvHUvxLez1dpo9JS7uYjFJayGKS3VW8mRJFtAgc4QktcEHLDYpwBc1//AJKnq3/YF0//ANH3tbYeTdRanNjIRVGTS7fmTUUUV6R4Q4Eggg4I5BFcpq/w+8MatcTS3enyoJpRPNDbXMkMMsoziRo1IXfyfmAHXnNdTRScU9yoylHWLscxD8PfCEdw1w3h6yuLhuWluy9yzH3MjNnpW/pWn2OjweTo9jaafF/ctYViB+u0c1YopKEVsgc5S3dyRppCPmkc9+WNcd4uUazrennQtU0ubxHo7S+bYTXm15YZFG+NsZKkFUbJBwVGcVv6/JqcWh38nh+OGXWFiJtEmOEaTI6546ZwDwTjNcd4A8PTpqEd/qVje2qaassdmL9ES4nuJ2Z7q6cJkc7hGg3EY3Y7Vx4yKrWw0qfNGd1Lokrfm3ZJervoa06UJU5Tk9une/6eZD4e8S303jKTwz4h0G9s472JZbYKm9kK5WQyFSQ0RPCyDA6A9ayPG/g6wju3uBckR/Mquozgge/YDvnNdz400S41KOy1TSpGTW9GMlxZpvKx3AIBeCTHO1woAOeDjqM189+J/HN5rBUo7eTKgdUbgIpGQpx1x+VfE47IfqOJjLCK0Gu+l+vnfbt5n6DwRXkoyhCpyRhut3q9LfO/9akuva/HHp0ENvbr5kaeVDJJyy9PmA7EY4PPNclDqF5CgSK5lVQSQobjmoJpXmkLysWY/pRFFJLu8qNn28nA6V304+zhy9Pw1PsK81Wrc9JPy6vv/m9Nixc3s1xbKrKQgOHYdGPbPp9KqFSFDFSFPAPY1taffpBZNpssGHmPzM0eTntjuBzVq308x2ESXMfmRhjhyp2k+xrH2qp6Wtr953xwc8Y1Jzu7dej00f4/cc9HPLEu2KV0X0B4qT7ZcGN0aVmVhghuajnz58mVVTuI2r0FMrosnrY832tSF4qTttuyvHxe3CnADBXUf3uMFh/I1P0ps8PmKudyMDlJAPun29fcUyGcM/lS4S47qOje6+oq372qOSL9m+WXV6fN3t69u6+ZLSchvb3qF8zXLRiSRI41G7YcEsenP0qxa6Sbs8I8w6bpnJH4e/0pPliryZUPaVpctKN/+Bv0Y5A+8Ki5duAuM5r2/wCEOn2+leIL26ksYp7v7BbyLNIgzbyOXG1D6NGqk4/rXnugfD2e4lj/AHl5CWOQIn5PqFU5xkdz0r2L4ZaHaaN4r8Q2FupksPsNpLeeZI0ghuwZPkDMSc+WQxGeMjpkV81nuNpTw06VOV9NUu11/Xnt6+dxBSxMMI6ULRqSas73to/L/htN9bdf4n8SR6P4cjvbolHk5Gw4zz/WsHwv490/Xm+y3BEm7nDt3Hof8as/EHS4fFGkyWcfyKi/u8jrj2rxnwp4b+xO9w1xgxTFSoPJK9j6D+dfN4DA4SvhZObamn/wx2ZVlVCvgVRxK5pWtJvvbTTrc921Kx0K8mnSPRtHuorj/j4/0SMtMx67iBnd79aq3Pw40uUARap4jigC4jtv7WmMaenU7uPTditDwFY20GjJcwYkaY7t5HIOOf8ACuiuplt4GkkOOMKO5PbFeVPF1sPN0qE3bbff5HgY/B4ec3Q5b208zz1/C3iqxzBpfi++ERUqPt2y6aPP8SsSpHHZtwq1f6Etl4dsNN0WWSKC0hSEDP3ii4Klh3P3s9ya6DT7CG6iZpncSg/MPb15q2qW1xZNbWUis0R3rz3/APr9K6Y5jKPuzSdmr2SX3u2u/r2ffmwlCllmITjWbk+krfhs3+Oh8/8AjCC5YW0aJmNVMhCkHnOM4Fed399crMyKGhUHAyMMffmvXvHGh3q3W+2Xy9kjujn5cg9s9iD2Nec6hBe2rTx3kH2pZGDmK5zvX1KNmvvcrrYapTVnb11/y/I/SalXEzwsXh2n3to/zf5mJa6nLGcT5lT/AMeFPuNSeceVbRspbjPVj9MU4XellCx02RZVJ2KJyUb/AHgRnj2IqJNUliVhbw28DFSoeNMMM9SG6jjj8a9f2FJO7f3f0jzVmeLdN01f52/PVkdtZNIjSzt5Fup2mRgevoB3NRTW7xSzIQG8s4JHT2NJc3M1ywa5mklZRgF2JwKt3t3ceV5EsEULOAzMq4aQdsnPt+daXhscijV+K2nXsv61HabqhtIjGwYgAgFT1B6qfarPh7V7bSdVhvIrYpJFxGzMX8sei5+5+FYf0oGScY/KuaVCE00+u52/W5tRU0pcu10n+O/3H0p4Y1vwz4rurO81GxtX1e2TZDdBQJEX0B798emTjrWh4t8LXMc6694Z2NqUSchshLqMA/upQCMj0bqp9s188eDJJY9ft1h3Zc4IBr608MtL9jIlJ3AISPRsc18JnGGllVWNSjK8ez1Vu3ofK8QZDg8TBYmC5ZPT+u612f8AwTI8NeNLTUr5rKSwvdM1GBFka0uoxjaTgMrKSrrnjINadr4j0DVtXk0q316wl1cE5tUmUtkdh2JGOQMkd64L4z6VpuoRG4lgdtYCpp+myQTNE4nlcbBkEDG4gnPYGvRNL8I2F54OsdC1HSrG9tLaNI9htwsJkUDLKO2Tk8c819NklaONgpzT12XS6tqtdV8lbbU/NZUKcakoJt2bWi6rdrV6D9Hv9O1pLttG1K1vhaSmCfyXz5bjqpP9elZJ8e+GLJiBrdldyOdiW1jILmeV+ypHHliT06Vr6v8ACvStaltnnE2nxxxR20tvYTGKG5t0YssEsY+Vo8k8cHBIziuusfDWn2OBawQwALtAghSLA9BgdPavcjlsIzU4XVjeOXtvmUX+R57dfEbwz/ZLT2mpxXl2+I49NhP+mPKTjyvJOGDZ4OQAOSSBzXJaLbXeneNbHVPiFLb2ljqME1tZzO37jTJ8h/JjlOFDSJuzIcbmTA4wK95TRNPW4E7W0ck//PR1Bb86h8XWNxqHhPWLLT47d72azljt1uEV4/NKEJuVgQRux1GKeIyqnipL2u39deny322vf0MJhZYeoqsXZr5/13LVjplnZ2gt4IE8rHO4AlvcnvU1vZ2tsxa3t4YmPUogGfyrnvhddWV18PdAGmi4SC3tI7RorgETRSRDy3jkBA+dWVlPHUccV1BAIIPSu+FClCyjFK22m3oei6kne73PNvB9rp2r+JdWmvbGzmaXMirNAjsfnP8AERngED8RXRa94D8OazbbJdMgtblG3w3tkggubdxyHjkUBlIP4HoQRxWV4dih0PxjcWjtGIbtD9lPU43ZCnuO498Cuz1J547KVrSNpJ8YRVxnJ78kD3r1cfFSrJx2aVjgwbcaTUt02cQde17wTlPGCvq+gr93XbSDEsC/9PUK9hz+8jG3j5lXrXd2V3b31pDdWU8VxazIJIponDo6kZBVhwQfUVHpt7DqFlFc2zbkcfiD3B9weK5Of4W+EpXmK2F1BHLIZXhttRuYItxO4kRpIFHPOABzXDJOLae51ppq6O2rE8V+I7Xw1YQz3UF3dT3Ewt7a0s4vMmuJSCQiDgdFYkkgAKSSK54+AdQtI/8AiS+OfFFoyk+UtzLFeRoD1BEqFm46bmOP0qfwx4NvbXXv7b8V60fEGq26GDT5mtlgS1iYfOVjU7fMc8M46gAAKMgoZW+weOPExzqd9D4U0xxza6cy3F6wOch52GyM9PuKx9GqKB/FXgu4exSx1PxfojgNaXAni+2Wzd4pmkdRIvdZPvDkNngn0OsLxj4ltfDGlfaZ0e4u5m8mzsov9bdzH7saD1Pc9AMk8A0AcXdeLfGGr63b+GbPQl8PahdR/aZLyW6iu2s7UEgu0a8CRmwqAllJDnkIRWxJ8P7i7kRtT8aeLbpE6RxXiWqke/kRoT+daPgLw7Potjc3msSQ3HiPVJBc6ncxAhTJjCxJnny41wig9gT1Y11FAFHQ9JsNC0m10vSLWO0sLVBHDDH0UfzJ7knkkknmr1FFABXK/Fj/AJJZ4y/7At7/AOiHrqq5X4sf8ks8Zf8AYFvf/RD0AcL4C/5ELwt/2CLL/wBEJW/4A/5KF4m/7Bem/wDo29rA8Bf8iF4W/wCwRZf+iErf8Af8lC8Tf9gvTf8A0be16Fb+CvkeLg/94fzOll8ZeHobG9u5tUgjis/tPnK+VkH2ckTYjI3NtI7A5yMZyMwN488OpqUli99Kk6M6FmtJhFvRN7RiQpsMgUElAdwweOKy9W+F3h/VNQ1G8uTeiW+vYL6QJKAqNGpUogxwrgvvHVt55HGJrn4dabcahPNJqGqfY5Lma9GniSMQJcSoyPKPk35+djgsVBOdteee0Fz8T/ClvDDLJe3pimge6jZNMunDwoFLSjbGcoA65boORnIONfw94o0XxT9sh0ud5/IRDNHPaywkpIDsYCRV3IwVsMMqcHBqlL4F0ySG2iae822+iy6EuHXJgkEe5j8v3/3S4PTk8el/RPDVno+qXV/bS3DTXFpa2TiRgVCW/mbCMAcnzWz9BgDuAclP40bQ9C1G8tbHS4NEstRXRrCOSQ2cMQjbypHllAZY4w6sqgJxtH97A0fCXxG0vxBdWsDtb6fNc20EkcF1cqk0k7oJHhSM4L7FZNzDu2MZBrX8LaNdaJc61AXhbTbm9kvbUqx8xGmJeVWBGMeYWYEHo2CBjJyF+GmkrqWm3ovNR8y0MbygvGReOkzTq8pKZ3ea7v8AIVyTg5GBQBseE9audSl1my1JIkv9LvWtZDCpVJEKLJG4BJxlJFyMn5g1bMtnbTXcF1Lbwvc24YQzMgLxhsbgrdRnAzjrisbwnotzpsus3upPE9/ql611IIWLJGgRY40BIGcJGuTgfMWroKACvMdf/wCSp6t/2BdP/wDR97Xp1eY6/wD8lT1b/sC6f/6Pva3w/wDERy43+BL5fmTUUVzuieKk1W3N4dLv7LTArv8AbrqS3WLCkgk4lLDoeqjpzivSbSPBUW9UdFRVLStX03WIXm0nULO+iRtjPazLKqnrglScGqut69Fpd1aWiWl3f390GaK1tQpcouNzkuyqqjcoyWHJAGaLq1w5Xexr0VlafrlrdRE3KyadcqjyPa3pVJVRCAz4DEFASPmBK8jmqsnjLw/Bf3Nneavp9pLAEb9/dxKJEdA6svzdMHocHjOMYJOZD5JPZG/RWZJ4h0WJ7NZdX05GvAGtg1ygM4PQpz834Zp9rrek3moTWFpqdjPfQkiW2iuEaSPBwdyg5GDxzRdC5X2Mr4n3p0/4ceJblSVf7E8SkHBBkIj4/wC+q+ULlxJMxVAigBVUdgBgV9H/AB9v7CD4c3enXko+16hJGtpCOWkZJFZm9lVep9x6185w6OpWIzXdzC0xAhQsSWB7n0HvXi5muepFLoj7vhKUqWHqytpJr8E/LzK9WdM1E2FyJEMcgBDMhIPSqEtoIzIpmuCVyMiU1XtooXggDwRt+7BztHpXlOnGSakfXxxNWlNOCs/X/gHselDTNZC3LW1uL5uDErgbj6hQc85r0u98LWs2lizMRWdkwNxxvYDOMf4dK+dfDX9nxzeTdadazJ1IKAMR7N1BHYiu6v7TSmi0iz0mwt4bu9uA6anE8huoI4/3jMjFjtbIClu27oa+TzDBSVWMYzaS8rrv/N07HdjauMlCFela1/5nvorar+rnMeJvDq2Ny6x5VsF1P94dwR65Brmbcx+fGZh+63Dd9K6HxisYnkMGpanOM7FeW7Z9xPLHntXKfZ8dLi5B7Zkzj8O9fQ4TmlSTmysbOUJxfs0pWu9fu00+Z1six3VuVJV4yOCvOPcVz2o2VxbRrJhWSOVGDgjA+Yc+1VIzexnMU0O4dwGXPucVeutWEmnSQ38BVm2gtE52yDI3LnqCRnitKdOdKS5HdXLxeOw+Ooz9vFwkou3Z6bX1/H5Mm0nT5NRup7ybkXMuVjQcvg4zx0yc9K9x+Hfg2J9slyi/Lwx7DHUD0A7nua878LNbpqkAQrsQFYtp4U4wtfQunwraeHoILcbTOViz7YyfzJNfLcQY+rpShpzHJn2LjkOXN0t7XbXV/wCV9uxU1zVtJ8N6JNqEthdSWseFiEWAZ3JCqij3YgVH4T8PT6RolsL147m5uZmu9QlhOd08rZfHqB8qg+iil8U2YuPFngW0kRHtPtV1IFcZBkjtn2H6jLEH1FbhsWindbOWSBgcNzkZ9K5a2S4mjh17B/FrJv7kr/j53Wmh+TUOIsVScZ4le0vd9ren/B1MHxvBdWUa/YTIIGJL7BltuPX0BrgPCuiIZ/s127P9pZmmYdGABOBn9a9YluZoP3Nx5N4ByV/jX3p0EE9z80WmQKFOV81i238B3qcFl2Yqi4eztfq2lfta+r76H1mB42w1LDezcWpPy1/yf3leyR9ItjZWagW4UbWQFgBjqDXA+KdU8RwXMpsoJnt1JU4zgL2IPXn1r1FbbV1jZxcqvOSpQYA9qWCxkELvcXflty4jiwgb3IrbB8P4mFRzqcj668z9X8P6nJhuMcPRk6kqLk33tr531PJ/Buv63Zaost5blLKXA2MSxOeP/wBdejSRm3vIpdPBIZPMCnkKM8g+1Nui1tdbHkeWLAIGcEA+lRi/KTvJKnmRYCgcLwOmQOPyrnngaGLxSipJdGtm+yV9G+m93fRM8PiPiPB5zGM6VP2dWL0fVen4f0kaDeXqscw8kRXCD5w/O72x3Hua8t8eWNvFbzKIEKCLzosj7hHUAjnFeq2IeOG41C4BDSLlVA6L2rgfGUeZLVnGUeN42Pr7flXHl+MdHEShQ0h/l5vX9D7HhCtXrQhUxN7v5adNFtpb7zwbW2sWuVZreWOVkBIjkG0n15BIrInMRf8A0dXVMfxsCf0FdnrWgyW7EzwCaAH5ZQOn19DVUaPZwYW4EaOeSuCxH19/av0ClilUgmtfuPt62Wc9V1Kc9Ja9W/PTU53S4fOu1JXMcfzE9s9hVjX4pEuIWkBCvHlc9xnmuhS0hkUrZSDjpEyhSfp2NR67o895aW0qR/6UoYN8w2lFA5z249fSqheU+ZoqvRjRwvsovVu76PRX27WX9X04844xRVswyQRqssKlXIlDBgcqOwIqO/kL3cjMAuT2Urn8D3rZ3Ts0eSlBw51K/wDT/wAjW8FzC312KU4+Urye3PWvqrwnfLdw7gOZFyR6OvDCvkHTJDHfRY6OdhHsa+hvhfq7/Z4Q+WcpvAz94r8rD8Rg18lxRhXUgqi6DxmHVfAc0d4t/wCZY+KfkLaLY6hItvY39/BbXF44+W0hdstNkggEAEKx6MVNe7aTrem6vpNpqOj3kF9YTkCKaBw4btxjuO46jBz0rzzxP9l/sk39y8MVqiZlknIVBGRzuzxgVQ+FkkniTx7q/iaysP7O0K5gESWyqUW6YEf6ZInQO2Cq8BinJ6ivY4I56mDm3C0U9+7tqvlp9/c/JKdP6niKtBrd3T736fL/AIJ7GsiMxVXUsOoB5FPqjqCW0dsPMjH91Aowc/XtVZtYjiWKGFJb658sMy2wDAe5bgDJ6dz2r7FU3JXidjqKL9416KrR31rJc/Z47iJ5wCSisCRjGc+nWiC+tZ5WjhuInkUkFFcEg/Sp5JdiuZdzgltv+EQ+KtlFYyzf2T4pFwZLISZSG9QGVp1U/dDqHDbf4tpxzkejVw3xcjVND0m/RmW+sdasJLUq2CWe4SJl9w0ckikdwa7mpKMnxFpMep2T7UVb2MbreYcMjjkYI5xmm+E5LuXQLV9QMpuWDFvOXDfeOMj6YrXYAgg9DSKoVQB0AxWvtm6Xs33uZ+zXPzoq6bYiwiljWV5EeVpRvAyu45IyBzyT1q5RRWcpOTuy0lFWQUUUUhhXn/hm3jvvi14yvL0G4uNNFpa2TSHItopIFd1Qfw7mOSep4HQAV6BXCeDP+SmfET/rvY/+kq0Ad3RRRQAUUUUAFcr8WP8AklnjL/sC3v8A6IervizxTpXhazjn1WdhJM3l21rChknuX/uRRjljyPYZ5IHNeUfEnVPFfiLwR4ka8MPhzSU0y6k+xQsJ7ycLE52yyfcjU4GVTc2MjcKqMXLYzqVYU/iZoeAv+RC8Lf8AYIsv/RCVv+AP+SheJv8AsF6b/wCjb2sDwF/yIXhb/sEWX/ohK3/AH/JQvE3/AGC9N/8ARt7XdW/gr5Hk4P8A3h/Mx/B//CSa14S0TVLrxtriXF9YwXMix21gFDPGrEKDbE4yeOTXWfDi81GdvElpqup3GptYamLeGe4jiR/LNrby4PlIin5pX5xnFc74Z0HxvofhvSdJ/srw3P8AYLSK183+2Z18zYgXdj7IcZxnGTXUeAdH1XSxr1xrkdjDc6lqAu1is7h50RBbQQgF2jQk5hJ+73FeTBT5nzbHZh411UbqbGd4Q8fS69qelQ3OlJZ2Ws2c19pc63XmvNHEyAiRNi+WxWRGADOMZyQRXVwa7pE+sz6RBqlhJq0C75bJLhGnjXjlowdwHzLyR3HrWH4Z8Caf4f1O3u7e91C5SzgktbG2uHQxWUUjqzpHtQMclEGXLEBQAQK62tjuCiiigAooooAK8x1//kqerf8AYF0//wBH3tenV5jr/wDyVPVv+wLp/wD6Pva3w/8AERy43+BL5fmTV5vbfDFYtNubJptEHmq2LuLR9l1u8wSDfJ5p3jIAK4GRxxXpFFelKKlueHGpKHwnGeHdE1+21jWbi9v4YzcalDctLDbKEuoVtkQoELsY/mGMkk/J6GtLxH4ek1O/ttQsbqG2vYYZLVxcW32iGeCQqWjdNykjKAjDDv1BroacoJIA6mlyq1gdR3uecQfDeaygH9mara2k8kN3bzbdP/c+XcOrlYoxINm0rhcluPWrWj/DqDTdfttV+2ieeK5SdjJBl3C2htwm7dwoJLjjj7vbNdDofinStcv5rTTnuGdIvtEckkJSO6hD7DLCx++gf5c8dQRkHNbVTGMJao0lUqxupaHmjfCwAw+XqgaLyFt7iKRZ1SVVkd1wIp4wPvkfNuHGQBznW0zwVe2/jCDW77Xpb0QNP5cUiSZCy/w8ylBtAAGyNc45yea7WnxKGlRSCQWAwOtP2cV0Jdab3Z8zfG7UNVHjy5fXVurGwijdNKUqJEeEEBnAU/xsMkn2HavPpdRtJY5LiS9DXnmZ6np6iun+JHijVPE3iR01K4sJoNPkngt2tYdiMhb+FiNzj5ec9CDjrXLcgYHA9BXzmMknUe5+m8PxqQwcdI7NbX+d01r69UVnvrZlb/SFyQecH/Cls1P2WDIx8g/lVjJ9aCe5rlurWR7Cpy5uabXyVv1Za0vP9oRYPqT9MV1WrWOoQ6DYXNs0KyG5Lx72KlEKkNyOoYDBHsK5fS4biS6R7WIybD8x6KB7t0H1Naup60oiFtbTSzJHwu7hFJ6ketcdejUlKM4rT/hz2MLWw8qEqFWVtb+fS1vO6MbWI7tpYhc3QDbSQsCbVXnvnJNUICS0kcrbpI26kYLL2NSXExRd7bpJGIVQTyx7CoBII52e4Yebt27YwWCL1647nnmuyEWo2PJxVaEq3Om1fe7b0t3el9P6RZxjpU1tO9tOk0eN6nIyMg/UVDketFK7TuW0mrGvDLFBcWd/Z5jJk2SxdgwweD6HOfYg+1fVekMLjTdEyfldDL+g4r5N05reaFrS5n+zCSRXWYgsqEAjkDnuOfavo/4XXdzL4LtftY/eWk6qjDkMp44PcEGvnuI6KfscTbRSSfzPnOJ4Sq5RVpX+BqXrG+v5G8ZBqvxItV5Nr4asmllI4zdXQ2ouO+Igx47uK37i53xCDcqJk+ZKOSXzyqD1z1PQe/blrCdofiT4pWECfOl2c7unS2kQyqqOO7Mrbx6AfSuhtzGkUW9t0iKFz1I+mK+llWjSw8XGPM2lbS/T9PO61Wh+aVpcqS8kaNpHGVH2W0RFA+/IOSe/vn61MZJU4kKRDsQu5f8AP1qCxlIclVdkI5wp5q+sgJxhx9VIpUKsqkeecLP8fXUzi7q5WCNIhEimYMMEiTg/Qdqy3cwwkMxih98MPp61rTQKjNIEBQj5wOox/EK5fVVkEykuXhx8h7V5+d4uWGoqpDrfvb5rVfh9xliKjpx5kRxwyajdyeUqp3J7KO1WLuzWwaOU/vkVgrq4GG4zn/PpVjS4Wk05hbTrHMz5c4yQPT2qPXf+XWIyGSZRhh6+h+tfm9TGTxNVqT/4f9E+3oem8uo0Mr+uy1qOzWu2ullt6rXqi8p22x8kebZyLkHBYxjHIwOcenp0rIn0s3MDRgwXcTDlF+9+R5BrUslGmWObp8FmztHOPYVnwizGoPObi4HO5SFwcnqDW1HEqupzkrSWvNa/NrbVWvd9Wnra9m7s+qw1bH04Up06fxbq9uX0/wAumxyN74flhVmsWR9vPlyj5j7ZPH4GuF1rwrJbXLzG1lIlOQpYRqp74Jznn6V6Xr2ti01PdOFEEimRiMcc9T6dKkbUtOu7Eo9xEEZD5iufvZ5B9/wr28PicRQpRrSlFp+rtp2S3fn/AJn22Gx+KotPkbT37v536eXc8it/DgkLLPugXnD7w5P4Dp+dQ3eiX9gTJYTNcR9CYshh9V9P0rqxXW+H7e2udFh823jcq7AkjknPXPWt6mbzo+/OOnloe7iMdUoR53qr7PVfjr+PyPK9J8HNeXQlNgUdmy5V9231wMYU/jXVxfCtp4czM5DdCwBGPTp+vFepwxJpuni5WKNmcDavZSTxxVi3057yEyzyyPIVBwrbQo9AKyp5pi8fNwoJNd+v66/f38z4DNuNZ4Cp9XwsLPdq+n49/T8N/HrP4Om1nla4uY7eFT8sx6kHt9fpXYxaRoXhbS5L29vJhb2ULSOyoRlQMkAHgk4/E108VrLFNaI6SN5TnBx8m09x6GsfXNIXxF8TPDmk3ECXkNjaz313FKu6KHzCEgcg8M+UkwOwyfSjC4LGZrzKvNqz2sl+fc8OrxrmWMap0lGELLRLrbXa3ocxq41XxNZQ+ItT0pbbQrD7ObPTp381HZ5UUyzEYBcB/lQE7TknnFeran40Tw94tvtGbT2nt0gsRZ29lGPPnuJ3uFKZZlTAWAHJK4AYk119/o2n6hos2k3tsk+nzRmKSFujKfp0PfI5zzXM6p8O9MfRbq00lRBezzQzm9vp7q6lDR/cPmeekoKgkLiQYyfUg/omGh7DD08Okkoq2m39fnvuc1OErudR3k9zL1f4vaLpWhLqeo6dfwQ+dc200MtxZpLE8DlJF2NOPMOQ2BHvzj3Gatz4j0PUdfNrHZ67DY/2hHYNdxNHHafaHhWReBIJMlHUbtuB3x1OhpHwl0CDQo7HVzdX9wUuY7i4iu7i289J5DJJGwSXLIS3R2c8cknJroovCOgRBoY7MDN5HqJXznz56RrGr/e7KijHTjpnNdFOpOm7wdipwjNWkjyvRfGepW2rxm1F1F4VfSLnUbdrqO1h+1RrNbqkis8o28SN/rGjB3A49PTvAHirSvGOkTalpMbIsFw9rLvaJz5igZw8TujDBXlWIrmbXwT4C867s2spkFvbmPL6jcGOKISpKRCTJ+7CyRofk27SMDvUGo6NbvrR8C+FriazsL6KTVNfuvPluZyjeXGsYlkZirzBXGSSQsbEDJzWlZ1G71Fv5E0lBK0OhNobXnxD8WaL4nl014PCOnxSzaat5JiS6uGKql0IQPlUJ5m3ec4YMAM16fUNlawWFlb2llCkFrbxrFFFGMKiKMKoHYAACpfoawNQYE4wcc0uarW7S/a7pZJo3QMpRFGGjG3ofXJyas02raCTuFFFFIYUUUUAFcJ4M/5KZ8RP+u9j/wCkq13dcJ4M/wCSmfET/rvY/wDpKtAHd0UUUAFcZ428apo9wuj6HFFqXii4XMVnvISBO89ww/1cS9fVui5J4g8e+KruC7Xw74XeI6/PH5k1zIu+LTIDx50i/wATHkJH/EevANYeiaTaaLZvb2Xmu0rmW4uZ23z3Up6ySv8AxMfyHQACt6NF1Hd7HHisWqOi1ZDpGjLZXk2pX1y+p69cLsuNSmQByv8AzziXpFEOyL16sSar+Pv+RB8U/wDYIvP/AEQ9blYfj7/kQfFP/YIvP/RD13uKjBpHjKbnNSk9Q8Bf8iF4W/7BFl/6ISt/wB/yULxN/wBgvTf/AEbe1geAv+RC8Lf9giy/9EJW/wCAP+SheJv+wXpv/o29rGt/BXyOvB/7w/meceBPCHhq68D+HZ7nw7o808unW7ySSWUTM7GJSSSVySTzmvRvgxY2mnR+LrXT7WC0tY9ZGyGCMRoubK0Jwo4HJJ/GvKdC1fS4tD06PSZ/iSNOS3jW2GzRuIgo2feGemOvPrXrPwVn0+40jXJbBtbaZtTP2s6wLcTeb9ngAx9n+Tb5fl++c5rxaNSEptRmm+yZ6dNWk9bnPfDK9X/hPpLWz8St4ot5ra5uZZ1u7sNYMJl2xTQyTvECQxVcIjARnjnNepwTaudZninsbBNJC5iuUvHad244aIxBVH3uRIeg454mbUrFTeBr22Bshuusyr+4G3dl+fl+XnnHHNM0fV9N1uz+16NqFnqFpuKedaTrKm4dRuUkZrqNy9RRRQAUUUUAFeY6/wD8lT1b/sC6f/6Pva9OrzHX/wDkqerf9gXT/wD0fe1vh/4iOXG/wJfL8yaiiivTPACnI21gwAOOx6Gm0UAY3hrw3YeHYpEsGuZWdREJLqYytHCpJSBM/diXccKPXJya2aKKSioqyHKTk7yeotSQgrKjN8ij5yx4AUdWz6e9R15N458O6hd+NvsNxr9/a+HNYcXos1P7u4ljTE9tuHK7kAcKflI3cZArHE11h6bqNXSNsNQ+sVFTva54zrsVreS3epGyhdZr2e5QODgxvI23oRkYIINZ1vDLfzhHkwETBkkztjUDAyew6CvYtTstMs54brXYlkhNu0aWgU4YjoMjgcHAFcb8V5LZ3D2UNtHLqCRS3KQzb5VICnG0YC/KSMdzk+lfO0ITrUnVrSs735eqv37f5dj9WrVqWGdOlhaTa5Lc6VlJx0dur03a0vprrbk3XTU+UPdSkdWAVAfw5qXTrjTY7+MTRSBCDhmkBP1xiudlR7aeZYoHj2gDiFo2HPcEc/lUW6djE8nmqw3gMseT2x2/oKmUL3WxpTxqpSU7NtWe+m9t9DrNeurcrDa2ACwqC8hXA3sTxnHoKxqoiS53qGDhsp8oT5SMDcSfzp9qZ98fms7BkJYFQNpyMdqzcHbVnQ8XGpUbjBq7/X+v+GJboOTA0cbPsfcdpGcY7Z9ak020uNQnkOnmJ1k253NgqxGAMAHmpF27huJC55IGcV2fw805X8TLujDSQ2ylE24MjPJ+u0L+BNYYjEewpOfY1p4dSqc8r2v6a2tv6Xbv8rGpovwe1i/tHkVLNQRKyzb28x9yEKjDbgKCRzk/dGBWLdfC/Vba5uU+xHy4RFuRI5ZBKQ2G+WNGYg5HIB6cjFfUKfZ57CCI3JtvKbLKpxmrly63VtKlnMgnYcHoxHpnrXwK4pxkZtu1n66a9zwauYVKbrfuLpL3fWz0X5a7nzhoPwb1S/037YbSxhMpnQW988kBhG75JApj3dj8rKhxjpmvcNMsoNI06w0a3kExjaMPKOhIHP680W9uksrRysY5Bxgj88/SsJtbGqO1n4Fc3d458o6oYGa0swPvSbyAsjjoqKTk9TjNevho4rNP3tdr2f4J32e+qS/U+BxOf4rMqLocijF76/hsv62Lvw1kN14cvpLmJvteo6pd3F/h8hHEzIIwe4Cxov0HvXY2ULrIqja6JztPBIrH0LRU0C10/TNKDnToEMe1yGcsTuLse5LFifc+ldKloVQnd+94II6Cvo6s51XFU7SprW3nd79npsulvU8qpLnndbEivM/RY1x1Utkj8qiWW7E+2SKLYOflPJHtmre1QcgYOMZpsib8EEqw6MO1d6kno0Mzr25mDhDEyoc98Z/xpEt7SW2USF4w3XcSBn+VXZBvQpcRCRfVRkfl1FZ1062hdo5WNvjcyn5sf59DXLWpwpN1Zq6e+v8AS+WhMklqySTQ7ZiWDOGPcHH8qy7/AEc2+WgZi4+YAnOfcH1rV066hul/0dmilHO3HB/D/Cp7xsR5mXYwPysDkGvPxGAwuLoSnQ/DT10MZ0qdSN4mMZodTgjWSVYbhD0boaryabPEyou2RiMgJ6evNXrizt7nJdcMf4l61r+HfDubZbuSd5drHyodxVSM4Ofr+VfK4TIsTUm8NSacXr6NbN9etnvoz6jLOIMU5RpVIc1uq7dbr/J7nl/ivw5Ndee4EhkmXa8LcErjHyH+lczb2LaZbRQPHI7RoQxkQ4UbifoDz1r6XfTtN1C1KPbIVBwRjDIf5g1xV/oSwXlxamZvLHKqVyCp9a9DFYbF5Hh37VqSdlp5a9V5aeV7n3eEz9VIxp1FotfwstvJv8NTyDarDMfA7gnp+PcVseF78QTmzkA2TtlG9G9Poan8X6NHp04liVVUsFkVemSMhh6Z9K8+s9SvV1d7a7y0AkKb1jwVI6EY/OuWFP8AtGn+7jur/wDDI+npRhjMO5KXu267/wDBse9sBe6N5cf+tiAyo9R/jTtDlaWKNc4ZGCg+1YvhPUybSOW4Z2BzFIwHBYfxVuaYiW+sTRA5V8SL9DmvPyiE8NjlRls33/r5H4/xXl/scRHELvyv8Wv1/A2rqdLeCSaQ/Kgz9fauK+EUc+sXHjHVoke3uNQ1WZUvA25xFFiKNQSMELtcgdBuIrs7yCCeDbdLuiUhyM4+7z/Ss34DW0sHww0m5mQedqBlvjtYEYlleRc++1hnHGc1+t4WUFG9ryv8v+CeXgafPJ/1/XQ9BgQxwxoztIyqAXbq3uafntXn83xW8OXUt3aeHW1LXr22kaGWPSrCSfyiOCxbAQrnuG57ZqG08e+QwZvCvjgscl92k53tx83B46dK20erZ7eq0RueMNfu9MuIbexa33yRktvyXX0IHTHXr6VwL6nfSXX2pryY3BwPMDYOBnA+gyaxfEHit5dau5rnw94rV5G3KG0ll+TovG72x+BrP/4ShP8AoAeKP/BWf/iq+jwiw9Kmtrtaux4eJnVqVHvY6DJ2hcnaOwPr1p3wo1yHR9a8aLOpNo+pmRZzksZRbx70Zv7inCqP4c4rnf8AhKE/6AHij/wVn/4qtb4LeILHStd8QW2u29xpQ1nUpZ7KTVLcwCYME/dqxyu84JKZB6cHtGPrUpwV9V9w8JCanpoz2LQdWvdSlm+1aXNZwhVaJ3YMHB68jv8AStumoqqoVAFVRgAcACnV4FSUZSvFWR7UIuKtJ3IfNTzmRceaMZBGM/41518XdK8Ralq3hv8A4RQtFdRreB7gKQEUxD5RIARGzYKq5BwTnBxXos6Ss0RhkRAr5fcm7cuOg54PTmpAMdTk1LsUrnhj6p4r0/VtNsPCml3uheH44rYW9tNp8zKzbz56z7LWZi3BG7zYgch9zg5rZ01/H139mJ1bUoZdRfVYds+nQrHY+XI4tZP9UDyFX75IYNwM816fE181yVkjt0gU/fDEl/TAxx+tW5EWRGSRVZGBDKwyCPQihqwJ3PE5fF3jHVvDNvrVpFq1rHqNyIraKxgSQWyRxYd5CLa4crJLvwQhGFQ7gCc+mfDu91bUfA2h3fiKGSDWJbVGu45YTEwkxzlMDafbArds7aCytIbWzgit7aFBHFDEgRI1AwFVRwABwAKlpDCuE8Gf8lM+Ig7+dYn/AMlV/wAK7uvP9Jc6H8Xteg1EeXH4iht59Olz8srwRFJYj6OAA4HdST/CcAHoFcZ478XTaVcw6J4fhhu/Et3EZY45WxDaRA7TcTkchAeABy5GB3Iv+O/E3/CM6RFLBbNe6neTraWFmp2+fO2cAn+FQAzM3ZVNcRoOlNpsd3PeTreaxqEv2jUL3aR50mMBVzyI0HyovYDPUmtqNJ1H5HLisSqMdN2P0PSY9ItJI1mlu7qeQz3d7NjzbqY9ZGx09Ao4VQAK0KWkr00lFWR4MpOTuwrD8ff8iD4p/wCwRef+iHrcrD8ff8iD4p/7BF5/6IelP4WOHxIPAX/IheFv+wRZf+iErf8AAH/JQvE3/YL03/0be1geAv8AkQvC3/YIsv8A0Qlb/gD/AJKF4m/7Bem/+jb2uet/BXyO3B/7w/meB+E/EeiQeFtGin1nTY5Y7KFHR7pAykIAQRng17Z+z1dW97o3ii4s54riB9Z+WSJw6tiztQcEcHkGoPDfifxvrXh3S9U/tLw3B9utYrnyv7HnbZvQNtz9qGcZxnArr/h5req6vHrkOuPYy3OnagLRZLO3eFHQ28EoJVncg5lI+92FfHZY8G8VP2FTmlZ3Vmuq8u57CwzpPnfU4m88LapdR/EOy07ws+m2+qyQ3Nrve2SG6aPZvUiORiDKVY5ZRkNliDxXZeBbDUE1rxNrGoabLpSapcQtDZzSRPIojhVC7eWzKCSOzHgDOOlQTfEiws5L1NW0jWtNa3s3voxcwx5uY1kWP92quxDF3QBXCk7h743PDPiOLXWv4TY3unX1jKsVzaXgTzELIHU5jZ0IKsDkMe+cV9CUW9H0+5sPtH2rV7/U/Nfcv2pIF8of3V8qNOP97J960aKKACiiigArzHX/APkqerf9gXT/AP0fe16dXmOv/wDJU9W/7Aun/wDo+9rfD/xEcuN/gS+X5k1FFFemeAVtUhu7jTbiLTbxbG9dQIrloRMIjkclCQG4yMH1zVtsEnAwPSm0UWC4UUUUAFYXjfQn1/QjFbXT2epWT/bbC6XnyZ0U4yO6kEqQQeDW7SqSCCDgjkGpqQjUi4SV0yoTlCSlF2aPmbRoNTvvAa3Oom1kG8zwyRXiTuxbLOHVT+7+8MKcHA6cVyGsRmC9WeEsFc7g3Qhh/nNeu+PtB07wP4kvPEcNvPFomrREXnlIXjt7ndnG0dFcEkZ4ByAecV57qdvY3MbCxu47u2ZjiSE5CHqBn+9jGa+Hr0pYPFzjy2jo126Xt8+h+3cPY2nmuWxoymnUV7Lr13+XX5nPXpjniS6Q4lclZlJH3v7wHof55qnU13bSWr4kAKn7rjoapSXG2ZolhkdgobK4xg+56V1X9pqiZx+re5U0JXdI13SOqr6scUowQCCCD3Heq5Jnnt3ELqqEndIAOCOgH5UJutmdFid4M7lKAHbnqMelPl+8yVZ3vb3e+va9/Tp/w+m74b05tT1WKFRkbh+favePCei22mePZopkYNZaNEgReXlaeVn3L6ACPBJ5JavDfh7rcWkeL9Pu9SfyNKZyspZCzIAM7yACeemK+m/hRpCrp19rF5aPBqOq3Ut3Ksw/fLG7loo2PUBUK/LnjOK8DMsNVxNf2F7Ra0+/X7knffdeR4fE2cyw2DhSw2km9b9+j9LbeZqSxWxG3ZPaSHhWl5XP17ViaFo2qabqzCZnmt2IZW3E5bPX24zk16BNbxyxspRRkenB+tcf4lu7/QPD+qX2kgTfZ7WWaOGQFgrqhI46kZHSvAxuRV8J7lF8ylpr/mfLZfxXiaF6OKXPGWl7ar+vL7mZPxGtf7a1rT/D1nvY3KG71RYmwRZocBScgjzHwnHJUPW3pt4tnBHamNVt4gERVG3y1HQAeg9KZ4As7CHR/ttpNNeX2orHc319cczXLleCewUA4VR8qjp3q/4ggQJHOAA5bax9RivJWYSw844ai3yw016t7tr7kutkup5+cZeqlF4/DyVt2ls9dX69/wDMs3N2tlsldWZQw+6M1pedNLbpKiNCSchHHzY9x+tc5FdxSWDQ3JIZVwCOpx0x71o6c9wIEaWbfJgZwd2K/QcBjcO8F7RfE3rrra3Rd11+Wup4VKrFxujUup2hgB4RjnJz0HrUdjdebgFw6t91h39qy7+Ka5gaPfuIIIJPX2p+mQyQRIjcyb92F5xXNUx1X62uVe5/Wn9akupL2lktDeqlqVsJU3gDcAQxx1H9autw2DwfQ0d69upBTi4vqdDV9DL0y2S3hZ7dcPn50znI/wAa0I5Y5QdjBsdR3H1rMYbZGHQg4qeziJd3X5WAABI4PtXFhcTG8aEY2sRCS0ikWZLeM5YKFfHUCtnQ7xEgSCTC55U9jntWaPfrVdz5SOrcoQduf5V6Sqcl59V+R00a0qMueJ1ZULfKy9XQhvfGMGue8YBbaSK6YlQSBkDJz9PcVW0vxF8qG8JWGJ9kc558xf4sj29RUnjC+02801B9thLLmSMBsksBwMe/NeZmOKwmaYKXJUV462ur3je617q67H1GAk66jUjF8svLv/V/xPOPE08P9mXD3AOZD8g65ftXESQxm6W7VSJ9u0lCQM9Pu+uK6a7vJNWUCxspXVQQJyvKseCBzjkcZPrXXaR8O72HR3NzcW8csnz+XGxyuB2k9f0r57AUMTUpy9nd331V16vb72rrbsfdwxVHLaajV0d9vJ+W/wDwd+jfEaHaamLwENNbwhh5u7+PvtC9yau3fjc6f44GjNY2sr2jWtt5Yvtt1L520lo4dh3BN3zfMMAE11ujhBBNc7GeSFfkBGccfzrJTwfp19Bqmo3l1cxzXZjvJLmJgHtniUhXiOOCBnOcg9MYOK4soX1nML1oXcV+N1r919z47izNKeIcMM4766eVv8/wIPEnxFtVvrnSPDt7aQ38EdxcXt5eRM0dlDCSsj+Xw0km4EKg4OC3K4zT07w5pPh+SHRR458WWOlCzl+12d3YzxrcQxjzXFvKY1SPALbhFlivAIPNYnhLwDa+LvEN74l1Dz7PT9SS1ura18+MzzgHPnsqj91HIhIKZJO9ySOAOi8ceE/Dnh3xpDdS23iTU7zU49QuJfsEEE0lvHIohcnEXnSLm4AVS7BcDjAxX6jFKL5Y9tfU8PBxjG6XSw/XPFfhrQvsfifwNezQJYvY6df6UtpJEt7ZuzLF5cUiAs6gsyOnUKynIxjsNJ+JNq/hm71bWhdWkK319DHNFpV26RQwTsgacBCYm2gFt+3nPAwQPKvEGl3Hii11DSrXwv4jj8VQx2At3+0WqR2aRvKbaeVlOY3xJLuT5iAo6da9E1X4J6Lqlmtvf6rq1wpW6MryrbSNI9xIZHkAeFlR9zHDoFYdM1bsnody1WpS8RXo1DW7u4RxJFu8uNlPBReBj9T+NZ3PHqav2GgyfbE0q3kQTRnysM24IBn7zAYJwB9efSlgsb+31CJFtGM+/Yqyx5Qtj7pzweDX18JwjFQT2R83OMpScmt2QWVncXlzHDBDI5ZwhKqcL65PQceten2nhyz/ALAfR9Tgt7+yfKvHNEGSQe6nIz/WuL0QapDrM1rZ6bBHe7mYs+9UhzwSMHBXngc54r0myWdLSFbuRZbgIBI6LtDNjkgdq8fNa0pWjdW/rU9LL6aV5W1OG/4RvxB4RG/wVe/2jpaD/kBarMxCj0t7k5ZOgAV96+61seGvGuma3evpkqz6XrsYzLpd+oinA5yyDOJE4++hYe9dRWP4m8NaR4ns0ttbsY7lI28yJ8lZIX/vRuuGRuOqkGvGPUNOSaON0R3Ad87R3OBk1IoGBivL9Pk8VeHZ55hDP4t0OzlaGMyFV1OBdo3FTwk46jB2vx/Ea7Xw34r0bxHaTT6Veo5tztuIZAYprZuflljbDIeD1A6VUo8r5epMZcyv0NyiiipKCiiigArnvHmkadrPhi7i1a4FlDbD7XHfhgrWUkfzLOrH7pTGc9MZB4JFS+I/Fvh/w0v/ABP9a0/T3MZlWO4nVHdRnlVzubpjgHJ4614R4e8Nar4u1m68T+Pm1AWdzMZ7Dw7d3TSwwRnDKZEyBkHGEIx6jtV06bqOyMq1aNGPNI6TwxPqvii5tPFPiVYRMlp9l0yKNCoETY8y62tyjTYXC9VQAZO411FKzF2LMSSTkmm16lOChGyPn6tV1ZOUgoooqzMKw/H3/Ig+Kf8AsEXn/oh63Kw/H3/Ig+Kf+wRef+iHqZ/CyofEg8Bf8iF4W/7BFl/6ISt/wB/yULxN/wBgvTf/AEbe1geAv+RC8Lf9giy/9EJW/wCAP+SheJv+wXpv/o29rnrfwV8jtwf+8P5nOeErXxPo/hXRtMufBWtPPZWUNtI0dzYFSyRqpIzcg4yPQV2fwysdStU8R3OraZPprX+pi4hgnkid/LFrbxZPlO6j5o34zmvJPCNvcah4U0W8u9b8SSXNxZQzSv8A27ejc7RqScCXA5J6V6Z8GZJzZ+Jree8vrtLbVvLhN5dSXDohtLZ9oeRmbG52OM9zXxGUPAfXJ/V4yU7O99t1fr3PqMRQq06alNqxAPh3rF3ba1FrniKyvZtTQBrxNMeO4jZGDwhSZ2QRowB2BBnkk5JJ6jwn4eutIvNX1DVL+G/1PU5UkmkgtjbxKqRhEVULuegJJLHJJ6dK43xD471/w7rOs2Nz/Z195Fibi2b7BNZAStNHGi5eRxOg80F2jwFxg4LADrPBus6peapr2k64bOW90qaJftFnC8McqSRK4+RmcqRkg/Mex4zivpzhNjR9D0nRftH9jaXYaf8AaH8yb7LbpF5jerbQMnk8mtGs7SNYttW+0fZYr+PyH2N9qsZ7bJ/2fNRdw91yK0aACiiigArzHX/+Sp6t/wBgXT//AEfe16dXmOv/APJU9W/7Aun/APo+9rfD/wARHLjf4Evl+ZNRRRXpngBRRRQAUUUUAFFFFAEd1bwXlpPa3kMdxazoY5YZF3LIp6givIPEHg238GWFx9ntlufC0r5Z8Ym08k/8tCB+8j5wJPvLxuyOa9joIVlZZESSNlKsjjKspGCCO4I4rkxmCp4ym6dRej7eZ6GW5nXy2sq1B7dO5806t4engDNAv2q268DJA9x3+orgtWs/J1WMxFfLul27T8ojK4wAfck8V7P4y0ybwEggtBLeaTcL5WltIDmCYsFFtI/TbhtyucHCleSM153DY6jMz6VcxWlw808fmGY+SUCtl4/UggY/vce9fFxo4nAzkq9rLr3Xf5b9Ox+z082o53gvaUouUo2ei1T7Pyeq0TSvdrYSy8MahJYOs9vINx3KOAV+metc9e2stnOYpgQR0OMZ/wADX1T4WsLG8tYliEY3qd7OgZiw6qc/5xXn/wAXvBBKtc6fFl05KgdP/rf59K8XBZ+qmIdKqrXKliaFef1ZR5ZxWnnbo/0PFLS5ls7qK4gYrLGwZSK+q/AHiZ9d8PQakmftKIFuYx1YD+Me+PzFfNnh3wtqWt6nHaRW8iAn5mI6CvpnwB4Q/wCEZhVS5+7gg9/wqOI8ZRoqE4StVjqrdu3zPGzzA0cVgZUMS+WW8e6ff0/M6xb5p4A0bKUb+JRzXP8Ajt3i8DeI5ImCOum3JDHt+6arGng2+oz25OFJOFPfuP0rA8eaol95PhXTryNb3VBJHdyRsHa0tFX965AzhmyI1zjl89q2wWMljIxrTe2/lbVn4xR5nO09HF6+Vty3pn/Eu0vSTYBoozZQhUJBGAgGD61av9SN7HGhjEZU5bnOT7VDHErm3tLGEQwRIsEES8iNFGAPwArZ1KCBLApgEQx5Ug9GPT86+dq18LUxMpezXV82unm07p3fS3prvthYYjE0K/s52prXXZvfTt3fyuYBHHNXLizmso45GdQXP8B5BqmBnjn8Ku2tjPIFeRSYh0UnBb6elWsPWr2p05p9dVb5p7Lz1XY8mkoSjKLjdvZ3tbu9tfwNzRkfUPsyEhXl4LAduef0rurKygso9kCAerHkn6muM06OKO4VipjuIzlYzlcD2x1/CurtYbe6QSxGVJAcPiQ7voT6V+i5VhI0I/vfj81rY+kyuMY3TXvfoX5I45BiRFYe4zWJq1qlvIjRDCPn5fQ1qJaLEuI5ZUTHTdkD86xdZZjOqpdbkUZJYA4P1GO1elXhFxvc7MfGPsm5LU8Q8G6RFG3hpdL0C9sNft7ySTUb1tPktUMG59yySMqibcCoUDdg4PGKxPBXhXX9G8Nxtb6a1lqV/wCHpba2eys2tnW4+9i6PJ835RskOBywwDjPvY3MBmdcZx8vGT9acIRjG6TPruOa5nK255v1h6+ZxHgeHw3b3yy6L4Zv9HuRabZ5p9PktgfmX5HZgBLJnncN/Rvm556HVpGufKjUlY2cIcdcHr+fStN422FDmRD0ycEfjVLUUWL7Mi95VyT15NeHnUqscPOUXZJP1uc8/wB5Nc211f7zyPxp4zmtryeFMqiHZHHGQu1ee/Xt29a53SNclvblWvLZtkpCK5JYEn1z9O1UviZE8fimdSvGSFA78mnaLosljcwXE7+Y6kH7OnXJ45J9M15WBhhqVKnNrW2n9fM/oqGCoUsFaCScl+i2/wAz2bw9pLrpcB2skRAZlHLEnk4z27VeuLG4hiby5HMQBIQMQcd+P88VX1CSTyrMB3WMwj5AcAEcVJpF48VwEkmHlkceYcgH0z2r5SOJrc0ppqLd9rr8tPwPyLEcSx/tCWGqx0Ttd2a/HX53Mi81uPRpYmZpQzgn5AD8o659fpV298SxaFDp13HZXV0NSuBbx2lvsy0jDII8xlAB75NaN9pFi+2W6dBEDvCsoYKf9kmsXxJ4XbxlbWccX2eKC1ukmiS6szdRSBN2Q6blyCT69q7Mon7bG0nT3T1a7fJam/EeKwM6FOlb97f5pd/S2hwnhrRtHl8Qy2umLcaLcy3dzqen6iqxfadO+zkRTWkgJZGgBOFwShGQRxmvYdATQNF1VNc17x1HqupPZ+XBNf3dvCkVu4Ex2IgVcMIw+45O1Bg4Brym78D3Wm/EbwvpFhq1tYXeow6nIzrYlLZEeKJPKhg8zgDBYDcRu5weleoyfDSytfCOv2Goasq295oltpkl2YRH5CW8LIZSSx4P3iuRjHU9a/W4xas31PKwr5ryvp/w5jeINcvvhr4h8Ta7cXHh3UdJ1C/geeN7z7Nfws0SIi85R1VI2YJwxG5s9a7Txt8Q9B8MeEp9b/tLTLom2e4soPt0afbdo6RNzuz0yoNec+B/At5438RWvxB8TXod1v0udPg+xeVDParCUSXy2dirOSjgsSV2f7XG3e/CG7bStQsdP8RQW6ajYTafdPNpxlPlvcTTqY/3q7CDOyn7wbAOAao6z0DQUsZL/VbmzRlmFy0E581HDsAp6IxxjPRsNycjkVb1azmvWtVidY1jlEpkIyVI6YH6H2qv4b0P+xZdYf7R5/8AaF/JfY2bfL3Ki7epzjZ1469K2a0VSXNzN6kezjbl6BRSHtzilrMsaxIB2gE+mcUFhkAEbiDjNZurT6nvSHSbaFy6km4mkwkZ/wB0DJP+FRxWl5ZaDPbwXD3OpGN3Esh6ytnkZ6DPQdq1VL3U21r/AFr2M3U1aS2/r5msvHy4xxk4HGa5rxV4J0fxHPHeXEctnq0QAh1KyfyrmMZzjd0Zf9hwy+1b9hu+w24eQyMI1Bc9WOOtTM20ZIPWs3o7FrVHDaVrHiLQfEOl6F4ra11O31JpIrLVrZPJcyJGZCk8XQMVVyGQ4O37q13dcD4y0PW7nV9M8T6Mtvd6hpDyLFp0rgxXMD43FGb/AFU+0EB+mCVPDE10XhTxRpvie2mfT2ljubZhHdWVynl3Fq/9yRDyD6HkHqCRzQ1Z2BO6ublFFeffGW8d9G0zw9azvFc6/fR2b+VJskFsv7y4Zcc48tGUn/bHqKEruwSkopyfQ5DwKlpqVlqGvvFDdXep6ndzfbZUEjyxJO6Q4JyVVVQBVHAxnqa6okk5JJJ5JPeo4IILaCOC0git7aJQkUMShUjUdAAOAKdXrwjyxSPmqk+ebl3CiiiqICiiigArD8ff8iD4p/7BF5/6IetysPx9/wAiD4p/7BF5/wCiHqZ/CyofEg8Bf8iF4W/7BFl/6ISt/wAAf8lC8Tf9gvTf/Rt7WB4C/wCRC8Lf9giy/wDRCVv+AP8AkoXib/sF6b/6Nva5638FfI7cH/vD+Z55pFppOl6VZafb/FvwK0NpAkCM8CFiqqFBOLwc4FenfCSytLXSdXnsvEel+IftuoGeW501QsMbiCGPy8CSTkLGrHLfxdK+bvC3/Is6R/15w/8AoAr3D9nrzB4c8U+SFMv9sNsDnAJ+x22Mn0r5TL5Yd4iSp0lF2et99Ufc5ll1TDYWFWVTmTa0ta2jfc663+HXheFblP7OkmSe3e0KXN3NOscLEFkiDuREpIBwm3oPQVseHvD+m+H4biPTIpVNxJ5s0s9xJcSytgKC0kjMzYAAGTwBxXhl/wCGfHSa14rn1WxW7vNQ0SP7TcWF3NIkgFwxaCANEgU+VlfLBzgg5Ysa9J+FllFa33iaTStMn0rw9PdRNYWstm9mARCglZYXClAWH90ZIJ5zmvbPAO/orO0eHVovtH9s3thd7nzD9ls3t9i+jbpZNx6cjb9K0aACiiigArzHX/8Akqerf9gXT/8A0fe16dXmOv8A/JU9W/7Aun/+j72t8P8AxEcuN/gS+X5k1FFFemeAFFFFABRRRQAUUUUAFFFFAEV5a21/ZT2d/bx3NncIY5oJBlZF9D/j2PIrxHW/BsXhnUILTUC9zY3BddP1DJDMyqW8qcdnVQTvHDAdjXudYnjPw5H4o0NrEy/Z7uNvOs7nP+pmAIBPqjAlWHdSe4FcOPwaxVJpfEtn5/5Hs5Jm9XK8Spwk1B2Ukuq/z7Hjq+P7Pw/FGRcTSu6D92Is+YRxwM9ff3612Pgn4lWniWePSNUgWy1cMSts8nmGRAMnY/0zwfQ14hJpEttfrJczm3vprn7Fc+cNxsZNxDjHQgFflGeeCa9U0LRPCGoNp+maLFP8mC13GwjuVlH3Zg+MhwcnPTnGMV+ZZvl+FpRftIty195dLd+ny3fkfquKX1uKrUYaW5l6W0u+76W0S096913Ws62ugeIZdI0Dw1eapfi3S4eSAxhYjIzKgbJGAdpJboPem+EPE2v6j4m1PRdaTTYpLWGKYyWwYiB2Y/uGLY8xinzblAAwRzmr3hXRNN8MyX9npVvI888mZrueRpZZyBjdI55J5PtycAVl+IvCLaz4ik1Cw1XVLG5mt0tp3tWVEkRS2MhlPzDccN1HavNeW4WWEUl8UkrNp3b01trZf13Pyatn9ZYl1XJtJtWfr8/v1+7Qn1577xheXun+FbmCytrdHt7nWXRnHmnIMUIUjLJyS+SFOByc4saR4Rh0SJLbS9PtoUChDJEqqXA7ucZJ75Oa1vDOjxeG7ODToYBb2qRiOAK3ygL2Puc5z1POau32qJbyCOICVx97ngf/AF68bE18Rh/9igrQWtmrN+b/AEWy6F1o4DGYb61iG6d3rbdvzVtXbXYigtDYiYhWmfytxIO0f7o9f/rVTtFk1KdmlbESkHagwM9gB/WnXGsTOHCIkeV27s5IrS8PW7RRxhhgnLkenpXp5ThZV6nLVWj5fTv6djyMbXoVeXD4Nv2a3Wy8vN/O5cTT8RbBsQf3QKfZRFHPm5Mq9OOPqDVsc4OT+VOr76nhaVOyS2MlBIjliSVNsihl96l0uSa0vvLgdXjkXG2Vj8pzxz6e361GTu4Gfw7VBPdQxXEYLAswK4HJ9a7IVXT3f3msKjpyUl0NO/vHikMF0+6Y9WBxF9APX2OazXtkaXOzBxknPGfcd6bNPFJE6K2GIONwxU0c6sFDELIeCp65q3iHWXtIP7tiqtd1nzMXyYjn92n5Uxo/LXMTFdo+7nINT0EZFZKbMriKdwBHfmsfX9yKZB0RkfPoAea0WEkKAhgyL1Urzt+vrT54UnjKuOCODXHmGF+s0JU4vcipFyjZHhXxciis/EFrdPGCvmhvqvf+QrtfDVjZ6vpNnGURvLy7OwzyD1HvzmtDxH4XttUSGHU7eSeOE/unjYbgPQ5649amsLAabbNBp1tIm4EF5WAxnr35Nfn+Jp4iNGGHUJKcOvQ/T6vGOBqZbTTbVWK2s/uKt3P5869RCnyJkZIUd/r3qJtu5tp3LngkYyKlntJrdf3iYXpuByKg6ZrmnTdnzRtJb+eu/r+B+N16s60pTq/E9WXtNsVuZEaclbcOAfUjPIHpxXrMSRW8KJGqRxKMKBwAK88tkWO2jVAQpXODz1rb5KqpJIUAAE5xX3PD1KOFhKyu3a7/AK6Hs5bVWETtG7djg/2h2Nnp9nqsDq2oWV5aXVqE++uyYDCnoWfeVx0IHNb1wviT4h6ethqWlN4c8N3CD7cZLtJLm9jP3oUEZIjRhwzFtxBIAGc1yXxoikistP1RYzLDpVzDqEkY/jjiY+YBnjIVyw/3a9T8B6i+o6KFkVWSAiKOVRxIm0FT9cEV91OPtMNGquiX6r/gHsYSvzzfnf8AQ6KKOOJVSNVRVUKqqMAAdABTgMDk5o461HA/mJuBDKeVIGOK4j0SWiiigYVBdW0d0gSbJQMGKg4DY9fap6KabTuhNX0YyRwmMgkscDAzzUUbPIjGJothb5GU7gR3/HrUjgh9y88YIpyKqKFRQqjoAMUaJC1bFBz6/lQfpmkXG3jOPenAYGKRQAYGB0rmPFfg+1124i1G1uJ9J8QWybLbVbQASoM52OCMSR56owI9MHmunpAAM4GKAOBg8dt4dkNh8R1t9IuFBMWpoSLG9AGfkY8xycHMTc/3Sw5rmtJvP+En8S6p4sO42cg/s7SN3/PqjZkmXn/lrJnBwCUjT1ra+Mzf2jJ4X8MiV0TUtRFzdKqg77a2UzOCT0+cQjI9a4jxd4g1Oz+JfhfSLG8EVnfGMTwRxI4AMj7vMBG5QyKAhUjG1ycgV00IpfvJHBjJuX7mPa79EdzRSmkr0TxQooooAKKKKACsPx9/yIPin/sEXn/oh63Kw/H3/Ig+Kf8AsEXn/oh6mfwsqHxIPAX/ACIXhb/sEWX/AKISt/wB/wAlC8Tf9gvTf/Rt7WB4C/5ELwt/2CLL/wBEJW/4A/5KF4m/7Bem/wDo29rnrfwV8jtwf+8P5nz5p/iDwvLYWz23w9kigaJWjQeL74bVIGBgJgYFe8fs+32m3/hbVm0nRDoyR6myTQnUZb4ySeRCd/mSAN90ouOg2+9fOOk+H/EFvpVlDL4Y8SLJHCiMP7HujghQD/yzr6E/Zu0++0/wprg1KwvrF5tWaSNLy2eB2T7PbruCuAcZVhnHY14GGdR1HzRsvSx+g5vh8FTwcJYepzTbV1zX6O+nTU7C28f+Hri2vbpLi9Sys0lea7l065jtwI2KviVowjEMCMKSSRxmtXw94g03xBDcSaZLKxt5PKmint5LeWJsBgGjkVWXIIIyOQeK8xvPhlq2pXOoXP2Pw1oVxJZyRZ0nzNl/P58csclwmxcAeWR1dv3jcnpXdeDdG1Sz1TXtW1wWcV7qs0TfZ7OZ5o4kjiVB87KhYnBJ+UdhzjNd58wdTRWdpGj22k/aPsst/J5772+1X09zg/7Pmu20ey4FaNABRRRQAV5jr/8AyVPVv+wLp/8A6Pva9OrzHX/+Sp6t/wBgXT//AEfe1vh/4iOXG/wJfL8yaiiivTPACiiigAooooAKKKKACiiigApR155FJRQB87+PNEit/iDq83iTxBp+nwi7GqK8u4y3UJ+6qKgIDKAEKnk4Dcg5rofhbd2JLano3gzxNcQ7iI51SIK5HUgs64zn3+vBrudcitPDnjKx8UyQW6Wd6Bp+qzvGD5TYxb3BOPlAOYmbIGGXPTjvN4kJw4badpwc49q/JOMcVUweJlQlBuMtU+Z281ZJO9+7dlbuffZXmeJqYNU4zskrOy7dP63PObLxjfQxMv8AwiOuMxkLN89uAAeuCZPm+lXI/H6tMkaeGfFDTE/Kn2JTk/72/b+tb2p2MCOotifPkb/V54x3PsK17HS4oY13Ab8ckDk/jWWUYqtjvgppRXXX/Nn59VpVMPWdCpFO3Zv+vkc7d+J7++szGngnxKQ/99bYY/ObrWG2o3yMFbwl4mU+hjtv5+divUEUKoVRgDoKr3cyBGj6ueMY6V9Bj8Fh669pXiuZLz/zRNWNKfvSjr8zjPBl1DqviSLSdS07UtKv3he5hW8SPZKiFQ2wo7AsN6kg+ua9KtdBjhSUCSTeDtVmxgjqOP0/CvLPGl3DZa34Q1KRl8qw1qLz3U4aNZVeIHd2Xc6bh3Fe411ZRh8K6N6cVdfPX/P/ADPUy7DYepTuonKMpR2RxhlOCPekrY1ay8wNPF98D5h6j1+tc3eTncY0OB3Pr7VtiZrDq8jjxNJ0JOL+Qy9nJPlocr/ER/Ks7esk21DnGcnH6CpZU3gKM4zzg9qltbeRwOAB03dq8pVHVbna8nol2/r5HJfm1I40aadVUcKa15QpRgwGPpmoEiFpllUsDy+Ov1qxG6yKGQ5Br0sNQdGN3/w3/B/rY0jGyIh+5fGP3bYAx0U//XqY54xUd0MwPgZ4zUisGUMpypGQa6JapSKIZS20LIVAd9vHp/jU/Sq0sJmdi2AF/wBXnseuf6VLG+8HIKsOoNVJe6rAPBz6/jQyhhhlBB7EUtNXJzkDrx9KzauBQurfyweN0TccjP4GsCaww5MTqFLYAY9K69iAMHv29apx20bTTcFVyDgHocV5OJyinXT00+7qtnqYVKEZ7lCxhk3BEZ3A+ZmkP8vStmOTeTlGUj+8KI40jXCDAPU+tPrtwmHjh6fKkaQioqyOb8e3mn2nh26bVk32oieSVdu790qkyce65GO+ai/Z/wD7VtvCVlY6lHJ5cdsrKzc7OTsQt0LeXszjoQa1fE2lw6zol5Y3A+SaJ0J7gMpBx+BNch8KfHDaNo6+GtXi8zVNOxGUVgjzQjhZ0BPzqygHjo24HHFfTYH95hnTgrv/AIb+vvPQwc4wlzN2t/X9fI9voqvZXUN9aRXNq4khkXcrDvU6sGXKnIrmaadme6mmroWiiikMKTv1/CvNNQ8T+J9H8Wanaalf6HNpmnWEGpy+VYGCWSOSaWPyxJLdiNCBFnexxz045m074taVqtpayaRpOrahPcT3MAt7VraQq0CozkuJvLI2upBVznp14oA9GpM1xFr8RrO8vtEgtdH1aa31i3S6tbpfs+zyigcu6+b5iKudpYoBuwATkZy7T4x6Fci8jhsNQku7WW2hNtby2lwztPL5SBWinZM7+CCwIyDjmgD0lHDjIztp9cJD8Qbe4ubULaXdq4+3R3FncxxCRZLZVLL5vneWv3hg5ZTnllwTV/wF460vxtHqB0pZEexkWKZWlhmGWXcCrwyOjDHo3BBBxQB1lFFFAHhXiXX5G8Q+KPFEVtJfSWUy+GtGtI1P76bcplzzxumKoW4wIsdTWlokWl65HpHitbC2/tO4sU8u5HzPErr80Yb2JZc4yORxyKpfEHQJtDvtWk1FjB4Y1jVbe/XVbSXy5tJux5aq7oRtMZkjQ788FzuB60vw/wDDuqeGLDU7LWLmGd5r57mJoi3IYDdIwP3WdhuKD5VJOOtd2Hd7JbfqeNjI2blJ63+9HT0UUV2HnhRRRQAUUUUAFYfj7/kQfFP/AGCLz/0Q9blYfj7/AJEHxT/2CLz/ANEPUz+FlQ+JB4C/5ELwt/2CLL/0Qlb/AIA/5KF4m/7Bem/+jb2sDwF/yIXhb/sEWX/ohK3/AAB/yULxN/2C9N/9G3tc9b+CvkduD/3h/M+arT4y/EWa1hlbxVMGdFY4sbTGSP8ArlX0L+zn4p1vxZ4P1S78R37X91Bqb28crRRxkRiGFgMIqjq7c4zzXjtt+zp43ht4ovtfhttiBc/bJxnA/wCuFe4fArwRqvgPwtqOn65LYy3NzqDXamzkd0CGKJACWRTnMZ7dxXkwU+Z82x9Zi5YV0oqj8Wl9+xV0r4u2ep6Pq+rWcOmT2lpGXtraHVUkvZsyCOMyQhcQqzMOSxIyMrXXeE/EN1q95q+n6pYQ2Gp6ZKkc0cFybiJleMOjK5RD0JBBUYIPXrWF/wAKq0V4Ps9ze6pcWkVrLaWUDyRqthG7Kx8plQMSCiYLl8bRXSeGfDkWhNfzG+vdRvr6VZbm7vCnmOVQIoxGqIAFUDAUd85rY80t6Prmk619o/sbVLDUPs7+XN9luEl8tvRtpODweDWjRRQAUUUUAFeY6/8A8lT1b/sC6f8A+j72vTq8x1//AJKnq3/YF0//ANH3tb4f+Ijlxv8AAl8vzJqKKK9M8AKKKKACiiigAooooAKKKKACiiigAeOKaOSG4jSa3lUxyxOoZZEYYZWB6gjgiuX+GcUthZXunSlyml30+m/vCS0cYbfb5J5KmJ02t3HHWuorIt5k0P4h2V3MI/7K8RxDSr4PgKlxErvbuT/tL5kf1CV4PEWUQzXCOlJ2a1T7P/LuetlGLeHrNdJKxr6Iim8ummwbgSEMT+g+mK3K8f0H4m6JqkyrNO0FyvyrMp+8ueNwPX8a7e18TW8gxFqdjL6bmKn+tfB5bmUcvorD4qm4tdUrp/caY3hnMsHUa9k5xbbUlrf18+507uqAF2Cj3rH1m4VIZJIWIYgKDjv7fhVa81C4WSF5UieKThTExP5e9Q6ykzGJURmjGScDPNXjM3hiqE/q+qXk7/1ufNYqU6fNTkmpLo99TEuNLXWreTS3giuBdqYfKlJCPkdCRyB7jkdRXf8Awl1RtQ8C6Zb3c08mradCljqKXP8ArormNAHV/U9CG/iBB5zVDwJpsras11NGVSGP5c/3m/8ArZpvjVH8I+JE8bWaGSykhSy1u2jQl3hD/u7lVUEs0W5sjBJRj/dFerwphpUcLKpPTmf5aHsZFSdOhKctLv8AI7+RlRGZyAoGSTXGXFsXYvGRk9Qa5zUfix4eupYIrSXUb6a4bFraWmnzM9zjJLR7lUOABkkHA/EVB/wm19u84+CfFH9nligmEEZl3YzzBv3he27pXs4qksQuWS0KxvNiGko6LvoN8aNfwTeHbK01A6WNT1IWsl2iI5UCGRwi7wV3MyADI9anl8Javcx+RdeOddNsxAdYYbaByuegdIwy/UHNZulmXxP8R7bVrnRNWstO0zTWWD+0rcxA3TSfeVSxG5Y8gNj+I+gr0EZrKFKOHSjBHK/3KUVv12PL/Cms6v4cs9QsNX8OeNNTma+nkSTCXaRwlsRokrSBmXYqnJ7s1a0njmWFWmbwX4zVUUs7GxiOVAyScS88V3Vc78Qry90/wH4hu9KSR76KxlaIIMsrbT8wH+yMtj2reM03sNTjUlrHfzNnT7231PTbW+sZRJa3UKzQyAfeRlypwfY0+2J8raQMoSpx0NU/DdtZWfhzSrbSZBLp0NpCltIDkPEEG1s98jB/Gr0ClI8Ec5P481nok0YSSTaRJSEelLRUiELAEAnk9KMjOO9LRQA0AA8DmoNqy3MmVBCgAnuTz3+lWO9UNLuluGlEClrZCds4PEjZ5/I9+9a04ycZTXT+v6Xz6AWdzRcuWaM9z1X6+1TE++Ks2li94CDlITwX7n6VoJD9gj+aFJYs4aXPzBfVgev4VcKLq6rQ6qOEnVXNsjGyQOcZ9q5Txd4Hs/EdrcPlo7qEefE8Y2ywOOfMhccqwIBx0PQ9a9GudLikYGL93nqR0/KnWmmrBvLuXZlK8DGAa2wzqYepdbPf0NqeBqxqJPbucB8CtaudT0bULbUpB/aNjcNbXMaD5BIvBdfQOCr47bq9Ox82cnpjFeGwG5+GfxOtnunUaP4jlFtOMg4uFQ+XKvfDKu1h2ZQe9e5KQygqQQeQQetehjF+851qn1PRwj9zlejQtFcpqFv4gtPEct5p5N3ZMgJgklCj3RfQ9wffmuh0+8W9gEixyxNnDRyqVZT6Ef1HFZVKPJFSTTT7dPJmsKvM3FqzMvXPCOh67Ndy6pZGaW6hht5XWaSNtkMjSx4KsNpV2LBlwffgVDpHgjQNJuEnsrSb7Qsk03mzXc0zl5VRJGZncliVjQc56cdTXSUVianHWfw18MWVwstpaX0OLeK0MaandCJ4Y02JG0fmbWUL2YHOSTkkkrYfDfwvYyxyQ2Ny7xfZhG09/cTFBbyeZCq75DhVfkKOO2McV2FFAHM3/gTw3qC3C3umLMtw1w8oaWTDGcKJeN3cKv0xxirnh3wxpfh6S8l0yO5E14Ua4lubya5kkKjC5aV2PA469K2qKACig+1UsXkT/fjmViTtIKlR6A8/rTSuJuxF4gm0+HR75taSNtKFvK135yb4hCEJfeD1XbnjBzXkvw9tWt/DzSpbvZWF7cNe6fYSOXaytnVSkZJJwTgvt6Lv2jpXo/iuy/4Sbwzq+hTR3NoL+2ktVmKZ2llIzx6deeDXi2ma34u8Tr4disbVbbTml87UNdhwkVzDFKyhIUJyPMCAkf7XHy8npoLkldnBjnzxSWx6NRTmILEgYGeg7U2vQPGCiiigAooooAKw/H3/ACIPin/sEXn/AKIetysPx9/yIPin/sEXn/oh6mfwsqHxIPAX/IheFv8AsEWX/ohK3/AH/JQvE3/YL03/ANG3tYHgL/kQvC3/AGCLL/0Qlb/gD/koXib/ALBem/8Ao29rnrfwV8jtwf8AvD+Z8QWNpbNZW7NbwljGpJKDJ4r6y/ZERI/h/raxqqqNZkwFGAP9Ht68Jgn+EohjETfEnywoC8af0xxX0f8As1t4bfwVqTeEDrZsjqb+d/bHk+d5vkw5x5Xy7duz3zmvIpq0nqfX4yopUYpQa21at0MfW4rqIeMNW8L6nr0emaRAdPLNql1debOXQ3MqLK7AeTHlQVH3t/8AdFdl8LL2K6vvE0elanPqvh6C6iWwupbx7wEmFDKqzOWLgMf7xwSRxjFdRa+J9Bu5r6G01vS55bFS92kV3GzW6jqZAD8oGDknFWdH1fTdbs/tejahZ6habinnWk6ypuHUblJGa3PKGaPNq0v2j+2bKwtNr4h+y3j3G9fVt0Ue09OBu+taNFFABRRRQAV5jr//ACVPVv8AsC6f/wCj72vTq8x1/wD5Knq3/YF0/wD9H3tb4f8AiI5cb/Al8vzJqKKK9M8AKKKKACiiigAooooAKKKKACiiigArlvim9p/wr/Wba8eAS3kDQ2cUoLNNcdY1jVfmZ9wBG0cHBPGa6msSwhg074vaXqV7Es/9rWT6bZXDjJsJ41aQhQeAJU3c9coR0asq0nGDN8NBTqpN2PlaPTfM1K0t7X7QtxLLtCSphlAOOSOCchhx6V6Pqvwm8QtdxzWF9braFQTLI5jCHvx3r3XXvAmnQ+IX18KoYufPjiQ7QzAZcA5wWPXBxk56k5WxiN9OJ5xjn91E3SNfUj1r86zipjKeMhRw0bK27Xuu9tnffy0t8z77G8XvA4aNPDrmnLV3bVrd7W28nrfyuZXhCxubPRdPtdQkS4mtUbdKpypYnjB78V1Wm2U1/OUhwAv33PRR/j7VfsNL89gQCUHWRhwPoK6WCGK1g2RKFReTgdfet8uyRwX7x6NtvzbPipU6uZ4meMxGnM7u2n3eQyws4rG3EUOfVmPVj6mufublri+uNzf6tyij0ArpYmZtxYKAD8pBzkevtXE3bNDqVyVOCJGBHY85r1sdUWFUEvh/4BWZNU6cIx0Vy+WJ6kmkpkTiSNXAxnt6U+kpKSujy73CiiimAUAKTh8bTwc9MUVleK7o2PhXW7tQ5MFjPKAn3jtjY8e/FNascVdpGF8Ht/8AwrbRN3m+Tsk+zCU5dbfzX8kE98R7BXZVh+Bbf7L4H8O2+5GMWm2ylkOVOIl5B7ityifxMqq7zb8woprMFBz27U6kQFIeASTxSBgS3P3eDTLmIT28kTBSHXGGGR+IppapMDFu1OragiRo7W8S584MVAPoPUnoa6PTYIjcQwlVSL+6OB9KhQEIoYgtjkgYyacMg5BII7it6uI51GCXux2X9d/QqMkpJtXOrAAAAAA6Yqnqt9b6fZTXF7IIoFU5ckfpRpl2LmHDH96v3h6+9eX+MLeXxN8V7bwv4lnNt4dltjc2dvDj/iYsm0yxSNnKgZB2qDuUHJAyD2UnGXvPY+iVTngnT6j/AAInjLxr4astbuvFkmj2lyZPLtdP0yJcxLIyo6vMHbDKFYHA+99K6EfDexnL/wBr694o1VX6pcatLGn/AHzDsX9K7eNEijWONFSNQFVVGAAOgAp1Dd3c2SsrHnWq/B/wlN4fvLHSdLttNvpAHt9RVDLPbyqQyOHcljhgMjIyMjvVOy8V+K/CekeZ438Mg6ZZ/Lcappt4twsaA4MphIV/LHXjcwXJI459RprosiMjqGRhgqRkEehp8zty9BcqvzdSK0ure8jMlrcQzoOC0Thhnr1FUn0hf7eXVIriaOQx+VLEpGyUDOM59M9q5W6+GWnWmotqPg69uPCl6YliZNLiiW2m2sxUywFdrkbmGeDg9eBVS+8UeJvAmn3E/jHTjrmj225jq+lhVmCEjaZbY4xjJBZGI4BwOcEZyje3XQJQUrX6HpC5IGRg+lLXKaL8QfCmtiUWWuWYkgRZJopn8l48nGGD4IIPykdjwcGtSz8SaLe63Po9pqlnNqkMK3ElqkoLiNgCrY7jBU5H94eoqSjW7cULnAz174paKACiikPBzk0ALRRRQBieNbKbU/B2vafaFhdXWnzwxbThtzRsowfqRXm/gW9tdQ8FaDPYCJYPsMMXlxHKwuiBXj9irAjB9K9jrxq10628MfEHXfD2mRpBpVzax61b24UKIpXkMUypj+DKxtjsWwOOK6cLPlnbucGYU+anzdjepKKK9E8UKKKKACiiigArD8ff8iD4p/7BF5/6IetysPx9/wAiD4p/7BF5/wCiHqZ/CyofEg8Bf8iF4W/7BFl/6ISt/wAAf8lC8Tf9gvTf/Rt7WB4C/wCRC8Lf9giy/wDRCVv+AP8AkoXib/sF6b/6Nva5638FfI7cH/vD+Z8IW08ItogZYwQgyCw9K+vv2O2V/hxrLKwZTrMnIOf+Xe3rzKL9pjxvJEj/AGDw2NwBx9ln/wDj1e8fATx3qnxA8I6hqmuw2MNzb6g9qotI3RCgiifJDMxzlz37CvIpqKk7M+wxtSvKhFVIWWmt/I4W3+H3imbS2s30h45LbTZ7dlurmBrd2NzHN5VqUYuI32EHzug2gY+bPqngWw1BNa8TaxqGmy6UmqXELQ2c0kTyKI4VQu3lsygkjsx4AzjpWfb/ABW0SSw+3TWeqW1lLaSXtlNJHGRfxo6ofKCuW3bpEAVwh+YcdcdL4Z8Rxa61/CbG906+sZViubS8CeYhZA6nMbOhBVgchj3zitzyS3o+n3Nh9o+1avf6n5r7l+1JAvlD+6vlRpx/vZPvWjRXLjxxpCv4nE63tvF4djEt7LcWzRqV2u2Yw2C4wh5AweNpOaAOoorh1+I9kFkhn0bWbfVhNbwx6XKkP2iYzq7RlSJDGARHITucY2NnFdH4Y1228RaQt/aRTwjzJIJILhQskMsbsjowBIyGUjgkehIoA1a8x1//AJKnq3/YF0//ANH3tenV5jr/APyVPVv+wLp//o+9rfD/AMRHLjf4Evl+ZNRRRXpngBRRRQAUUUUAFFFFABRRRQAUUUUAFYHju3vX0AX2jwmfVtIuYtUs4hn948R+ZMd90bSDHUkjHNb9OVijKynDA5B96mUeZNMqEnCSkuh2+k6jZa3pNrqWnTpc2F3CssUg+6yEZBwen0PSnR6daJ5rQxqrStvLjk546Z6dK8z+Hkw8P+NJfCh2jSLm3fU9LZ/kaOQysZ7ZCOJFUv5gz8yiTHIwR6yOK8mcXF8rPooONaKlbQiEZVEVHYBTyTySPSmzQeac+dKnpsbFT0UrtGlkIvAAJyfWsLXNIa4nFxbEB24dcdcdx71vUVhXoQrx5Ki0Mq9CFeHJM5FU8tRGARt4IPWnVv3NglwCXY+ZnhwOg9PesS4he3lMcg5HII6Eetcs6Ps9FseHiMLOhvsR0UUVBzBSMAylWAZSMFSMgj0IpHJVchSx9BTqV9RHC6B5/hPxHD4Va4EuiS2k17pbS5MsCxuoe1yT86qrgoeoUYOQAa7lTuVWwRkZweori/FcovfHvg/TrRXmvLKeXU7hAuFitzFJD5hfrne6gIPvc5GBXbbG4+VvyrWeqTtqb1bu0urQ0jIpaqQ6lYz3V1bQ31pJc2ozcQrOheEf7a5yv41W8Oa/pXiTT2vtCv4b60WQxNJEThXGMqc8g8g/Qg1HK7GbhJK7RpjPPSlpAQT1zVZXmS6G/LQyDIGOUb047EU4x5rklqo5i6gFBnDDIx2qSq/2uL7WbZSWnUBmUD7qnuT+FEItvRXsBYBIOQSCOhBxXLeOFuL3X/AkKXEiS/24jrIvLqqQyu4HsyqUbttY+1dTXL+LPPl8S+CrbTUZtV/tQ3cWR+7W3jQpclz2GyYAY5LMvYGroNqeh1YPmdZJHqlFFFdx9CFFFFABUN5awX1pPa3kMc9tOjRyxSLuV1IwVIPUEGpqKAPIovDfhjQfiCdE1XRrAaBexxzaPHe2iSwx3rblnjhcghCyRwtsJ+ZgxXvWV4x8A6domoyJ4dt10V55/t9jeWy/8et1gKSgPATgAxj5SpIx0x0nxH1D/hJ79fCvhy0u59f0+9t7n+0PLK22lSriRZHc8Odh/wBWM7g+DjkjpfiEXTw4udrETR7jt/UenNdeBa9soyV1LT7zlxifsnJOzWpJ8OfEU3ivwZp2r3VuttdTB454UOVWWN2jfb7bkJGecEV0teZ/AyeRdJ8QaXtDW+navOkU448zzds7KR/eUylSe+B716ZXPUjyScezOiEuaKl3CkIpaKgoKKKKACvNvixa3Fje6R4st7aSWDSFnj1FIsGR7OVRuKj+IoyI+Mg4DY5Nek1y3iXxxoWhXS2ct015rDHbFpdgv2i7c4zxEvIGBnc2FHc04vld0TOCnFxezOR0PWtL16za70W/hvbdW2O0eQY2xna6nBVsdiKv1xHiqHWNJ8RaH4qvLK00e51bUotMk0uxjErSwSFmd7uRfvyjBZSgwpz8zAkjuWGCR6V6lGr7RangYmh7GVk7obRRRWpzhRRRQAVh+Pv+RB8U/wDYIvP/AEQ9blYfj7/kQfFP/YIvP/RD1M/hZUPiQeAv+RC8Lf8AYIsv/RCVv+AP+SheJv8AsF6b/wCjb2sDwF/yIXhb/sEWX/ohKp6nrv8Awi/im6vLfxT4b0qe9sreGS21aLexWJ5irrieMgEysOh+7161hUi5Ukl5HXhpqFduXmeDQ/A74kpDGjeF5MqoBxfWvp/11r6Q/Zr8J654P8E6lY+JbA2N3Nqb3CRmaOTMZhhUHKMw6o3Gc8Vkf8LRvP8Aoffh9/4Cn/5No/4Wjef9D78Pv/AU/wDybXBHCuLuvzR71bNfbQVOb0Xk/wDI3rj4Q2V5f6tfXEumWl3cwPBbNpWlpaLCTIsnmyDcxmk3InJIGAcAbia6/wAJ+HrrSLzV9Q1S/hv9T1OVJJpILY28SqkYRFVC7noCSSxySenSvMv+Fo3n/Q+/D7/wFP8A8m0f8LRvP+h9+H3/AICn/wCTav2M/wCmjl+tU+/4P/I9f0fQ9J0X7R/Y2l2Gn/aH8yb7LbpF5jerbQMnk8muUu/At7qd/wCL/wC19WtJdN8Q2n2RoLexaKWBVDLGRIZWDEK5z8gBIB+UcHi/+Fo3n/Q+/D7/AMBT/wDJtH/C0bz/AKH34ff+Ap/+TaPYz/poPrVPv+D/AMjqX+Hmo3N82sX2v28viRJ7WaC7XTykCCBJUCtF5pLbhPLuIdeoxjFdV4M0D/hHNGa0kuRd3U1zPeXNwI/LEk00jSOQmTtGWwBk4AHJ615Z/wALRvP+h9+H3/gKf/k2j/haN5/0Pvw+/wDAU/8AybR7Gf8ATQfWqff8H/ke4V5jr/8AyVPVv+wLp/8A6Pva53/haN5/0Pvw+/8AAU//ACbVO08X6RLr99q+ueNfCtzc3FrBaKtnIluiJE8zAkNPISSZj3HQVrRpyjNNmGKrQqUnGO/o+52lFc9/wnHhP/oZ9C/8GEX/AMVR/wAJx4T/AOhn0L/wYRf/ABVd/NHueP7OXY6Giue/4Tjwn/0M+hf+DCL/AOKo/wCE48J/9DPoX/gwi/8AiqOaPcPZy7HQ0Vz3/CceE/8AoZ9C/wDBhF/8VR/wnHhP/oZ9C/8ABhF/8VRzR7h7OXY6Giue/wCE48J/9DPoX/gwi/8Aiq3raeK6t4ri2ljmglUPHJGwZXUjIYEcEEc5oTT2E4tbofRRRTEFFFFABRRTgMnAGSfSgDL02L7d8XfD8LYC6bpd3qAOMlnkeOED2wAx/GvWGGcckYOeDXkHhOdtT8f6trNm3+g6bZjRoZ1wVmmaQSzlT3CFY0z67vSvRtJupTdCKR2dXB+8c4NeLXrL2zR62HxMKajRa1/zNrJ3Yxx60tNddwwCRzTqD0xgB3sSBjjFPoooAKq3tol2gDHay9GHarVFJpSVmTOEZx5ZLQw/7HmBOJUIPqDSNpVwOjRn8TW4SeMClrL2EDjeX0X0/Ew00mc9XjUfiTWhZ2EVt8335P7zD+XpVkoDIHycgEYzxT6qNKMXdGlLB0qb5ktTjfG/gi38WX+n3H9o3umzWiTQSvaBVeeCZQHj3EHAO0cjkY4weRTh+Efg23YG10+8tsJ5Y8jU7qPEfXZxJwuecDjNd9RWh02RyjfDrwY1hbWknhjRmt7YYjD2iMVHf5iMnPfJ575ryfwlol5baB4Q8T+G/Dz3721zdxGW3lSG4vdP/fLaq6MQhQ7oicklAgI9B9BOflPQ+x71wvwOVU+FXh+L5xNDE8U8bghoplkYSRkHptcMuO2PSgb13MjxLZfEI+FtV1FtT0KwvLe0lmisbDTGuXLKhZVEsjjLEjGdmPauk8HRw6z4R0a/j1Jb157OJ5LqIDbK5Qbmx/Dk547dK66uM1L4b+H57uW/0qGbQtWc7/tukym3bdnO5kH7t8853q2cnNRKEZboxnh6dT4omldafNACw/eJ6qOR+Fc5deItGtPEFro1xfQx6tdqDFBglmHzEZIGBna2ASM4OKst4a8a25Etn49e4lX/AJZahpNu0Tex8oRsPqG/CqUPwzN/Hqd34j1aSXXb65t7tbzTo/sy2jwIVi8pSX6B3zuLBtx4rJ4dX0OOeWwbvF2Rt4zj2rF8KM2q/FPWZpW8tNC0+KwghJ5c3BE8k2OykJGgPcxv6Vg+HfHVlGlnpHjG9i0rxTGxtr2KaJ44hKDgPvxsCONrKc4O7A54rsvEXhrUhqsPiHwjfRQ6vFaLaSW10C1tfQqzOqPjlGBdiJFzjcchhxSo03GTuRgKE6dSTkvI7OiuKsPiV4ek8PXOpapeQ6Xc2Sy/btPnlU3Fs8RxIhRSS2D0IB3AqR1FXfB/jGDxNeajZrpWraXd2KwvJDqMKxuUlDbGAVm/uNwcEY6V0nqnUUUUUAFFFFAHlbJql/8AEvxhfaBd2mk3mm2lrZSQzWslybxSDKJ3jVkzgFo4yGJ4lB7AZOja14p8U6Nq9xrF1pDaZaBSsEVsbe9WVXH+ti82Ty127jhiG6ZAqj8Q9Wsrbx74jtNdTTIZbtdMttPXUrtreGSIecz3BZSCQryOhUdMAng1z0fiDw/BoGq6/wCHNAht3t7MPO8F08xuAIo5GgLHssjYbGeFB74rpwabrRa6a/dqc+KaVKV+un3mh4W8e6f4H8Y3en/aXudJ1C6L31tFBK8mnXTKWaVSqENG+F3LnKk5HBIr0qX4s+F5U8nR7i51TVZCEt9OgtpEnnY9ABIqgDqSxIUAEk1xvwWsLvStXZdd1LSWN3NJcQSpclZtQuZEDSYibsiYA28bQvvXs9lqNlfvcrY3ltctbSmCcQyq5ikGMo2D8rDI4PPNGLSVR20vuuwsK26auc74e8bWeoXlxpusW0uha5bKry2N86AlGJCyRuCVkQkEZU8EYIBqW+8feFrDXzot7rlnb6iCFaORiqqxGQhcjYHI5Ck55HHIq/rnhjQdfkjk1zRdN1GSNSiNd2ySlVPUAsDiiy8L6FY6G+jWmjafFpLkl7MW6+U5yDllxhjwOT6VzHSY3jzxtb6DYJb6RJa6h4kvdiadpwk3NMzsF8wquW8tclmbphTzmqNxJ8R9JPlxr4e8Qi4+RJTvsGtnP8TrmQSRr1IUh/Y9a6PSdA8PeFYrqfSNJ0/TFkG+ZrW3WMsAO+0ZOOcClttd0+/0qw1iK6SLSrhIporqf90sglwIgN2CNxdQAeckDqaaVxNnO/8ACCavfJ5uteO/ETXjZ3f2a0VnAoPZECMfxZie+c10nhvwzo3hq0+z6Hp1vaKfvui5klPdnc5Z2PqxJrZpDk9DSGeWfEpZLr4ieDdPnCyWEK3OqIqcSJcRKFV3Y9Y/3uNo6sRnIFXKb8UIVt/FHgO7j3rN9tuLInPymOS2dmU/8CiQj/dp1ejhfhZ4mYX9qvQKKKK6ThOb8W+K18O6v4b082Run1q8+yhhKE8oZUbuR8xy4446HnpXTEYJHXFc54v8I23iuFI2u7qwvRGbdLq22lvKZ1coVbgjciMCMFWUEHtVrSvFGk69b38+h3Y1KazLCe2h4nDrn5djY5YggE4BPeoTak1L5GjUXFOO/X9DXrD8ff8AIg+Kf+wRef8Aoh6qeCfGEPiu41qGPT7vT5dMmSNobwbZirg4Z06ocqw2nPY55q34+/5EHxT/ANgi8/8ARD0SkpQbQKLhNKQeAv8AkQvC3/YIsv8A0Qlb/gD/AJKF4m/7Bem/+jb2sDwF/wAiF4W/7BFl/wCiErf8Af8AJQvE3/YL03/0be1hW/gr5HXg/wDeH8w074oDUtPtb6y8IeJJLW5iSaJ91iNyMAVODc5GQR1rpvB/iaLxNb37x2F9p8tjdfZJoLzy94fy45AQY3dSCsq9/WvGPAXjHwza+BvDtvc+ItGhni022jkjkvolZGESgqQWyCD2r0D4OXtpqaeMLrTruG6tZNZGye3kWRGxY2gOGGQcEEfUVz1aUIwTT1O3D4ipUqOMlZHYW3iTQ7rWZdIttZ0ybVYs+ZZR3SNOmOuYwdwx9K1q8a0zwv4iXQfDHhv+wltLnRb5Ll9ceaFoZfLJJkRVYyl5c4YMi/ebJPetNoPjVvCFpb2dt4jt9bSeBtWmudX+0LfKFkD/AGYLdp5Y3lWwDB8uB221znae3UV4Fr+h/EttD0u20yPV5b23tiy3rX3lS+Z57sI5UF/5eAgQB2+0Fgfmwc12Om+HvE1t4qtdUe51VlfXbs3EcmpM8A09opfKxCXKD5/Lxhd4z2HQA9MooooAKKKKACiiigAooooAKKKKACvFvhz/AMk98Mf9gu1/9FLXtNeLfDn/AJJ74Y/7Bdr/AOilrrwnxM83MvhidDRRRXeeQFFFFAC1zSSar4l1/WdO0nVTo1hpEq2s9zbxJNPcTNGHIVmBSNVDAcZfd124ANrxZc3kcWkWWn3LWcuq6nDpz3UahpIEdXYtGDxv+TAJztznBxXa2vh2z8N6bb2Okw+Vp8QwoyWbcTlmZjyzMckseSTXn46vKEeWG50QpSVN1Ur/ANblLQ9Ks9D0ey0vTIvJsrOIRRJnOAO5Pck5JPck1p2j7LqFvRx/hUVWdNi829jHZfnP4f8A168SN3JGNPmnUVt7nR03dl8DBA689KdVNLedNRaQSqbVlJKY+YPwOvcYFekkne59M3YwviX4oHhHwjdakslrHdM8dtbG7bbF50jhFLnIwgzubkfKp5Fc5o/xVtrnw7oV0dOutV1C+trqSVNJaJo0a1ZFnIaSRRty4K8nI9eM99qGk2WoXen3N5D5s2nzGe2JdgEkKMm7aDgnazAZBxnI5rOHg/Qhq1xqYscXk/neY4mkwfOWNZcLu2jcIY84H8OepJKGc/cfFDTB5ctnp2q3lj/oRnu4Y4hHB9rKCFXDyKxJ8xCditgMM1jeMvieY/CGt3GjW2pWU32K8l0zUp4YjDcPBkMUG5m6gkeYi5A4zV/WvhXa32raa9ldRafpVp9jD20S3BkmFswMYZvP8tsBVXLxMwGcNnBG1L8N/Csv20S6a7x3cc0LxNdzGNEmOZREm/bFuPJ8sLQBF/wsXSF8eQeE5YpU1Cd3jicXFtIrMqFzlElMqcKeXRRkY9K7SuYg8CeHoNfTWYrSdb5LmS8T/TZzEs7qVeQQ7/LDMGbJC85z1rp6ACiiigDkNW+JXg7SdRuLDUPENjDeW7bJYixJRvQ4HB9qpR/FvwPg+Z4l08HPGC/I7dqPhR/rfG3/AGMl3/6DHXeUAebeJPit4U/4R7UzofiXSZNXFrJ9jWSXAM20+WDn/axW58Jxpw+HHh86MZXtGtVbzJkKSSSH/WO4PO9n3EnuSTk11tFABRRRQAUUUUAQ3tpb31rLa3sENzbSrtkhmQOjj0KngivL9Ts4fhb4ii1TQdFvE8I3FpL/AGpb6coeO1lRkK3BiJ+UCPzdxTJOB8pIFerUHmgDmtU8JeE/FMDXWoaLpGpJeokn2owI7SrgbWEgGSMYwQelY3g6KO3+KPjaCCNY4YbTTI40UYCqEmwAKp6d4N8WaTavoGi6/p2n+GBNLJBNFaM19bxPIz+Qm5jHgBiquRwAPl9J/hX4O13wvqfiK58RasmqtevEltO0jPN5MZk2iQsByA4HfoTnngA9DooooAK5/wCIOq3uheBte1XS0ie9srKW4iExwgKqTk+oGM474x3roK83+MOpPdxWHgqKGeB/Eri0bUpFAtoY85lTceszRq4RO5PXigDnPFHhTfpGha1dat4j17X7l0j09po7SMwmSMu4EUkRjiyqckqXyqqDycppOl2/iHwvf3EGu6xqGnQqsTWl9bWkSFJoY5Sy+TGpB8ubBBPXOR0Ndj8Zkt/+EMzcWOiXqxzoUh1efyot2Gxt6bn9FyM881R+GVgbn4aT29lajTjcPIUi/s37CoJA6IXfcp/v7jkdOgrWhLkqRl5mVaPPTlHyPJvBHh3xB4t0jwxJp8kK3WiC52XUz4EVzE2yEuudxVvJVWwDwW9a67R/AviXw7HeQC31W906XWWu7tNM1FLS5vg1nGvnBxJHgeeHLKXUnIOCBgweCtQ1H4banq9vrujs+iRzyzzajBMryW0ckhkDPCPmKKXO5lJ4AbGM17vBNFcQRz28iSwyqHSRGDKykZBBHUEd60xa/efJfkZ4V3p/N/meOafpHjEa54ebVNP8Rv8AYoYmuLm21wGK4l52pNGbhV8tBt3ssTNIQccffxdM0H4j3kWqxONWsLe4SzXYuquzRyLeRtP5Ur3czY8kuNwMe4LjYDwfdbuRzPHbwqQ8oJeQY+RRj9TnA/H0q1GixxqiDCqMAelYWsjovdnkcfgzxHZ6klza3GszhNYniCXWrvOn9mtaybcrJIQx85lwTlxx2HGN4Y8L+N7Dw5Y2djba3potrHTLeeC61ZJfMnjuYTM8G2ZxHEIVkUqCu4EDb6+70VIzwO+sPGH9r/2W82u2mu6hZauq3j6uTa3MuP3DQxrKREFDLzsQjP8AFgmtDXLD4jauL6e0tNU023L2A+ySX0bSyxpHMJ9nlXKBSXaInEqFgo56rXtlVpbuKOTywd83aNOT/wDW/Gmk3sJu254R4yurjQtA+H9hrVzqUvjH+1N1g96AibWl2PHOwlmXBhcoDvd+Qc53V3bgB2C52g8Z61W+NMlwbbwbE0aqsniWyDbW3A43tyMDI+Ud+oB56Gc9eK7sJszx8x+NeglFFFdZ54tRR21tFNLNDbW8U0v+tkjiVWk/3iBk/jUlFACxRR/aC5RFeUqJJAoDOBwNx74HTPSvMv8AhIdc13wf8SYNa023trfTrTULWG4jDoZSIpMLsbkgLg7+M5xivTKxPiAzN4A8T7mJxpF4Bk9P3D1nUjpoaU5JOzXYTwF/yIXhb/sEWX/ohK3/AAB/yULxN/2C9N/9G3tYHgL/AJELwt/2CLL/ANEJW/4A/wCSheJv+wXpv/o29rGt/BXyOvB/7w/mcZonxH8b6pothf8A2nw3F9rt45/L/sudtu5Q2M/aRnGa9D+FniPVfEdhrJ1w2LXNhqH2RXs4HhR08iGUEqzuc5lI69hXlHh3wz4w03w/pljP4O1RprW1igcpd2RUsqAEjNx0yK9N+D2karpWna8+tadNp0t5qf2iKGaSJ2MYtoI8kxuyj5o24znisq6oqC5Nz0aLqub59jodP8WaRc+FovENzdR6bpb5Blv5EhCYcp8zFtoyw457iqY8b6XJrtna291ZTaXcaZcal/aiXaGFVhlijIyPlx+9JLbuNuPpgQeBPEtv4YXQbbxba29lC++GS306aGYjzd5R5EuQSpBYHZsboQwwQcey+C7W62cj+IpGu7NrqaF/szMnnTXMc6l1klcyIpjwVdiWyG3BgDXIdJ6UfE+gjUl0863pf9oNH5wtvtcfmlNu7fsznbt5zjGOal0TXtH16KWXQ9VsNSjibZI9ncpMEb0JUnBrz+5+FDT+ILvUZtTtrmC6uDeyWt1DdNGJ2i2FlRbpY9vXhkZtpK7jwR1PgTwzfeGrG6t73WGv0kcGGNVlEdsoXG1POllfHfBcgdAAKALlv4x8M3KXj2/iPRpUs8faWS+iYQZbaN+G+XnjnvxSnxd4b/sf+1v+Eh0f+yvM8n7b9ti8nf8A3d+7bn2zmvPIfg/fzXF5PrPiuTUpri0W0aSa3mcsBcRTbmEk7qM+WV2oEX5s7eMHfvfh9c/8JFPrml6vb2+oNqbahELix86JA1qluyFRIpJ/d7gwIxnGDzkA3vDHiq01jwXZ+JLxoNPs54fOZpZwY41yRkucDHvx1p+n+NPC2o3Vvbaf4l0S6ubgkQxQX8UjyEdQoDZP4Vkr4F/4tcPB0mohz9n8hrwwdfm3Z8vd+maZd+AI59X1C+S+WI3WsWerBVtxmP7PFHH5ed3OdhO7HG7oe4BpXXjzwxFp2o3dvr2kXYsF3Txw6hb5Uk7VUlnCqS3yjcyjPetCHxLokupHTl1fTv7TEfmtZ/aozMq43ZKBs4xznpXk+r/DXxDpum69dDU7zxTqup6Nc6IicxlfO5E0jT3LKqqRysSqPm4SultfhrcRXcIfWIjpkV9LqawCz/ffaJImjYGbfzGNxIUIDjA3YGKAO5sNc0nUbeafT9UsbqCFVeWSC4SRY1ZQ4LEHABUhhnsQelZyeMtAkvhBFqunSRiIyPcJewFIzuiUKw37snzo8Hbj5hkgsoJofhlNJ8AWXhiKdStvpy2BuFi2hiI9hk2Z4JOWxnv171hv8N7Oe20+1u7kSWdtoEuhPEkITzBIYT5oOflIMOcYPLZzxyAdLqfifQNKEx1TXNLshDIIZDc3ccexyoYK24jBKkHB5wc0Xfijw/ZyGO71zSoHC7ist3GpxsD5wT02kN9DnpXAXfwjknsNLb/hIJX1q2e6kur2RJo1vGuNm8ssE8TDAjRQA+NowQeMa1l8N4LLR9ZsoJrFv7QtrO3US2srRwrbxIgH+uEhHy7l/eAqcfMSMkA7TSNW07WrIXmj39pqFoSVE9rMsqEjqNykjIryP4c/8k98Mf8AYLtf/RS16b4O0a80LRVs9R1WXVJxI7+dJv8AlUnhB5ju5A9Wdj715l8Of+Se+GP+wXa/+ilrrwnxM83MvhidDRRRXeeQFFFORS7hVGSTgUAZeh20erfFqGC+Mj2+jaYmoWcKj939oleSNpZP9pVXagPZnIr1h1WRCrgFSMEHvXm3wejOpX3ijxSkhNnqd0lpZDs1vagxCQH0dzKwHpj1r0okAZPQV5NaXNNs+iw8OWlGLKg0y1/55n/vo1Lb2sNuzGJNpbgnJNTAggEHINLWKhFapFRo04u8Yr7goqMLtdmLsdxGAeg+lEibyh3uu05+U4z7H2qzQkooopDCiiigAooooAKBSEnBwMmopX/dkBSWPGFPP59qaVxN2OJ+FH+t8bf9jJd/+gxV3lcH8KP9b41/7GS6/wDQY67ykMKKKiulma2lW1kjjuChEbyIXVWxwSoIJAPYEZ9R1oAlorzDR/GutwQaxrOsT6TqPhizxDBdWcC2DXM2/a7I1xcmMxLyNxYbiDtzj5nw/GHRrnTobzTdJ1i/V7e7u5EthbsYY7ZwkrM3nBWGWBGxm3A8ZoA9Mory3WviVLcW1sNI03VrS9jv9O8y1mig8y5trlm2bPnKjeEYfMVZcc7a0bf4lWdxfOot7qAW9peS3NncJDHLHLbzRRspmacRL/rRxypyDvGMMAeg0VzPgLxppvjbTbu80lZEW1uWtZVeSKTDhVbh4ndGGHHKsf0rpqACiiqes6jBo+kX2pXhcWtlBJcy7F3NsRSzYHc4B4oAuUV5/ba14z8VW8VxoGm2Xh/SpgHjvNWP2i5kRgCHW3jYKv8AwKTPTipH8AXeqIF8V+Ldc1WI8PawMljbyL/dZYgGYeoLnNAGjrPxC8MaVemxk1NbrUcH/QrCN7ufPoUiDEfjiub8Qz+I/H2jz6bYeFTpmnTbWW+1y4MEsbKwKvHDETIrqwDKWZCCK7/RdE0vQrU22iabZ6fbk5MdrCsSk+pCgZPvWhQB4zPYa/pZh8G+J9Y07V49RlE2m6vremC5ilkAYy2roJF2yZ+eMknK7lHK1p+HNY0L4dWk9jr3i3wxFCrlza2ivG6Odo4RppGC4HQADvxzn0XW9I07XdOl0/WbK3vbKTBeGdA6kg5Bwe4Izmquk+GNB0eJ4tJ0XTbKORdji3tUj3jGMNgc/jQByuo+Fr+/1LUL23mhkWTbPaSlgyyZ/hI9MYAPQ8e9UvC13J4M1PTdMuQ0PhfWCU08TAqdNvM82hJ/5Zuc+Xk8EFBkFK2Pg8og8IS2MQb7JYanf2dqWYt+5jupFQDPOFACgdgoq/rumaQvgnV7PxK6S6O6TPctev8AKEJLZz1XB5BHIIBHNdVXESrwUZ7q1vu/4Y56dGNGbcdnv/X3nSxuki74yCORkexxj86fXK/Cy41G6+G/hqfW1mXUpLCFpzM26Rm2j5mP95hgnPOTzzXVVym6IJbgJIEVJHY9dgyF+ppBJO5BSIIv/TRsE/gKsUU7rsFn3K3kyynM8u0f3IuPzPX+VSwxJCmyJQq+gqSihtvQEkjzX9oVrmH4Z3d1ZwwNJZ3EF2Z5bgQm28uQOJEJBBfKhQvfd36GHS9Rt9Y0y01OyINreRLPGAQdoYZ2nHcHIPuDXW/EDXdG8PeFry98Qmya1Cny7e6ZQtzKAXSNQwOWJXgAE8ZxxXnvgSxuNO8HaVb3qGO6aNrmWIqV8lpnaYx4PPy+Zt5/u11YRu7XQ83MkrRfU3aKKK7zyQooooAKw/H3/Ig+Kf8AsEXn/oh63Kw/H3/Ig+KP+wRef+iHqZ/CyofEg8Bf8iF4W/7BFl/6ISrE2mXiazPqWla7qWlT3FvFbzLbR27q6xtIyE+bE5BBlfoR2qv4C/5ELwt/2CLL/wBEJW5UxipQSZfPKE24uzKHl+I/+h313/wGsP8A5Go8vxH/ANDvrv8A4DWH/wAjVfqtqN/Z6Zatdald29pbKQGmuJFjQZ4GWJApexp9i1iqz+0yHy/Ef/Q767/4DWH/AMjUeX4j/wCh313/AMBrD/5Gq3bXEN1bxz20sc0EihkkjYMrA9CCOCKl6DJ4FHsafYPrVb+Yz/L8R/8AQ767/wCA1h/8jUeX4j/6HfXf/Aaw/wDkaoYPEmh3FtdXEGtaZLb2uPtEqXUbLDnpvIOF/GmjxR4fOnNqA1zSjYLJ5JuftcflCTGdm7ON2OcZzS9lS7D+sV+7LHl+I/8Aod9d/wDAaw/+RqPL8R/9Dvrv/gNYf/I1XYpEmiSSJ1kjdQyupyGB6EHuKz5vEGjQaoumTavp0epMyqLR7lBKSeQNmc5ORjin7Gmugliaz2kx/l+I/wDod9d/8BrD/wCRqPL8R/8AQ767/wCA1h/8jUltrmk3RuxbapYzGzz9p8u4RvIxnO/B+XGD19Km0zUrHVbX7Tpd7bXtvuK+bbyrImR1GVJGaPY0+w3ia6+0yLy/Ef8A0O+u/wDgNYf/ACNR5fiP/od9d/8AAaw/+Rqv0Uexp9hfWq38xQ8vxH/0O+u/+A1h/wDI1Hl+I/8Aod9d/wDAaw/+Rqv1Xa+tF+1brqAfZRm4zIP3I27sv/d4557c0exp9g+tVv5mQeX4j/6HfXf/AAGsP/kajy/Ef/Q767/4DWH/AMjVGviHRW0ttSXWNOOmq2xroXKGIN6F84zyOM0txr+j20do9xq2nxJeY+zNJcoonzjGwk/N1HT1peypdh/WK/dj/L8R/wDQ767/AOA1h/8AI1P0XTodI0aw022aRoLOCO3jaQgsVRQoJIAGcD0FWJ7iC38v7RNHF5jiNN7BdzHooz1J9KbbXltdmYWtxDMYZDFKI3DeW46q2OhHoauMIw+FGc6tSovedyaiiirMgrF8Xa1BpGlyRb3fU7+KW3060hBaa5mKYAQD0LKSx4A5NbVYWr3VrB468AiWaIXP9pyhYgwEpR7aVdwHXZuAB7E4zWdWTjBtG1CCqVFF9T0jwLpjaL4L0HS38oyWVjBbOYjlCyIFYg9xkGt2iivJPowooprZyMdO9ADJAkuULDKEMfbByKkUhlDKcg8g1Qv4s4dJkhkDhgWXOTwPXnjj8adaCeLToBsLy4BZWONoPOPwzj8K05fdTTI5tbWL1FVM3bvcIyxxqNvlOGyT65H1q3UNWKTuFFFFIYjEKCzHAAyTSIwdQynIIyKJBuRgMEkdzimxRJEu1FCjOSB60aWFrckpixqsjOowzdfen0UDOD+FH+t8bf8AYyXf/oMVd5Xn/gh/7D8eeLfDt1JEZLyca9aNuw0sU3yOu31jeLkjPDpnFegUAFV9SsoNS066sbxWe2uYmhlVXZCUYEEBlII4J5BBHarFFAHGx/DXw2lnFaeXqzW0OzyYn1q9ZYChBRowZv3bLtGGXBAyM4JFWbDwB4bsY5kt7CT99Bc28jSXU0jOlw6vMCzOSSzKpznI7EZNdTRQBzN/4G8P328z2cyu62yeZDdzQuBblzDtZHBUqZH5BBOec4FQP8OfCz2f2V9MLR+TLAWNzMXZZJUmcl9+4uZI0beTuBXg11tFAGP4b8OaZ4cju00qKdTdzfaLh57qW4eSTaq7meRmYnaqjr2rYorE8Z61b6D4Z1K+ub62smjt5GikuJAi+YEJUc9TkdKAKviXxrpGgXsenytc32ryoZI9N0+Bri4Zf7xRfuL/ALTlR15rHm8V+Jrostv8OdUlsXXaftN9aROexBjMh4+pq78KNEttJ8EaTOlo8OpX9pBdahNOCbie4aMF2lZvmLbieD06DA4rsKAPL/hDqt9beG9Q059Hv0h0rVLmzht2kSSS1gG2SOIned21JAowTwoFdVd+L7WGTy4rLUJnX/WKsBBj9jnviql78O9GudTvr+O41qzmvZfPnWy1W4t43k2hS2xHAyQq847VSbwNqOjzpe+EPEV/Ddkt9oh1iaW/t7oEAZZWcMrDAwysOBggjptTnTXxxv8AOxlOM38MrfIv3/jCeCYRQ6Le72+75yld3HYAHNbmi3t7ew+Ze6e1l2Cu+WJ9cdh+NclbeO7vRZptP8b6RewX8RBju9KsLi6tLuMjO9CisyFeQyPyOoLA5rpvDXinQ/E9vJNoOp218sZxKsbfPEfR0OGU+xAqp1aco8sYWfe7FCnNSvKd16I145UlDeWwO04PsawvHfiKPwz4Zu77Ia8ZTDYwBDI1zdMCIolQcsWbAwO2TkAEjTvPkdJIW2znom3PmD0P+PasjxpokXi7whqGnJsju5Ima1lkyGtLkAmKUEcqyNg5HPHvWLjpdGilrZifDvQpfD/hKytrwu2pzA3eoSO4YvdS/PM2RxjeWxjjGKT4kaZb6t4H1m3vHZbf7LK746EBGyCPSqfgrxQbyzmsdeH9na7pMQGo21zKp+UDi4V8ANGwBO4AAHIOCMVz1jaeIviPpN7eP4j/ALM8L6lJPbRWdrYqZprMM0ayCZ+VMqgtnacKy7cHkkZODUkEoqScWdl8OpZp/h94YlunaS4k0u1aR2OSzGJSSffNdDUFjawWFjb2dpGIra3jWKJB0VVGAPwAFT1JQUUUUAFFQ7yLgo33WXK49uv8xXAfEjxtqPhqXT9G8O2UOreIL+TbHHI5ItoehuJlUE7FYgHpn1zVcpLklqzJ+KdzB40uZPBtpBbz21vLHNqmoMA32MBgRDEcH/SHXIzxsViTyRWtI292bGMnOKy/Dmjw6BolrpkEz3Ah3NJcOPmnldi0kre7MSfYYHatGvSo0vZx8zwcTXdaV+i2CiiitjmCiilHWgArE8exv/wr7xS2xtv9kXhzjj/UPUWip4s8RX2vDRrrQbOLTdQeyW1vrSWSTaqqVkZ1kUfOGDgAdCB61n/ET4Q6ZD4P8Q6/q2p6lqOr2+jXks8hmaKO5mEbsjmNThVToqD5QOu7knkq4mNnFHoUcDOTUpOy3NPwF/yIXhb/ALBFl/6IStysPwF/yIXhb/sEWX/ohK3K6YfCjhn8TCub8ZWV5PcaFfWVo1+NOvvtElojorSKYpI8rvIXcpcMMkdDzXSVi+Obqex8E+ILu0kaK5g0+4likXqjLGxBH0Ipy2CDfMrEXgPTbrSfDMFtfRiKcyzzGIMG8oSTPIEyOOAwHHHHHFbsxIicqnmEKcIMfN7c8U6s231J5fEt/phjUR21pb3IfPJMjzqR+Hkj8zQtEkDbk3I4e20y+v7bVJ9Z8IXizzW0VtHZRXVvDElukgIijeOXJcbi+4hB8oUbe62ek69aXGn6lPp19fw2t7ctDYT3cctzDBJEqrmR32sQyv1ckLJjJxXpNZvhjUn1jw1pOpyxrHJe2kNyyKchS6BiB+dRyI09rK17FXwNplxo/hHSrC9Ci5ghCuqnIU9doPfGcfhXP6npGozeLzc6Vp+oadJJdI1zqKagGtriBYtpDQb/AL/AUfJxgHdXVeIdSfS7CK4jjWRnu7W2IY44lnjiJ+oDk/hWlVcqenYlTabl3PIE8Ia7c6LbWbaWtq+naJ/ZxDzRlL6QSxP8u0khWETcuFOZOnWu58I2d6uqa9qd7YyaemoTRNFbSvGzgJEqFm8ssuSR2Y8AdKueH7qe41bxNFNIzx22oJFEp/gU2lu+B/wJ2P41Y8T6k+j+GtW1OKNZJLK0muVRjgMUQsAfyqYxS1LlUlL3e/66mlRRWbcak8XiWw0wRqY7m0uLkvnkGN4FA/Hzj+QrRuxilc0q8yufD2oXCeNbWy8PtYw6g8U9vuaBY7ho9u9SEckGQhuSB1+bB4r02s3wxqT6x4a0nU5Y1jkvbSG5ZFOQpdAxA/OplFS0ZcJOF2jhpNG1mXXD4h/saZUXVI7r+y2mh81kW1aHfkP5e4MwYAv0XqDxWU3hLXrbR9QgGk/a5NV0u4slRZogLF5LiaQbizDKgTLnZuOY+B0r0a7up08a6TaLIwtpdPvJXj7MySWwU/gHb8zW1UezTuae2kktP6RyXjnQtQ1fRNKsdPuZop4ryF5LqMqHjVQQ0g3cZ5+tYJ8Oa3LbaVpwtrrTrWws7yGQ6dftBHPMfL8mQbXDnJEh+bod2SQcn0uiqcE3czjVlFWOO8FaTrGl6kx1Ca+ltZtNtWl+1XhnxeZk87bljtGCnC4X06V2NFFUlZWJlLmd2FcZ4xbRdO+IPgDXdcmFqtnPeKZ+eVEBKpgAliXIwoBJLECuzrJQQH4r+CxdorhrbURbhhkLMBC24eh2Bhn61liP4bOjB/xo/wBdDqI/ir4IMcpm8R2VrLErNJb3Za3nXHUeVIA+eRgYye2agi8U+LtURr3QPB8R0stiE6pfmzuLhegkEXltsXjOHIYg/dFdxLbwzMjSwxuyMGUsoJUjoR6Gpa8s985vwb4ttfEsM8Lwvp+tWbGK/wBLuHXz7Vx64+8jdVcfKwII7gb80yQ7PMJ+dgigAnJP0rE8T+ENI8Ry29xfRTQ6hbZEF9Zzvb3MQOcqsqENtOTlSSD6VjL8LfDG4STJq81x1aeTWbwux7knzeppq3UTv0NTV7tbfVkLRzTNHGU8rYTuDYO7PTHGM9vyrS0rVEvmKoshxkiTyyFIB9fxHFcw/wAKvCzli0WrfN1/4nN5/wDHaWL4V+FIiTHbamjEYJXWLwE/X97W0qkJQUbaoyjTmpXvodzRXFf8Ky8OD7n9tJ67dbvRn/yLR/wrPw//AM9Nd/8AB5e//HawNjtaK4r/AIVj4aP3l1hj3J1u9yf/ACLVCFtV+H19NALPVdc8JTt5lu8Be7u9Oc/ejdWJeWE/eVhllO4EEbSAD0SiuCf4q+HbVWOrwa7pI3YT7do9zH5g/vKQh4+uD7U0/F/wQCFbV5lkYblibT7kSMuM7gnl7iuO4GKAO+PGST+tM86PP+sTpn7w6etYT+LPDs+jnUI9d0c2DBT58l2giwemTnjPoawtQ8W+GLDT1v8AS9b0Z4TnEramgiPY/wARyR7Z5NaU4Kbt1M5z5NehveKPDmmeLNPiE7slxATJZ39q+2e1k/vxuOh9R0I4II4rN8J+JrpdRXw14t8u38SRqzQyquyHUol/5bQ9s4xuj6qfVcGuIsvinFcXJTTLjUdWeGMgw2FjJdbm9cogU/8AfQ4pnifUPEfivQ4rWbwRfxRJKJ0vtSvoLB7SUcpJEwLSI6nocHjIOQSK0qYfk+0vvM4V+f7L+49sorzfQrL4oT6ZDDqmu+FoG25+2W9lLcSuOxI3ImfcDHoKkuPD2tQS20F38TtRi1y63C0Q29mkcu0ZYLAY8vhck/Nkdc1znQeiUV4YvxHvvDUrXw1nUPGXhqOXy7q7GjGLyVBKtJFcxqIZVVsArjJyNrHkV6BbfEvw1NqNvaST31p9ok8iOe+0+e1habk+T5kqKvmEAkLnnHHNAHZ0Vz2j+NvC+s6g9hpXiDS7u9RipgiuUZyR1wM5YD1GayvF3iqaTUbbwz4QurSXxHelt8pImTTYVxvnlQHqMgIpxuY+gNACa1reu6v4jutA8HG0thYqn9o6tdxNKlu7jKwxRgjfLtIc5O1Qy5yWwJtF+HehWV2moanE+u62OW1LVD58obOfkB+WIZ6BAoArX8J+HLLwxpbWdi00ryytcXNzO++a5mbG6WRu7HA6YAAAAAAFbVABRRRQAUUUUAFeX/HDQoE0KTxPZfatP1Sy8uO41PT5nhuI7IyoZj8mPN2qpYK2QMEj0PqFcf8AGCSOL4W+KTNcvbI2nzR70QOxLKVCAHqWJC/8C7daAOuUDO4EkEeuaguraCT55Mo3TerFW/MVX8NwS23h3S4Lm3jtZ4rWJJIInLpEwQAqrHkgHgE88Vo002ndCaT0PPPihoc8uizalZrdTa3p8Er6dNaIjTsxXmBlYbZY3A5UjnHHzYNJ8Co9Rh8Fzx6pbzW+2/uPs0TQPBGsO4FRFHJ86RddqtyBx0Arvb1EktpFkfy1xw+cbT2P4Go7OcmR4ZkEdwPmIByHH94e38qprmXMSnyuxboork/FHj/QfDc1xZ3t4JtXjjR49Mt/nuZzI21FjTjcSePbqcDmoKbsdZXLeJvHmgeHbwWF5dvPqrLvTT7KJri5Ydv3aAkA+rYHvXE6iPEPioH/AISa6bStKb/mC6bOQ7j0uLleT3ykeB2LNVvRdJ07Q7RrXRbG3sIHO50gTbvPqx6sfqTXTTw0pavQ4KuYQjpDX8iHW/EviLxM8NrpGk6l4Ys3bbdaneNCLkQ4OUhiVmw5O3DtwvJwTTtF0XT9FjnXToCklw2+4uJXaWe4b+9LKxLOfqcDsBWhRXZToxgebWxM63xbBRRRWpgFV9RuZLOyknhs7m+kTbi3tgpkfLAHbuIHAOTz0BqxRQwQ4gAkAggdx3rO8QatFoejXWozRNOYgFit0yXuJmO2OJcZOWYgfiT2q/WPchE+I3giS8j+1Wjy3UMNuGIMd15W9bjb0cLGkic/d8zIrOrNwg2jWhTVSooPqdv8O/Dk3hvQCmoTfaNYvpmvtSnB+V7lwN230RQqqo9FHfNJ8WP+SWeMv+wLe/8Aoh66quV+LH/JLPGX/YFvf/RD15J9GkkrI4XwF/yIXhb/ALBFl/6IStyvzzorsji7JKx5sstu7834f8E/QyqetadDq+jX+m3LSLBeQSW8jRkBgrqVJBIIzg+hr8/6Kf1z+6JZbbXn/D/gn3X/AMI/qX/Q3a7/AN+bL/5HqunhO6j1Ge+TxXroupoo4ZH8uz5RC5UY+z44Mj8+/sK+HKKn60u34lfUH/N+CPuv/hH9S/6G7Xf+/Nl/8j1X07wldabp1rY2XivXYrW1iWGJPLs22ooAUZNvk4AHWvhyij60u34h9Qf834I+47/wldX8Cw3fivXZI1ljmA8uzGHjdZEPFv2ZVP4c1Y/4R/Uv+hu13/vzZf8AyPXwpRR9aXb8Q+oP+b8Efcdr4SurWe8mg8V66kl3KJpj5dmd7hFjB5t+PlRRx6euaNR8JXWpaddWN74r12W1uomhlTy7NdyMCGGRb5GQT0r4coo+tL+X8R/UJb834I+6/wDhH9S/6G7Xf+/Nl/8AI9V38J3UmowXz+K9dN1DFJDG/l2fCOULDH2fHJjTn29zXw5RR9aXb8RfUH/N+CPuv/hH9S/6G7Xf+/Nl/wDI9V9O8JXWm6da2Nl4r12K1tYlhiTy7NtqKAFGTb5OAB1r4coo+tLt+IfUH/N+CPu/TvD0lrrMepXms6lqU8UElvGtysCqiyNGzEeXEhJzEnUnvW7X550U1i7fZ/ETy5veX4f8E/Qyivzzop/XP7pP9mf3vw/4J+hlFfnnRR9c/uh/Zn978P8Agn6GVkeKdOur7TVuNIcxa9pzNd6XMCBicKRsOeCkgJRgeMNnsK+CqKUsUpKziVHL3BqSnqvL/gn6beDPE9h4s0OLUNPfD/6u5tn4ltZgPnikU8q6njBHuOCDW9X5V0Vxnpn6qUV+VdFAH6qUV+VdFAH6qUV+VdFAH6qUV+VdFAH6qUV+VdFAH6H/ABH0nQ/DujS+INO8L+Hptb+1QQxTXNkgAknnSMuzKu4435OOfzqgvgfxLd3z3VzD4C0+8chjfWmhtPcZ9i7gZ9zmvz/ooA/RlfAeo3YU61438SXJH/LOzkisY8egESBv/Hqmt/hb4LjuftM+gwX9xjHmajI94f8AyMzV+cFFAH6BppfijwnqNz4d8F2ay6HeoJrG6uCvk6O7O3nKVyGdACrRoAeSRkKONeL4XeGp7G5j8QWr6/e3e03V/qLmSeUqdwCkY8tQeiJtGOx5r85aKAP1HutKsLrRpNJns4W0ySA2zWwQCPytu3YAOgxxgVw3hjy457zwD41hXUTGzzaZLqCCdNRsgwK5ZgQ0sWQjgjOAr87s1+eNFAH6b634R8P63pMemapo9nNYxKFhj8sJ5IHTyyuCmO20irOgeHtH8O2v2fQtLstOhIUMttCse7AwCxA+Y+5ya/L+igD9VKK/KuigD9VKK/KuigD9VKK/KuigD9VK4v4ym1Pwy16G9MoW5hFtEYovNYTSMFiwMjnzCmCSADjkV+b9FAH6j6I97Jo1g+qwpBqDQRm5iR96pJtG5Q3cA5Gau1+VdFAH6qVBdQpOoDgHB69x7g9Qa/LKimnZ3Qmrn6Z69rNloei39z4guo7ezs4xJJcSIxDJx2HJbJAwOpIx1xXnsMd74i8SW/inXrT7E9rHJFo+nyKPOtI5AA8s7D/lq4AGwHEa8csSa+DqK1jUUXdowrUZVI8qlY/Q2kr886K3+uf3Ti/sz+9+H/BP0Mor886KPrn90P7M/vfh/wAE/Qyivzzoo+uf3Q/sz+9+H/BP0Mor886KPrn90P7M/vfh/wAE/QysDxbcJpd34Z12fMdrpOqrLd3C8mC3kieF2I7rl03Y6DntXwlRUzxXPFxsaUsB7OampbeX/BP1Urlfix/ySzxl/wBgW9/9EPX5q0VyHon/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    %: percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Zour&eacute; HG, Wanji S, Noma M, et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis 2011; 5:e1210. Copyright &copy; 2011 Public Library of Science (PLoS).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8889=[""].join("\n");
var outline_f8_43_8889=null;
var title_f8_43_8890="Diclofenac (systemic): Drug information";
var content_f8_43_8890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diclofenac (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/32/20998?source=see_link\">",
"    see \"Diclofenac (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31560?source=see_link\">",
"    see \"Diclofenac (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8016815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8016831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cambia&trade;;",
"     </li>",
"     <li>",
"      Cataflam&reg;;",
"     </li>",
"     <li>",
"      Voltaren&reg;-XR;",
"     </li>",
"     <li>",
"      Zipsor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8016832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Diclo Rapide&reg;;",
"     </li>",
"     <li>",
"      Apo-Diclo&reg;;",
"     </li>",
"     <li>",
"      Apo-Diclo&reg; SR&reg;;",
"     </li>",
"     <li>",
"      Ava-Diclofenac;",
"     </li>",
"     <li>",
"      Ava-Diclofenac SR;",
"     </li>",
"     <li>",
"      Cambia&reg;;",
"     </li>",
"     <li>",
"      Cataflam&reg;;",
"     </li>",
"     <li>",
"      Diclofenac ECT;",
"     </li>",
"     <li>",
"      Diclofenac Sodium;",
"     </li>",
"     <li>",
"      Diclofenac Sodium SR;",
"     </li>",
"     <li>",
"      Diclofenac SR;",
"     </li>",
"     <li>",
"      Dom-Diclofenac;",
"     </li>",
"     <li>",
"      Dom-Diclofenac SR;",
"     </li>",
"     <li>",
"      NTP-Diclofenac;",
"     </li>",
"     <li>",
"      NTP-Diclofenac SR;",
"     </li>",
"     <li>",
"      Nu-Diclo;",
"     </li>",
"     <li>",
"      Nu-Diclo-SR;",
"     </li>",
"     <li>",
"      PMS-Diclofenac;",
"     </li>",
"     <li>",
"      PMS-Diclofenac SR;",
"     </li>",
"     <li>",
"      PMS-Diclofenac-K;",
"     </li>",
"     <li>",
"      PRO-Diclo-Rapide;",
"     </li>",
"     <li>",
"      Sandoz-Diclofenac;",
"     </li>",
"     <li>",
"      Sandoz-Diclofenac Rapide;",
"     </li>",
"     <li>",
"      Sandoz-Diclofenac SR;",
"     </li>",
"     <li>",
"      Teva-Diclofenac;",
"     </li>",
"     <li>",
"      Teva-Diclofenac K;",
"     </li>",
"     <li>",
"      Teva-Diclofenac SR;",
"     </li>",
"     <li>",
"      Voltaren Rapide&reg;;",
"     </li>",
"     <li>",
"      Voltaren SR&reg;;",
"     </li>",
"     <li>",
"      Voltaren&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8017469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID);",
"     </li>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8017009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Analgesia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet: Starting dose: 50 mg 3 times/day (maximum dose: 150 mg/day); may administer 100 mg loading dose, followed by 50 mg every 8 hours (maximum dose day 1: 200 mg/day; maximum dose day 2 and thereafter: 150 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Maximum loading dose day 1: 200 mg/day; maximum dose day 2 and up to 7 days: 150 mg/day (50 mg every 6-8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release capsule: 25 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Primary dysmenorrhea:",
"     </b>",
"     Oral: Immediate release tablet: Starting dose: 50 mg 3 times/day (maximum dose: 150 mg/day); may administer 100 mg loading dose, followed by 50 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Maximum loading dose day 1: 200 mg/day; maximum dose day 2 and up to 7 days: 150 mg/day (50 mg every 6-8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Immediate release tablet: 150-200 mg/day in 3-4 divided doses; Delayed release tablet: 150-200 mg/day in 2-4 divided doses; Extended release tablet: 100 mg/day (may increase dose to 200 mg/day in 2 divided doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     150 mg/day in 3 divided doses (75-150 mg/day of slow release tablet)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal suppository (not available in U.S.):",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Insert 50 mg or 100 mg rectally as single dose to substitute for final (third) oral daily dose (maximum combined dose [rectal and oral]: 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoarthritis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Immediate release tablet: 150-200 mg/day in 3-4 divided doses; Delayed release tablet: 150-200 mg/day in 2-4 divided doses; Extended release tablet: 100 mg/day; may increase dose to 200 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     150 mg/day in 3 divided doses (75-150 mg/day of slow release tablet)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal suppository (not available in U.S.):",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Insert 50 mg or 100 mg rectally as single dose to substitute for final (third) oral daily dose (maximum combined dose [rectal and oral]: 150 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ankylosing spondylitis:",
"     </b>",
"     Oral: Delayed release tablet: 100-125 mg/day in 4-5 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Migraine:",
"     </b>",
"     Oral: Oral solution: 50 mg (one packet) as a single dose at the time of migraine onset; safety and efficacy of a second dose have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8017010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No specific dosing recommendations; elderly may demonstrate adverse effects at lower doses than younger adults, and &gt;60% may develop asymptomatic peptic ulceration with or without hemorrhage; monitor renal function.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8017011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended in patients with advanced renal disease or significant renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8017012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May require dosage adjustment; use oral solution only if benefits outweigh risks.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8017239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid filled, oral, as potassium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zipsor&reg;: 25 mg [contains gelatin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral, as potassium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cambia&trade;: 50 mg/packet (1s) [contains phenylalanine 25 mg/packet; anise-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as potassium: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cataflam&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, enteric coated, oral, as sodium: 25 mg, 50 mg, 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as sodium: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Voltaren&reg;-XR: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F11590267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Voltaren&reg;: 50 mg, 100mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8016834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule, oral solution",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8016830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cambia&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM169077.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM169077.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cataflam&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135935.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135935.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Voltaren&reg;-XR:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089822.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089822.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Zipsor&reg;:  file://zipsor.com/patient/html_pages/medication_guide.html",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8017044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Do not crush delayed or extended release tablets. Administer with food or milk to avoid gastric distress. Take with full glass of water to enhance absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral solution: Administer immediately after preparing; food may reduce effectiveness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal suppository: Remove entire plastic wrapping prior to inserting rectally.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8016835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule: Relief of mild-to-moderate acute pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate-release tablet: Relief of mild-to-moderate pain; primary dysmenorrhea; acute and chronic treatment of rheumatoid arthritis, osteoarthritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Delayed-release tablet: Acute and chronic treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended-release tablet: Chronic treatment of osteoarthritis, rheumatoid arthritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral solution: Treatment of acute migraine with or without aura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository (CAN; not available in U.S.): Symptomatic treatment of rheumatoid arthritis and osteoarthritis (including degenerative joint disease of hip)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8016886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Juvenile idiopathic arthritis (JIA)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8016829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diclofenac may be confused with Diflucan&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cataflam&reg; may be confused with Catapres&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Voltaren may be confused with traMADol, Ultram&reg;, Verelan&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diclofenac may be confused with Duphalac brand name for lactulose [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin: Brand name for diclofenac [Argentina], but also the brand name for cyclobenzaprine [Chile] and orphenadrine [Israel]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin [Argentina] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], ofloxacin [U.S., Canada], and perfloxacin [Philippines]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8016928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI perforation, heartburn, nausea, peptic ulcer/GI bleed, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver enzyme abnormalities (&gt;3 x ULN; &le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal function abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, alopecia, anaphylactoid reactions, anaphylaxis, angioedema, aplastic anemia, anxiety, appetite changes, arrhythmia, aseptic meningitis, asthma, azotemia, blurred vision, chest pain, CHF, colitis, coma, confusion, conjunctivitis, cystitis, depression, diplopia, disorientation, dreams abnormal, drowsiness, dyspnea, dysuria, ecchymosis, eosinophilia, eructation, erythema multiforme, esophageal lesions, esophagitis, exfoliative dermatitis, fever, fulminant hepatitis, gastritis, glossitis,hallucination, hearing impairment, hearing loss, hematemesis, hematuria, hemoglobin decreased, hemolytic anemia, hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity, hyper-/hypotension, hyper-/hypoglycemia, infection, insomnia, interstitial nephritis, intestinal perforation, jaundice, laryngeal edema, leukopenia, lymphadenopathy, malaise, melena, memory disturbance, meningitis, MI, nephrotic syndrome, nervousness, oliguria, palpitation, pancreatitis, pancytopenia, paresthesia, pharynx edema, photosensitivity, pneumonia, polyuria, proteinuria, psychotic reactions, purpura, rectal bleeding, renal failure, renal papillary necrosis, respiratory depression, seizure, sepsis, somnolence, Stevens-Johnson syndrome, stomatitis, stroke, swelling of lips and tongue, syncope, tachycardia, taste disorder, thrombocytopenia, toxic epidermal necrolysis, tremor, urticaria, vasculitis, vertigo, weight change, weakness, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Rectal suppository",
"     </b>",
"     (CAN; not available in U.S.):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Also refer to adverse reactions associated with oral formulations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &lt;1%, postmarketing, and/or case reports: Local: Bleeding, hemorrhoid exacerbation, proctitis, rectal irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8016863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diclofenac or any component of the formulation; hypersensitivity to bovine protein (capsule formulation only); patients who exhibit asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Uncontrolled heart failure, active gastric/duodenal/peptic ulcer; active GI bleed or perforation; regional ulcer, gastritis, or ulcerative colitis; cerebrovascular bleeding or other bleeding disorders; inflammatory bowel disease; severe hepatic impairment; active hepatic disease; severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) or deteriorating renal disease; known hyperkalemia; patients &lt;16 years of age; breast-feeding; pregnancy (third trimester); use of diclofenac suppository if recent history of bleeding or inflammatory lesions of rectum/anus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8016939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Genitourinary effects: Long-term NSAID use may result in renal papillary necrosis while persistent urinary symptoms (eg, dysuria, bladder pain), cystitis, or hematuria may occur anytime after initiating NSAID therapy. Discontinue therapy with symptom onset and evaluate for origin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Transaminase elevations have been observed with chronic use, generally within in the first 2 months of therapy, but may occur at any time (manufacturer labeling). A recent clinical trial concluded that transaminase elevations occur 4-6 months after initiation of therapy (Laine, 2009). Significant elevations in transaminases (eg, &gt;3 x ULN) occur before patients become symptomatic. Periodic transaminase monitoring should occur in patients on chronic therapy beginning 4-8 weeks after initiation. Rarely, severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use. Use with caution in patients with hepatic porphyria (may trigger attack). Patients should be educated about symptoms of hepatotoxicity. Avoid concurrent hepatotoxins if possible and use the lowest effective dose for the shortest duration. Discontinue therapy if hepatic injury is suspected (persistent or worsening LFT abnormality, clinical signs/symptoms of liver disease, or systemic manifestations of hypersensitivity (eosinophilia, rash).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause photosensitivity as well as serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension. Monitor blood pressure closely with therapy initiation and during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics and ACEI, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid chronic use (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent); nonselective oral NSAID use is associated with an increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, &gt;75 years or age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Capsule: Contains gelatin; use is contraindicated in patients with history of hypersensitivity to bovine protein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral solution: Appropriate use: Only indicated for acute treatment of migraine; not indicated for migraine prophylaxis or cluster headache. Not bioequivalent to other forms of diclofenac (even if same dose); do not interchange products. Contains phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8016932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C9 (weak), CYP2E1 (weak), CYP3A4 (weak), UGT1A6",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8016933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May increase the serum concentration of Diclofenac (Systemic). Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Diclofenac (Systemic). Management: Consider using a lower dose of diclofenac when used together with voriconazole.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8016937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, grapeseed, green tea, ginseng (Siberian), guggul, horse chestnut, horseradish, licorice, prickly ash, red clover, reishi, SAMe (s-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8016838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (oral)/D (&ge;30 weeks gestation [oral]) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8016839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, manufacturers classify most dosage forms of diclofenac as pregnancy category C (oral: Category D &ge;30 weeks gestation). Diclofenac crosses the placenta and can be detected in fetal tissue and amniotic fluid. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of a NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including: Myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). Product labeling for Zipsor&reg; specifically notes that use at &ge;30 weeks gestation should be avoided and, therefore, classifies diclofenac as pregnancy category D at this time. Use in the third trimester is contraindicated in the Canadian labeling. The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. A registry is available for pregnant women exposed to autoimmune medications including diclofenac. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at 877-311-8972",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8016842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excreted in breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8016844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low concentrations of diclofenac can be found in breast milk. Breast-feeding is not recommended by the manufacturer. Use while breast-feeding is contraindicated in Canadian labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8017042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral formulations may be taken with food to decrease GI distress. Food may reduce effectiveness of oral solution. Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Diclofenac potassium = Cataflam&reg;; potassium content: 5.8 mg (0.15 mEq) per 50 mg tablet",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8017266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Zipsor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $342.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Cambia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $29.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Diclofenac Sodium ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $281.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Voltaren-XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $1026.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Diclofenac Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $142.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $147.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $177.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cataflam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $583.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Diclofenac Potassium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $156.55",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8017046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor CBC, liver enzymes (periodically during chronic therapy starting 4-8 weeks after initiation), BUN/serum creatinine; monitor urine output; occult blood loss",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abitren (IL);",
"     </li>",
"     <li>",
"      Actifen CR (PH);",
"     </li>",
"     <li>",
"      Acuflam (PH);",
"     </li>",
"     <li>",
"      Allvoran (DE);",
"     </li>",
"     <li>",
"      Almiral (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TW, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Anterin (TW);",
"     </li>",
"     <li>",
"      Araclof (ID);",
"     </li>",
"     <li>",
"      Arcanafenac (ZA);",
"     </li>",
"     <li>",
"      Arthrifen (PH);",
"     </li>",
"     <li>",
"      Artrites (CO);",
"     </li>",
"     <li>",
"      Berifen (CR, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Betaren (IL);",
"     </li>",
"     <li>",
"      Bi Su Fu (CL);",
"     </li>",
"     <li>",
"      Cataflam (AE, BE, BH, CN, CY, EC, EE, EG, HK, ID, IE, IL, IQ, IR, JO, KW, LB, LY, NL, NO, OM, PE, PT, QA, SA, SY, TR, TW, UY, VE, YE);",
"     </li>",
"     <li>",
"      Cataflam D (ID);",
"     </li>",
"     <li>",
"      Cataflam Drops (MY);",
"     </li>",
"     <li>",
"      Catanac (TH);",
"     </li>",
"     <li>",
"      Catas (KP);",
"     </li>",
"     <li>",
"      Cencenac (TH);",
"     </li>",
"     <li>",
"      Clofec (TH);",
"     </li>",
"     <li>",
"      Cordralan (PE);",
"     </li>",
"     <li>",
"      Curafen (PH);",
"     </li>",
"     <li>",
"      D-Fiam (TH);",
"     </li>",
"     <li>",
"      Declophen (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Demofenac (IL);",
"     </li>",
"     <li>",
"      Depain (KP);",
"     </li>",
"     <li>",
"      Depain Plaster (KP);",
"     </li>",
"     <li>",
"      Diclac (CL);",
"     </li>",
"     <li>",
"      Diclax SR (NZ);",
"     </li>",
"     <li>",
"      Diclobene (AT);",
"     </li>",
"     <li>",
"      Diclofen (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, TW, YE);",
"     </li>",
"     <li>",
"      Diclofen Cremogel (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Diclofenac (CO);",
"     </li>",
"     <li>",
"      Dicloflam (ZA);",
"     </li>",
"     <li>",
"      Diclomax (IN);",
"     </li>",
"     <li>",
"      Diclon (DK);",
"     </li>",
"     <li>",
"      Dicloran Gel (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Diclosan SR (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Diclosian (TH);",
"     </li>",
"     <li>",
"      Diclowal (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Difena (TW);",
"     </li>",
"     <li>",
"      Difene (IE);",
"     </li>",
"     <li>",
"      Difengesic Gel (TH);",
"     </li>",
"     <li>",
"      Diflosid (PH);",
"     </li>",
"     <li>",
"      Dioxaflex (DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Disflam (EC);",
"     </li>",
"     <li>",
"      Divoltar (ID);",
"     </li>",
"     <li>",
"      Doflex (IN);",
"     </li>",
"     <li>",
"      Doloflam (PH);",
"     </li>",
"     <li>",
"      Dolotren (DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Dycon SR (PH);",
"     </li>",
"     <li>",
"      E (GR);",
"     </li>",
"     <li>",
"      Ecofenac (CH);",
"     </li>",
"     <li>",
"      Epifenac (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Eurofenac (HK);",
"     </li>",
"     <li>",
"      Fenac (AU);",
"     </li>",
"     <li>",
"      Flamquit (TW);",
"     </li>",
"     <li>",
"      Flector (FR);",
"     </li>",
"     <li>",
"      Flexagen (ZA);",
"     </li>",
"     <li>",
"      Flogozan (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Fortfen SR (ZA);",
"     </li>",
"     <li>",
"      Imflac (AU);",
"     </li>",
"     <li>",
"      Inac (SG);",
"     </li>",
"     <li>",
"      Inac TR (SG);",
"     </li>",
"     <li>",
"      Inflamac (CH);",
"     </li>",
"     <li>",
"      Inflanac (HK, MY, TH);",
"     </li>",
"     <li>",
"      Kadiflam (ID);",
"     </li>",
"     <li>",
"      Lesflam (MY, SG);",
"     </li>",
"     <li>",
"      Merflam (ID);",
"     </li>",
"     <li>",
"      Monoflam (CZ, DE);",
"     </li>",
"     <li>",
"      Nepenthe (PH);",
"     </li>",
"     <li>",
"      Ofenac (KP);",
"     </li>",
"     <li>",
"      Olfen (BB, BM, BS, BZ, GY, HK, JM, MY, PR, SR, TT);",
"     </li>",
"     <li>",
"      Olfen-75 SR (MY);",
"     </li>",
"     <li>",
"      Osteoflam (IN);",
"     </li>",
"     <li>",
"      Panamor (ZA);",
"     </li>",
"     <li>",
"      Profenac (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Raost (ID);",
"     </li>",
"     <li>",
"      Remethan (DE, MY, SG);",
"     </li>",
"     <li>",
"      Ren (HK);",
"     </li>",
"     <li>",
"      Rewodina (DE, MY, RU);",
"     </li>",
"     <li>",
"      Sefnac (TH);",
"     </li>",
"     <li>",
"      Sodinac (KP);",
"     </li>",
"     <li>",
"      Soproxen (TH);",
"     </li>",
"     <li>",
"      Swiss Relief Dual Release (IL);",
"     </li>",
"     <li>",
"      Taks (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Vartelon (HK);",
"     </li>",
"     <li>",
"      Vesconac (TH);",
"     </li>",
"     <li>",
"      Voldic (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Voldic Emulgel (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Volna-K (TW);",
"     </li>",
"     <li>",
"      Volta (TH);",
"     </li>",
"     <li>",
"      Voltaflam (PK);",
"     </li>",
"     <li>",
"      Voltalen (HK, NZ);",
"     </li>",
"     <li>",
"      Voltalen Emulgel (NZ);",
"     </li>",
"     <li>",
"      Voltaren (AE, AR, AT, BE, BF, BG, BH, BJ, CH, CI, CO, CY, CZ, DE, DK, EE, EG, ET, FI, GH, GM, GN, HK, ID, IL, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PH, PL, PT, PY, QA, RU, SA, SC, SD, SE, SL, SN, SY, TH, TN, TR, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Voltaren Acti-Go (IL);",
"     </li>",
"     <li>",
"      Voltaren Dolo (FR);",
"     </li>",
"     <li>",
"      Voltaren Forte (PH);",
"     </li>",
"     <li>",
"      Voltaren Rapid (AU, NZ);",
"     </li>",
"     <li>",
"      Voltaren SR (HK, NZ, PH);",
"     </li>",
"     <li>",
"      Voltarene (FR, GR);",
"     </li>",
"     <li>",
"      Voltarol (IE);",
"     </li>",
"     <li>",
"      Voltfast (SG);",
"     </li>",
"     <li>",
"      Voltine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Volton-CR (HK);",
"     </li>",
"     <li>",
"      Voltrix (BR);",
"     </li>",
"     <li>",
"      Voren (PH, TW);",
"     </li>",
"     <li>",
"      Votalen SR (NZ);",
"     </li>",
"     <li>",
"      Votalin Emulgel (CL);",
"     </li>",
"     <li>",
"      Votan (PH);",
"     </li>",
"     <li>",
"      Votan SR (PH);",
"     </li>",
"     <li>",
"      Voveran (IN);",
"     </li>",
"     <li>",
"      Vurdon (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Yingtaiqing (CL);",
"     </li>",
"     <li>",
"      Yuren (TW);",
"     </li>",
"     <li>",
"      Zolterol (MY);",
"     </li>",
"     <li>",
"      Zolterol SR (SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8016953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8016955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cataflam&reg; (potassium salt) is more rapid than the sodium salt  because it dissolves in the stomach instead of the duodenum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suppository: More rapid onset, but slower rate of absorption when compared to enteric coated tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: ~1.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; undergoes first-pass metabolism; forms several metabolites (1 with weak activity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cambia&trade;: ~0.25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cataflam&reg;: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Voltaren&reg; XR ~5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zipsor&reg;: ~0.5 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suppository: &le;1 hour;",
"     <b>",
"      Note:",
"     </b>",
"     Suppository: C",
"     <sub>",
"      max",
"     </sub>",
"     : Approximately two-thirds of that observed with enteric coated tablet (equivalent 50 mg dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet, delayed release (diclofenac sodium): ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~65%); feces (~35%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arnold MM and McKenna F, &ldquo;A Double Blind Comparison of the Endoscopic and Clinical Effects of Tenoxicam and Diclofenac in Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Br J Rheumatol",
"      </i>",
"      , 1995, 34(Suppl 1):95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/7704474/pubmed\" id=\"7704474\" target=\"_blank\">",
"        7704474",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brogden RN, Heel RC, Pakes GE, et al, &ldquo;Diclofenac Sodium: A Review of Its Pharmacological Properties and Therapeutic Use in Rheumatic Diseases and Pain of Varying Origin,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1980, 20(1):24-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/6772422/pubmed\" id=\"6772422\" target=\"_blank\">",
"        6772422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brooks PM and Day RO, &ldquo;Nonsteroidal Anti-inflammatory Drugs - Differences and Similarities,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(24):1716-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/2034249/pubmed\" id=\"2034249\" target=\"_blank\">",
"        2034249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clinch D, Banerjee AK, and Ostick G, &ldquo;Absence of Abdominal Pain in Elderly Patients With Peptic Ulcer,&rdquo;",
"      <i>",
"       Age Ageing",
"      </i>",
"      , 1984, 13(2):120-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/6731166/pubmed\" id=\"6731166\" target=\"_blank\">",
"        6731166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clive DM and Stoff JS, &ldquo;Renal Syndromes Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1984, 310(9):563-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/6363936/pubmed\" id=\"6363936\" target=\"_blank\">",
"        6363936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Court H and Volans GN, &ldquo;Poisoning After Overdose With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Adverse Drug React Acute Poisoning Rev",
"      </i>",
"      , 1984, 3(1):1-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/6541425/pubmed\" id=\"6541425\" target=\"_blank\">",
"        6541425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      George S and Rahi AH, &ldquo;Thrombocytopenia Associated With Diclofenac Therapy,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1995, 52(4):420-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/7757871/pubmed\" id=\"7757871\" target=\"_blank\">",
"        7757871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graham DY, &ldquo;Prevention of Gastroduodenal Injury Induced by Chronic Nonsteroidal Anti-inflammatory Drug Therapy,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):675-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/2642452/pubmed\" id=\"2642452\" target=\"_blank\">",
"        2642452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurwitz JH, Avorn J, Ross-Degnan D, et al, &ldquo;Nonsteroidal Anti-inflammatory Drug-Associated Azotemia in the Very Old,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(4):471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/2366280/pubmed\" id=\"2366280\" target=\"_blank\">",
"        2366280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haapasaari J, Wuolijoki E, and Ylijoki H, &ldquo;Treatment of Juvenile Rheumatoid Arthritis With Diclofenac Sodium,&rdquo;",
"      <i>",
"       Scand J Rheumatol",
"      </i>",
"      , 1983, 12(4):325-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/6361986/pubmed\" id=\"6361986\" target=\"_blank\">",
"        6361986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al, &ldquo;Omeprazole Compared With Misoprostol for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/9494149/pubmed\" id=\"9494149\" target=\"_blank\">",
"        9494149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(10):1108-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/9605782/pubmed\" id=\"9605782\" target=\"_blank\">",
"        9605782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Helfgott SM, Sandberg-Cook J, Zakim D, et al, &ldquo;Diclofenac-Associated Hepatotoxicity,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(20):2660-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/2232043/pubmed\" id=\"2232043\" target=\"_blank\">",
"        2232043",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoppmann RA, Peden JG, and Ober SK, &ldquo;Central Nervous System Side Effects of Nonsteroidal Anti-inflammatory Drugs. Aseptic Meningitis, Psychosis, and Cognitive Dysfunction,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1991, 151(7):1309-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/2064481/pubmed\" id=\"2064481\" target=\"_blank\">",
"        2064481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Isdale A and Wright V, &ldquo;Misoprostol/NSAID Fixed Combinations. Help or Hindrance in Clinical Practice?&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):291-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/7669258/pubmed\" id=\"7669258\" target=\"_blank\">",
"        7669258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobi J, Fraser GL, Coursin DB, et al, &ldquo;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):119-41. Available at file://www.sccm.org/pdf/sedatives.pdf. Accessed August 2, 2003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/11902253/pubmed\" id=\"11902253\" target=\"_blank\">",
"        11902253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kulling EJ, Beckman EA, and Skagius AS, &ldquo;Renal Impairment After Acute Diclofenac, Naproxen, and Sulindac Overdoses,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(2):173-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/7897758/pubmed\" id=\"7897758\" target=\"_blank\">",
"        7897758",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laine L, Goldkind L, Curtis SP, et al, &ldquo;How Common Is Diclofenac-Associated Liver Injury? Analysis Of 17,289 Arthritis Patients In A Long-Term Prospective Clinical Trial,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(2):356-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/19174782/pubmed\" id=\"19174782\" target=\"_blank\">",
"        19174782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2000, 13(11):1161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/11078175/pubmed\" id=\"11078175\" target=\"_blank\">",
"        11078175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2000, 160(6):777-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/10737277/pubmed\" id=\"10737277\" target=\"_blank\">",
"        10737277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pillans PI and O'Connor N, &ldquo;Tissue Necrosis and Necrotizing Fasciitis After Intramuscular Administration of Diclofenac,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(3):264-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/7606072/pubmed\" id=\"7606072\" target=\"_blank\">",
"        7606072",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pope JE, Anderson JJ, and Felson DT, &ldquo;A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(4):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/8435027/pubmed\" id=\"8435027\" target=\"_blank\">",
"        8435027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riad LE, Sawchuk RJ, McAlary MM, et al, &ldquo;Effect of Food on the Multiple-Peak Behavior After a Single Oral Dose of Diclofenac Sodium Slow-Release Tablet in Humans,&rdquo;",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 1995, 2(4):237-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/11850655/pubmed\" id=\"11850655\" target=\"_blank\">",
"        11850655",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robinson MH, Wheatley T, and Leach IH, &ldquo;Nonsteroidal Anti-inflammatory Drug-Induced Colonic Stricture; an Unusual Cause of Large Bowel Obstruction and Perforation,&rdquo;",
"      <i>",
"       Dig Dis Sci",
"      </i>",
"      , 1995, 40(2):315-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/7851196/pubmed\" id=\"7851196\" target=\"_blank\">",
"        7851196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robinson PM and Ahmed I, &ldquo;Diclofenac and Post-tonsillectomy Haemorrhage,&rdquo;",
"      <i>",
"       Clin Otolaryngol",
"      </i>",
"      , 1994, 19(4):344-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/7994893/pubmed\" id=\"7994893\" target=\"_blank\">",
"        7994893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smolinske SC, Hall AH, Vandenberg SA, et al, &ldquo;Toxic Effects of Nonsteroid Anti-inflammatory Drugs in Overdose. An Overview of Recent Evidence on Clinical Effects and Dose-Response Relationships,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1990, 5(4):252-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/2198051/pubmed\" id=\"2198051\" target=\"_blank\">",
"        2198051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vale JA and Meredith TJ, &ldquo;Acute Poisoning Due to Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Med Toxicol",
"      </i>",
"      , 1986, 1(1):12-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/3537613/pubmed\" id=\"3537613\" target=\"_blank\">",
"        3537613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verbeeck RK, &ldquo;Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 19(1):44-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/2199127/pubmed\" id=\"2199127\" target=\"_blank\">",
"        2199127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wafin F, Valindas E, and Wuolijoki E, &ldquo;Comparison of Diclofenac and Indomethacin Suppositories in Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Clin Rheumatol",
"      </i>",
"      , 1984, 3(1):67-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/6380897/pubmed\" id=\"6380897\" target=\"_blank\">",
"        6380897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Willkens RF, &ldquo;Worldwide Clinical Safety Experience With Diclofenac,&rdquo;",
"      <i>",
"       Semin Arthritis Rheum",
"      </i>",
"      , 1985, 15(2 Suppl 1):105-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/3909410/pubmed\" id=\"3909410\" target=\"_blank\">",
"        3909410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yeomans ND, Tulassay Z, Juhasz L, et al, &ldquo;A Comparison of Omeprazole With Ranitidine for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):719-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/43/8890/abstract-text/9494148/pubmed\" id=\"9494148\" target=\"_blank\">",
"        9494148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9103 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8890=[""].join("\n");
var outline_f8_43_8890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016815\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016831\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016832\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017469\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017009\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017010\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017011\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017012\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017239\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11590267\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016834\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016830\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017044\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016835\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016886\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016829\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016928\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016863\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016939\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016932\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016933\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016937\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016838\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016839\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016842\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016844\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017042\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017266\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017046\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961970\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016953\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016955\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9103\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9103|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/63/15348?source=related_link\">",
"      Diclofenac (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/51/10036?source=related_link\">",
"      Diclofenac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/1/32787?source=related_link\">",
"      Diclofenac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/32/20998?source=related_link\">",
"      Diclofenac (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31560?source=related_link\">",
"      Diclofenac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/21/24920?source=related_link\">",
"      Diclofenac (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/29/2518?source=related_link\">",
"      Diclofenac (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/43/1720?source=related_link\">",
"      Diclofenac (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_43_8891="Unintended loss rate after MPR by starting number";
var content_f8_43_8891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Unintended loss rate after MPR by starting number",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Starting number (n)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loss rate (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        2 (30)",
"       </td>",
"       <td class=\"centered\">",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        3 (549)",
"       </td>",
"       <td class=\"centered\">",
"        5.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4 (294)",
"       </td>",
"       <td class=\"centered\">",
"        5.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5 (86)",
"       </td>",
"       <td class=\"centered\">",
"        4.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &ge;6",
"       </td>",
"       <td class=\"centered\">",
"        12.9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stone J, Eddleman K, Lynch L, Berkowitz RL. A single center experience with 1000 consecutive cases of multifetal pregnancy reduction. Am J Obstet Gynecol 2002; 187:1163. Copyright &copy; 2002 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8891=[""].join("\n");
var outline_f8_43_8891=null;
var title_f8_43_8892="Mechanisms of globin mutations";
var content_f8_43_8892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Molecular mechanisms underlying globin mutations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mechanisms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Single base substitution leading to amino acid replacement",
"       </td>",
"       <td>",
"        Hemoglobin S",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin E",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two replacements in same subunit",
"       </td>",
"       <td>",
"        Hemoglobin C-Harlem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Fusion hemoglobins",
"       </td>",
"       <td>",
"        Hemoglobin Lepore (delta-beta)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin Miyada (beta-delta)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin Parchman (delta-beta-delta)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin Kenya (gamma-beta)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deletion or insertion",
"       </td>",
"       <td>",
"        Hemoglobin Gun Hill",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Insertion",
"       </td>",
"       <td>",
"        Hemoglobin Grady",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin Catonsville",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Deletion and insertion",
"       </td>",
"       <td>",
"        Hemoglobin Montreal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin Galicia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Extended subunit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Termination codon mutation",
"       </td>",
"       <td class=\"sublist_other\">",
"        Hemoglobin Constant Spring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"1\" rowspan=\"2\">",
"        Frameshift mutation",
"       </td>",
"       <td class=\"sublist_other\">",
"        Hemoglobin Wayne",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin Cranston",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"1\" rowspan=\"2\">",
"        N-terminal mutation leading to retention of initiator methionine",
"       </td>",
"       <td class=\"sublist_other\">",
"        Hemoglobin Long Island",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin Marseille",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8892=[""].join("\n");
var outline_f8_43_8892=null;
var title_f8_43_8893="Perfusion imaging LBBB";
var content_f8_43_8893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Myocardial imaging with vasodilators in LBBB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 260px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 245 patients with a left bundle branch block (LBBB), myocardial perfusion imaging with a vasodilator identified high-risk patients (large fixed or reversible defect or cardiac enlargement and either increased pulmonary uptake or decreased resting ejection fraction) who had a lower three year survival compared with low-risk patients without these findings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Wagdy HM, Hodge D, Christian TF, et al. Circulation 1998; 97:1563.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8893=[""].join("\n");
var outline_f8_43_8893=null;
var title_f8_43_8894="Genetic syndromes associated with obesity";
var content_f8_43_8894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70658%7EPEDS%2F82307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70658%7EPEDS%2F82307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected genetic syndromes associated with obesity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Locus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Obesity onset (type)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albright hereditary osteodystrophy (Pseudohypoparathyroidism type 1a) (MIM #103580)",
"       </td>",
"       <td>",
"        20q13.2",
"       </td>",
"       <td>",
"        GNAS1",
"       </td>",
"       <td>",
"        Early (generalized)",
"       </td>",
"       <td>",
"        Short stature, short metacarpals and metatarsals, round facies, delayed dentition, +/&minus; hypocalcemia and/or subcutaneous calcium or bone deposition(osteoma cutis), precocious puberty, mild cognitive deficit",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Alstr&ouml;m (MIM #203800)",
"       </td>",
"       <td>",
"        2p13",
"       </td>",
"       <td>",
"        ALMS1",
"       </td>",
"       <td>",
"        Age 2-5 yrs (central)",
"       </td>",
"       <td>",
"        Blindness, deafness, acanthosis nigricans, chronic nephropathy, type 2 diabetes, cirrhosis, primary hypogonadims in males only, normal cognition",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"15\">",
"        Bardet-Biedl (MIM #209900)",
"       </td>",
"       <td>",
"        11q13",
"       </td>",
"       <td>",
"        BBS1",
"       </td>",
"       <td rowspan=\"15\">",
"        Age 1-2 yrs (central)",
"       </td>",
"       <td rowspan=\"15\">",
"        Mental retardation, hypotonia, retinitis pigmentosa, polydactyly, hypogonadism +/&minus; glucose intolerance, deafness, renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16q21",
"       </td>",
"       <td>",
"        BBS2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3p12-q13",
"       </td>",
"       <td>",
"        BBS3 (ARL6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15q22.3-q23",
"       </td>",
"       <td>",
"        BBS4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2q31",
"       </td>",
"       <td>",
"        BBS5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20p12",
"       </td>",
"       <td>",
"        BBS6 (MKKS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4q27",
"       </td>",
"       <td>",
"        BBS7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14q32",
"       </td>",
"       <td>",
"        BBS8 (TTC8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7p14",
"       </td>",
"       <td>",
"        BBS9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12q",
"       </td>",
"       <td>",
"        BBS10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9q33.1",
"       </td>",
"       <td>",
"        BBS11 (TRIM32)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4q27",
"       </td>",
"       <td>",
"        BBS12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17q23",
"       </td>",
"       <td>",
"        BBS13 (MKS1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12q21.3",
"       </td>",
"       <td>",
"        BBS14 (CEP290)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2p15",
"       </td>",
"       <td>",
"        BBS15 (C2ORF86)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Beckwith-Wiedemann (MIM #130650)",
"       </td>",
"       <td>",
"        11p15.5 in most cases; deregulation of imprinted genes including IGF2",
"       </td>",
"       <td>",
"        multiple",
"       </td>",
"       <td>",
"        &minus;",
"       </td>",
"       <td>",
"        Hyperinsulinemia, hypoglycemia, hemihypertrophy, intolerance of fasting",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Carpenter (MIM #201000)",
"       </td>",
"       <td>",
"        6p11",
"       </td>",
"       <td>",
"        RAB23",
"       </td>",
"       <td>",
"        (central)",
"       </td>",
"       <td>",
"        Mental retardation, short stature, brachycephaly, polydactyly, syndactyly of feet, cryptorchidism, umbilical hernia, high-arched palate, hypogonadism in males only",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cohen (MIM #216550)",
"       </td>",
"       <td>",
"        8q22",
"       </td>",
"       <td>",
"        COH1",
"       </td>",
"       <td>",
"        Mid-childhood (central)",
"       </td>",
"       <td>",
"        Mental retardation, microcephaly, small hands and feet, cryptorchidism, hypotonia and failure to thrive in infancy, prominent central incisors, long, thin fingers and toes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Prader-Willi (MIM #176270)",
"       </td>",
"       <td>",
"        15q",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Age 1-3 yrs (generalized)",
"       </td>",
"       <td>",
"        Microcephaly, short stature, hypotonia, almond- shaped eyes, high-arched palate, narrow hands and feet, delayed puberty, early failure to thrive with hyperphagia and increased weight gain by 2-3 years, mild to moderate cognitive deficit",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Pediatric Obesity. In: Pediatric Nutrition Handbook, 6th ed, Kleinman R (Ed), American Academy of Pediatrics, Elk Grove Village, IL, 2009. p.751",
"      </li>",
"      <li>",
"       Hoppin AG. Obesity. In: Pediatric Gastrointestinal Disease: Pathopsychology, Diagnosis, Management, 4th ed, Walker WA, Goulet O, Kleinman, RE, et al (Eds), BC Decker, Ontario, 2004. p.311.",
"      </li>",
"      <li>",
"       Leibel RL, Chua SC, Rosenbaum M. Obesity. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York, 2001. p.3965.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Single gene defects associated with obesity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Single gene disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leptin deficiency",
"        <em>",
"         (LEP)",
"        </em>",
"       </td>",
"       <td>",
"        7q31.3",
"       </td>",
"       <td>",
"        Severe, early onset obesity, hypometabolic rate, hyperphagia, pubertal delay, impaired glucose tolerance, hypothalamic hypogonadism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pro-opiomelanocortin&nbsp;deficiency",
"        <em>",
"         (POMC)",
"        </em>",
"       </td>",
"       <td>",
"        2p23.3",
"       </td>",
"       <td>",
"        Severe, early onset obesity, red hair, hyperphagia, adrenal insufficiency, hyperpigmentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proprotein convertase 1 (",
"        <em>",
"         PCSK1",
"        </em>",
"        , also&nbsp;known as prohormone convertase 1)",
"       </td>",
"       <td>",
"        5q15-q21",
"       </td>",
"       <td>",
"        Early onset obesity, abnormal glucose homeostasis, hypogonadotropic hypogonadism, hypocortisolism, elevated plasma proinsulin and POMC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melanocortin receptor 4 haploinsufficiency",
"        <em>",
"         (MC4R)",
"        </em>",
"       </td>",
"       <td>",
"        18q21.3-q22",
"       </td>",
"       <td>",
"        Early onset, moderate-severe obesity, early onset hyperphagia, increased bone density",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leptin receptor deficiency",
"        <em>",
"         (LEPR)",
"        </em>",
"       </td>",
"       <td>",
"        1p31-p22",
"       </td>",
"       <td>",
"        Severe, early onset obesity, hypometabolic rate, hyperphagia, pubertal delay, hypothalamic hypogonadism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <ol>",
"      <li>",
"       Hoppin AG. Obesity. In: Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis and Management, 4th ed, Walker WA, Goulet O, Kleinman RE, et al (Eds), BC Decker, Ontario, 2004. p. 311",
"      </li>",
"      <li>",
"       Leibel RL, Chua SC, Rosenbaum M. Obesity. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York, 2001. p. 3965.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8894=[""].join("\n");
var outline_f8_43_8894=null;
var title_f8_43_8895="Valsalva blood pressure response";
var content_f8_43_8895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Normal blood pressure responses to the Valsalva maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal Valsalva response: Normal changes in systolic blood pressure during 10 seconds of straining (shaded). Phase 1 - systolic blood pressure rises with initiation of the maneuver. Phase 2 - systolic blood pressure returns to baseline after several seconds. Phase 3 - systolic blood pressure drops below normal after strain is released. Phase 4 - systolic blood pressure rises transiently before returning to baseline.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_43_8895=[""].join("\n");
var outline_f8_43_8895=null;
